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Clinical and Biological Insights 
into the Novel Epigenetic Regulator TET2  
Stellingen 
1. At the start of this PhD project, there were 0 papers published on the gene/
protein TET2. Shortly before this thesis was sent out for printing, a Pubmed 
search for TET2 generated 532 hits! 
2. TET2 is trending...
3. Associating genetic mutations with patient survival is crucial, but it is merely the 
beginning of a very long road towards more sophisticated, targeted treatments. 
4. It is my observation that the superficiality that seems to be taking over the 
world has reached the scientific community, and much more attention and 
credit is being given nowadays to finding new disease mutations, rather than 
taking that long road.  
5. “I realized recently that if I examine it in a day-to-day sense, I have one job in 
science. It’s not curing malaria, which is what my grant says it should be. My 
job, in essence, is to move small amounts of liquid from one place to another. 
That’s it.” (Adam Ruben, Science website, Experimental error series)
6. “The most exciting phrase to hear in science, the one that heralds new 
discoveries, is not, “Eureka!” (“I found it!”) but rather, “Hmm... that’s funny...” 
(Isaac Asimov)
7. “We are, quite literally, star dust.” (Christof Koch, Consciousness: Confessions 
of a Romantic Reductionist)
8. “Ultimately, though, pinning a variant to a function is the part of science least 
amenable to high-throughput approaches. You can easily generate data that 
now demands years’ worth of work to digest.” (Mark de Pristo)
9. Research is driven by pre-postulated hypotheses. Often, in our pursuit to prove 
these hypotheses, we forget that disproving them is just as important.
10. It is rather arrogant to assume that most of our hypotheses on the works of 
Nature will prove to be correct, when the matter of fact remains that modern 
day scientists are attempting to decipher over 4 billion years of evolution.
11. “One’s ideas must be as broad as Nature, if they are to interpret Nature” 
(Sherlock Holmes, A Study In Scarlet, Arthur Conan Doyle)
12. One CAN spend the happiest hours of their PhD in the dark….room, where 
the microscope is located!
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C h a p t e r  1
Introduction
Parts of this section have been previously published: 
*   Langemeijer SMC, Kuiper RP, Berends M, et al.: Acquired mutations in TET2 are 
common in myelodysplastic syndromes. Nature Genetics 41:838-U102, 2009 
** Langemeijer SM, Aslanyan MG, Jansen JH: TET proteins in malignant 
hematopoiesis. Cell Cycle 8:4044-8, 2009 
*** S.M.C. Langemeijer, M.G. Aslanyan en J.H. Jansen: TET2 mutaties komen 
frequent voor bij myeloïde maligniteiten. Ned Tijdschr Hematol 2010;7:131, 2010
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11. tet2 mutations in myeloid neoplasms
1.1 Discovery of TET2 mutations in MDS and MPN 
In the past decade, novel technological developments, such as SNP arrays and 
next-generation sequencing, have allowed researchers to gain better insight into 
the genetic background of myeloid malignancies. Consequently, a number of 
previously undetectable recurrent somatic alterations have been identified and 
their repercussion on clinical outcome of patients has been extensively studied 
resulting in improved risk stratification.
In 2009, two original reports were published implicating for the first time 
the TET2 gene in the pathogenesis of myelodysplastic syndromes (MDS) and 
myeloproliferative neoplasms (MPN), respectively 1,2. Due to the limitations of 
traditional karyotyping and FISH analysis, gross chromosomal aberrations (such 
as -5q, -7q, -7,) could only be detected in approximately half of the MDS patients, 
leaving 50% of the cases unexplained (box 1). In addition, mutations in NRAS 
(15%), TP53 (10%), RUNX1 (10%), and FLT3 (5%) had been described. Using 250k 
SNP array-based genomic profiling, we identified a microdeletion encompassing 
a minimal region on chromosome 4q24 containing only the TET2 and PPA2 genes. 
Sanger sequencing revealed that the PPA2 gene was unaffected, but the remaining 
copy of TET2 carried an acquired nonsense mutation introducing a premature 
stop codon in the midst of the protein. Subsequent analysis of the rest of the MDS 
patient cohort showed that nonsense, missense and frameshift TET2 mutations, 
scattered along the whole coding region of the gene, were present in 26% of the 
MDS patients with/without 4q24 abnormalities. In several subjects, more than one 
TET2 mutation was detected suggesting biallelic inactivation. Afflicting a quarter 
of the patients, TET2 became the most frequently mutated gene in MDS thus far 1. 
Based on a report in 2005 3 describing six MDS/AML patients with acquired 
rearrangements on 4q24, Delhommeau et al. 2 further pursued the potential 
implication of this chromosomal region in leukemogenesis. Employing an alternative 
approach, the authors discovered involvement of the 4q24 region in patients with 
myeloprolifertive neoplasms (MPN), as well as MDS and AML. A large percentage 
of MPN patients (box 2) harbor a common genetic defect in the Janus kinase (JAK) 
2 gene, namely the JAK2 V617F activating mutation. Evidence from mouse models 
and patients had suggested that the JAK2 defect alone cannot always account 
for the progression of the disease. This led the authors to the hypothesis that an 
additional early genetic event may arise in the hematopoietic stem cells which 
could be common to MPN, MDS and AML. Similar to our study, they also reported 
truncating single or double mutations affecting the whole coding portion of the TET2 
gene in an overall 15% of patients with diverse myeloid malignancies. Fractionation 
of the CD34+ population of progenitor cells into CD34+CD38- (immature HSCs) and 
CD34+CD38- (more committed cells) indicated that TET2 mutations were present in 
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a small number of stem cells and increased in the committed progenitor population, 
implying that TET2 defective cells have a proliferative advantage. To prove that 
further, CD34+ MPN patient cells carrying a JAK2 V617F mutation either with a TET2 
or without a TET2 aberration were engrafted into NOD-SCID mice. TET2 positive 
cells had an increased proliferative capacity and eventually a clone carrying only a 
TET2, but no JAK2 mutation, outgrew and completely dominated the bone marrow 
skewing blood cell reconstitution towards the myeloid lineage.
Box 1
MDS represent a heterogeneous group of clonal hematopoietic stem cell 
disorders characterized by dysplasia of one or more of the myeloid blood cell 
lineages (erythroid, granulocytic, monocytic and/or megakaryocytic) (Fig.1). It is 
among the most prevalent hemopathies affecting the elderly population with 60- 
65 years being the median age of onset, occurring more often in males than in 
females. Patients suffer from peripheral blood cytopenias and have an increased 
risk of progression to acute myeloid leukemia (AML). Although about 30% of 
the cases progress to AML, most MDS patients eventually die of complications 
arising from bone marrow failure. MDS can be very difficult to diagnose since the 
initial symptoms are not specific to the disease. At present, diagnosis is based on 
careful cytomorphologic examination of the bone marrow, cytogenetic analysis, 
molecular studies and recently, flow cytometry has become a powerful tool in 
discriminating MDS from other disorders. Depending on the type of MDS and the 
age of the patient, treatment options include palliative care, erythroid stimulating 
agents (ESAs), lenalidomide and hypomethylating agents. Hematopoietic stem cell 
transplantation (HSCT) remains the sole curative option but its use is restricted to 
younger patients due to the age-associated morbidity and mortality.
Box 2
MPN are clonal bone marrow stem cell disorders characterized by an expansion of 
mature cells from the myeloid, erythroid or megakaryocytic lineages. Classic MPNs 
comprise: polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PM). Although diagnosed as distinct entities PV, ET and PM show 
considerable overlap in terms of morphology, clinical presentation and symptoms. 
Interestingly, all three types of MPNs also share a common genetic defect within 
the JAK2 kinase, the activating JAK2 V617F mutation ( ~95% of PV, 50-70% ET, and 
40-50% PM)4 which renders the protein in a constitutively active state. As for MDS, 
the treatment for MPN is mostly supportive. At present, the most promising new 
therapeutics available for MPN patients are JAK2 inhibitors.
14
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1.2 TET2 mutations in other myeloid malignancies 
Following the discovery of TET2 mutations in MDS and MPN, a number of groups 
addressed the question whether recurrent TET2 defects were restricted to MDS/
MPN, or occurred in a wide spectrum of myeloid disorders. This effort resulted 
in the addition of systemic mastocytosis (SM), chronic myelomonocytic leukemia 
(CMML), de novo AML, as well as secondary AML (sAML) to the list. TET2 aberrations 
affected 29% of SM patients and segregated with KIT D816V mutation 5. The highest 
frequency of TET2 mutations however was reported in patients with CMML, where 
the incidence reaches up to 50% of the cases suggesting a particularly important 
role for TET2 in the pathogenesis of this disease. According to initial reports, the 
incidence of TET2 mutations reported in AML ranged between 12-19%, and was 
higher in the case of sAML 7. 
In contrast to adults, where TET2 represents a common pathogenic denominator, 
pediatric disorders seem to be driven by a distinct set of molecular events. TET2 
mutations are in fact rare in younger patients. TET2 aberrations were absent in 
juvenile myelomonocytic leukemia (JMML) 8 and precursor B-cell ALL 9, and were 
only found in 3,8% of childhood AML cases 9. Only one patient with childhood 
MDS/MPN has been described to harbor a TET2 mutation so far 10. 
Strikingly however, TET2 mutations were recently found in normal elderly 
individuals with clonal hematopoiesis without signs of hematological malignancy 11. 
This finding may indicate the presence of TET2 mutations already at a pre-disease 
stage which could further progress towards distinct myeloid disorders depending 
on the additionally acquired genetic defects.
2. the tet2 protein and its (dys) function
2.1 Function of the TET proteins
The TET2 protein belongs to a family comprising TET1, TET2 and TET3. Long before 
TET2 entered the stage, TET1 had already made a short appearance. In 2003 
Lorsbach et al. 12 reported TET1, i.e. the (10;11)(q22;q23) ten-eleven-translocation, 
thus giving the TET (ten-eleven-translocation) proteins their name, as novel fusion 
partner of the promiscuous MLL gene in a case of AML. 
Employing a bioinformatics approach, Iyer et al. 13 predicted that the TETs 
belong to the superfamily of 2OGFeDO dioxygenases. All three members 
share a homologous C-terminal region, the 2OGFeDO (2-oxoglutarate and 
Fe(II)-dependent dioxygenase) catalytic domain responsible for their enzymatic 
activity. Unlike TET2, TET1 and TET3 have a CXXC domain in their N-termini. The 
DNA-binding CXXC domain present in the TET proteins occurs in several other 
chromatin modifiers, a prominent representative being the maintenance DNA-
methyltransferase 1 (DNMT1) protein. Interestingly, TET2 lies in close proximity to 
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Figure 1. Hematopoiesis. Hematopoiesis (from Ancient Greek: haima blood; poiesis to 
make) is the process of blood cell formation. All mature blood cell types are progeny of 
the pluripotent hematopoietic stem cell (HSC). The conventional model of hematopoiesis 
represented in (A) has been widely accepted for over 30 years. It depicts blood cell 
development as a branching tree with two main trunks giving rise to either the CMP or the 
CLP. Myeloid cell production begins with the CFU-GEMM (colony forming unit that generates 
myeloid cells: granulocytes, erythrocytes, monocytes, megakaryocytes). The more restricted 
CFU-GM gives rise to granulocytes (neutrophils, eosinophils, basophils) and monocytes 
(which in turn can either become macrophages or myeloid-derived dendritic cells).  B-cells, 
A
B
Adapted from W. Lensch, daley.med.harvard.edu
Adapted from Ceredig et al. 4 
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the CXXC4 gene, implying that during evolution TET2 has lost its CXXC domain 
due to a local chromosomal rearrangement (Fig. 2). 
Iterative sequence analysis showed that TET proteins are the mammalian 
homologues of the Trypanosome JBP1/2 proteins. JBP1 and JBP2 are DNA-
modifying enzymes which catalyze the first step in the formation of base J (β-D-
glucosylhydroxymethyluracil), a modified thymine, present in trypanosomes. 
Similar to 5-methylcytosine (5mC) in mammalian DNA, base J has been associated 
with gene silencing. A landmark paper in 2009 by Tahiliani et al. 14 showed that 
TET1 is able to modify 5-methylcytosine in mammalian DNA by converting it into 
5-hydroxymethylcytosine (5hmc). Cells transfected with wild type TET1, but not 
a catalytic mutant form, displayed a decline in 5mC levels with a concomitant 
generation of 5hmC. In addition, in-vivo evidence demonstrated that the novel 
cytosine species is present in undifferentiated mouse embryonic stem cells (mESCs), 
and its levels decrease upon RNAi mediated depletion of endogenous TET1. 
T-cells and NK (natural killer) cells are all derived from the CLP. However, recent models 
have challenged this apparent dichotomy and proposed a less strict separation between 
the various routes the HSCs can take. The cyclical hematopoiesis model (B) proposed by 
the group of Geoffrey Brown 4 suggests that intermediate progenitors have both myeloid 
and lymphoid potential. Abbreviations used are: CLP (common lymphoid progenitor); CMP 
(common myeloid progenitor); ELP (early lymphoid progenitor); GMP (granulocyte–monocyte 
progenitor); HSC (hematopoietic stem cell); LMPP (lymphoid-primed multipotent progenitor); 
MBP (myeloid–B-cell progenitor); MEP (myeloid–erythroid progenitor); MPP (multipotent 
progenitor); MTP (myeloid–T-cell progenitor).
Figure 2. Schematic representation of the TET proteins. The TET protein family consists 
of three members (TET1, TET2 and TET3) which share a homologous C-terminal region. 
The C-terminal portion encodes the catalytic domain of the TET proteins, the 2OGFeDO 
(2-oxoglutarate Fe(II)-dependent dioxynegase domain). Box 1 and box 2 regions are highly 
conserved between all three TET paralogs, as well as in TET orthologs. Unlike TET1 and 
TET3, TET2 does not contain a CXXC domain.
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Back-to-back with the study of Tahiliani et.al, another report appeared, showing 
that 5hmC is also present in very high levels in mouse cerebellar Purkinje neurons 15.
These findings led to the “re-discovery” of 5hmC as a normal physiological 
constituent of mammalian DNA after its original discovery in 1953 16 remained 
largely neglected or failed to be reproduced by others, likely due to technical and 
methodological variations. 
2.2 TET2 in the active DNA demethylation pathway
Fine tuning of gene expression is mediated via the intricate interplay between 
genetic and epigenetic regulatory mechanisms.
Note 1
Epigenetics is the study of heritable changes in gene expression caused by 
mechanisms other than the underlying DNA sequence.
The epigenetic code consists of two main components: DNA methylation and histone 
modifications (Fig. 3). Whereas DNA methylation directly operates at the DNA level 
through the addition of a methyl group (-CH3) at the 5
th position of the cytosine 
pyrimidine nucleotide, histone modifications occur at the “tails” of histone molecules 
around which DNA is tightly wrapped. Together they form nuclear chromatin. Open 
chromatin allows for easy access of the RNA Pol II transcription machinery, hence 
signifying active gene expression, while compact chromatin ensures gene silencing.
DNA methylation is a crucial epigenetic mark associated with transcriptional 
repression, which has a broad range of regulatory roles in diverse biological 
processes. Cytosine methylation occurs prominently at promoter regions of genes 
within CpG islands (box 3). 
Box 3 
CpG dincleotides form CpG islands (CGIs). CGIs are short interspersed DNA 
sequences with an average length of 1000 base pairs which have an elevated G+C 
base composition (at least 55% GC content). Most, perhaps even all, are sites of 
transcription initiation and approximately 70% of the currently annotated gene 
promoters are associated with CGIs making them the most common promoter type in 
vertebrate genomes. CGIs are important regulatory structures where local changes 
of DNA and chromatin composition strongly influence transcription activation 
and repression. The CGIs of most genes are devoid of DNA methylation. CGIs 
may become methylated during normal development which leads to permanent 
silencing of the associated promoter 18-20. Abnormal promoter methylation is among 
the hallmarks of cancer.
18
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Figure 3. Components of epigenetic regulation. Cytosine methylation is mediated via the 
DNA-methyltransferases (DNMT1, the maintenance DNMT, and DNMT3a and DNMT3b, the 
de novo DNMTs). DNA methylation represses gene expression. The TET proteins (TET1, TET2, 
and TET3) further convert 5mC into 5-hydroxymethylcytosine (5hmC), an intermediate in the 
active DNA demethylation pathway. DNA is wrapped around histones to form nucleosomes. 
Each nuclesome consists of ~147 DNA bases wound around a histone octamer containing 
2 copies of each of the core histones, H2A, H2B, H3 and H4, as well as ~80bp of linker 
DNA and the H1 linker histone. Histones have N-terminal “tails” which are subject to a 
variety of modifications, such as acetylation, methylation, phosphorylation, ubiquitination 
and sumoylation. These modifications result in complex structural and functional alterations 
which either repress or activate the associated genes. DNA together with the histone proteins 
forms a higher order structure called chromatin, whose further compaction results in the 
formation of chromosomes.
Adapted from Qiu 17
In most mammals, 5mC is required for allele-specific expression of imprinted 
genes, transcriptional repression of retrotransposons, and X-chromosome 
inactivation in females 21. Disturbances in 5mC signatures are among the hallmarks 
of cancer initiation and progression. DNA methylation and the proteins which 
 
= 5mC  = 5hmC 
Chromosome 
Histone 
Histone tail 
DNA 
DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) 
TET proteins (TET1, TET2, TET3) 
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orchestrate this process have been the subject of extensive research. Once de novo 
methylation has been established by the DNA-methyltransferases 3a (DNMT3a) 
and 3b (DNMT3b), the pattern is faithfully maintained through cell divisions by 
DNMT1. DNMT1 is recruited to replication foci during S-phase of the cell cycle, 
where it preferentially binds hemi-methylated DNA to copy methylation marks onto 
the daughter DNA strands 22.
DNA methylation must be kept in balance for cells to function normally from 
the very conception of life. Mammalian germ cells undergo dynamic global re-
patterning of methylation signatures at two stages: upon fertilization in the zygote, 
and in primordial germ cells (PGCs), which are direct descendents of the sperm 
and oocyte. Currently, it is considered that these dramatic waves of demethylation 
and re-methylation allow the zygote to erase the epigenetic signatures inherited 
from the gametes (with the exception of parental imprinting) and regain a state 
of developmental totipotency. Notably, the loss of methylation occurring in the 
paternal pronucleus has been firmly linked to TET3 in the last few years 23,24. 
Parental imprint erasure, and subsequent re-establishment of genomic imprinting 
as to correspond the gender of the embryo in PGCs, also plays a central role in 
the restoration of developmental potential 25. 
Two main mechanisms exist for reversion of DNA methylation. Passive DNA 
demethylation is achieved by simply blocking methylation of the newly synthesized 
DNA strand during replication which results in the replication-dependent dilution 
of DNA methylation. Although several potential mechanisms for active DNA 
demethylation had been proposed, the process remained largely a mystery, as did 
the proteins responsible for it. An active DNA demethylation pathway could involve 
oxidative deamination of 5mC, which would result in the generation of a thymine, 
creating a guanine: thymine (G: T) mismatch on DNA. This would trigger the activity 
of the base excision repair (BER) machinery thus restoring unmethylated C, at 
the place of 5mC. The search for the mammalian DNA demethylase yielded a 
number of potential candidates, including the thymine DNA glycosylase (TDG) 
and the Growth Arrest and DNA Damage  (GADD45a) and GADD45b among 
others. However, evidence for the involvement of these proteins in active DNA 
demethylation remained controversial.
The discovery of the TET proteins and the product of their enzymatic activity, 
5hmC, put active DNA demethylation back in the limelight. Essentially two main 
mechanisms have been proposed involving the TETs and 5hmC: the deamination 
pathway and the oxidation pathway (Fig. 4).
Mice lacking the activation-induced cytosine deaminase (AID) exhibit significant 
defects in genome-wide DNA demethylation in primordial germ cells 26. A report 
from Bhutani et al. 27, demonstrated that promoter demethylation of the pluripotency 
genes OCT4 and NANOG during in vitro nuclear reprogramming was facilitated by 
AID. Notwithstanding, AID is unable to operate on dsDNA and deamination of 5mC 
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in vitro occurs at a very low rate as compared to unmethylated C 28,29.These results 
have raised the question, whether the involvement AID in active DNA demethylation 
occurs directly, or it requires an intermediate. In 2011 Guo et.al 30 provided evidence 
that upon overexpression of TET1 in HEK293 cells, there was a prominent increase of 
5-hydroxymethyluracil (5hmU), the product of 5hmC deamination. They suggested 
a model in which the TET proteins would first generate 5hmC through oxidation of 
5mC, which would subsequently be deaminated by the AID/APOBEC deaminases 
to yield 5hmU. Eventually, 5hmU would be excised by the BER machinery and an 
unmethylated C would be restored in DNA.
Adapted from Branco et al. 36
Figure 4. Active DNA demethylation pathways. Active DNA demethylation has been suggested 
to occur via two alternative mechanisms: the deamination and the oxidation pathway. 5hmC 
can be deaminated by the AID/APOBEC enzymes to generate 5-hydroxymethyluracil, 5hmU. 
Alternatively, 5hmC is oxidized by the TET proteins to its formyl-, and carboxyl- derivatives, 5fC 
and 5caC. 5hmU, 5fC and 5caC are all recognized as mismatched bases by the base excision 
repair (BER) machinery and excised by the thymine DNA glycosylase (TDG).
DNMTs TETs 
TETs 
BER (TDG) 
BER (TDG) 
C 5mC 5hmC 
5fC 5caC 
5hmU 
21
1In
tr
o
d
u
c
tIo
n
Shortly after these findings, an alternative pathway of DNA demethylation was 
reported by two independent groups. Ito et al. 31 hypothesized that 5mC could 
be oxidized first to 5hmC, and then further to the aldehyde 5-formylcytosine 
(5fC), and carboxylic acid, 5-carboxylcytosine (5caC), by the TET proteins. Using 
thin-layer chromatography (TLC) and mass spectrometric (MS) methods, they 
were indeed able to show the presence of all three oxidized cytosine species, 
5hmC, 5fC and 5caC, in genomic DNA of mouse ESCs. Knockdown of Tet1 in 
mESCs led to a decrease of all three nucleotides. Based on the same surmise, 
He et al.  32, demonstrated that purified TET2 incubated with 5mC and 5hmC 
substrates generated a product which eluted in HPLC at the same time as a 
chemically synthesized 5caC standard. DNA of HEK293T cells transfected with 
wild-type TET2, but not a catalytic mutant, also contained the oxidation derivative. 
Furthermore, incubation of TDG with 5hmC and 5caC –containing DNA substrates, 
showed that TDG was able to excise 5caC but not 5hmC. Ectopic expression of 
TDG in HEK293T cells diminished the amount of 5caC generated by the co-
transfected TET2 protein, while not affecting 5hmC levels. Depletion of TDG in 
mESCs resulted in reduced 5caC excision activity. Maiti and Drohat 33 provided 
biochemical evidence that TDG recognizes and rapidly excises 5fC and 5caC, yet 
it cannot remove 5hmC. 
Interestingly, a report by Nabel et al. 34 has challenged the plausibility of 
the deamination pathway. Purified AID/APOBEC had low deamination activity 
on 5mC as compared to unmodified cytosine, and no detectable deamination 
activity towards 5hmC. Furthermore, upon overexpression of AID/APOBEC, 5hmU 
was not found in genomic DNA, whereas the oxidation intermediates remained 
detectable. Further support of this notion came from another study 35 showing that 
AID was not capable of deaminating 5hmC likely due to the size of the modified 
cytosine i.e. AID’s enzymatic activity is inversely proportional to the electron cloud 
size of C5-cytosine making it an unlikely candidate in 5hmC removal from DNA. 
Hence, biochemical and cell based assays have confronted the feasibility of the 
deamination step. 
2.3 Genome-wide distribution of TET/ 5hmC and potential functions of 
DNA hydroxymethylation
The discovery of 5hmC posed somewhat of a technical puzzle, when it became 
clear that classical methods for detection of 5mC, such as bisulfite treatment and 
methylation sensitive restriction digestions 37,38 do not distinguish between 5mC 
and 5hmC. New tools were required in order to address the position and function 
of 5hmC in mammalian DNA.
A rapid succession of studies has accumulated mapping the position of 5hmC, 
and recently 5fC, in the genome and their putative role in the regulation of gene 
expression. Since these modifications represent < 1% of the nucleotides, as 
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compared to the normal DNA constituents (A, T, C and G), highly selective and 
sensitive methods for detection and quantification have been developed within 
a short time. Initially, chromatin immunoprecipitation (ChIP)-sequencing based 
approaches were employed, either making use of antibodies recognizing 5hmC 
itself, or by pulling down of 5hmC after chemical conversion. 
The groups of Helin and Zhang performed mapping of both TET1 and 5hmC in 
mouse ESCs 39,40. TET1 was detected with highest density around the transcription 
start sites (TSS) and within the gene bodies of 6,573 genes 39. Both studies 
confirmed the presence of TET1 at the TSS of pluripotency related genes and 
a highly significant overlap with bivalent domains regulated by polycomb group 
(PcG) proteins (box 4). 
Box 4
Besides DNA methylation, CGIs can also be silenced by the polycomb group 
proteins (PcG). Originally identified in Drosophila as regulators of the Hox genes, 
PcG proteins are evolutionary conserved epigenetic modifiers with repressive 
functions. There are two PcG complexes in mammalian cells, polycomb-repressive 
complex 1 (PRC1) and PRC2. PRC2 mediates the tri-methylation of lysine 27 of 
histone 3 (H3K27me3) which in turn recruits the PRC1 complex and leads to the 
inhibition of transcriptional elongation and/or chromatin compaction 41,42. In 
ES cells, CGIs silenced by the PRC2 complex possess the so-called “bivalent” 
domains. Those are marked by the active H3K4me3 modification, as well as by the 
repressive H3K27me3 mark 43. Bivalent domains in ES cells are located within the 
CGIs of developmental genes which are in a poised state for expression. Upon 
differentiation they provide a quick “on-off” switch between active transcription 
and stable repression.
Similar to TET1, 5hmC was found to be enriched at TSS with intermediate- 
and high- CpG content and in gene bodies. What was somewhat surprising, the 
predicted association of TET1 and 5hmC with active state of promoters, was 
disproved by both studies. Moreover, TET1 contributed to transcriptional silencing 
via direct interaction with the SIN3a co-repressor complex 39. 
An alternative approach for determining the position of 5hmC in the genome 
of mESCs was taken by Rao and colleagues. Two methods were developed 38 
utilizing chemical conversion of 5hmC and subsequent ChIP followed by genome 
sequencing. Both the GLIB (glucosylation, periodate, oxidation, biotinylation) 
and CMS (cytosine 5-methylenesulphonate) techniques detected 5hmC at the 
promoters of genes with “poised” chromatin configuration 38. 
Detailed re-assessment of the results generated by ChIP sequencing-based 
techniques 44,45, revealed that there was some degree of bias intrinsic to the 
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specific methodologies applied. For instance, anti-5hmC antibodies recognize 
more efficiently modification-dense regions 38, as well as CA repeats 40. To 
overcome the limitations of affinity-based genome-wide profiling, methods for 
single-base-resolution mapping of 5hmC have been developed. These have 
attempted to provide more accurate and quantitative information regarding 
the precise position of 5hmC in the whole genome. Making use of different 
properties of modified cytosines, two groups independently designed modified 
bisulfate sequencing approaches for single-nucleotide-resolution mapping of 
both 5mC and 5hmC 46,47. Booth et al. 42 made use of the fact that potassium 
perruthenate (KRuO4) specifically oxidizes 5hmC to 5fC which is subsequently 
deaminated under repeated bisulfite treatment. Consequently, in a DNA sample 
treated with KRuO4, 5hmC would be read as a thymine, whereas 5mC would 
be read as an unmodified cytosine. Oxidative-bisulfite sequencing (oxBS-Seq) 
is an elegant and simple approach allowing the concomitant detection of both 
5hmC and 5mC without a prior enrichment step. The second method designed 
by Yu et al. 43 is called TAB-Seq, standing for TET-assisted bisulfite sequencing. 
Briefly, 5hmC is protected from the activity of the TET proteins, by blocking 
it with glucose using the β-glucosyltransferase. Next, all 5mCs are oxidized 
by mouse tet1 to 5caC which subsequently undergoes deamination during 
bisulfite treatment. Upon DNA sequencing these bases are read as thymines. 
The only remaining cytosine signals, generated after Tab-Seq, stem from the 
protected 5hmCs. This technique also does not rely on an enrichment step 
preceding the procedure. Tab-Seq has uncovered some new features of 5hmC 
such as its significant enrichment at distal functional regulatory elements, its 
distribution near transcription factor-binding sites, and the sequence bias and 
strand asymmetry associated with 5hmC sites. 
TET2-binding sites on the genome were first reported by Chen et al. 48. ChIP-
sequencing was performed using anti-mouse Tet2 antibody in mESCs. The authors 
found that 47% of the 5hmC-positive genes were bound by Tet2. Most Tet2 targets 
were localized in intermediate- and high- CpG dense promoters, which were 
enriched for the active H3K4me3 mark. Unlike TET1, TET2 does not bind to the 
repressive SIN3a complex 39, but is prominently present in a complex with the 
O-linked beta-N-acetylglucosmaine transferase (OGT) protein 48. TET2 facilitates 
the binding of OGT to chromatin and hence regulates histone 2B O-GlcNAcylation, 
a mark associated with active transcription. These data suggest that TET1 and 
TET2 may antagonize each other in the regulation of gene transcription in ESCs. 
5fC and 5caC are continuous products of TET-mediated oxidation of 5hmC 
which are eventually excised by TDG to restore unmodified cytosines (see 2.2). The 
level of 5fC is about 10 fold lower than that of 5hmC in mESCs, and that of 5caC 
is yet 10 fold lower than that of 5fC. In fact, 5caC has so far only been detected 
in mESCs, but not in other tissues 31,49,50. Mapping of 5fC and 5caC poses an even 
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greater challenge, given these cytosine species have a low abundance, and are 
expected to be much shorter lived, as compared to 5hmC. Raiber et al. 51 used 
a biotin-streptavidin based pulldown approach to determine the genome-wide 
distribution of 5fC in ESCs. Similar to 5hmC, the distribution of 5fC followed a 
similar pattern and was primarily found in euchromatic regions, including CGIs, 
exons and promoters. 5fC was also associated with active gene expression, with 
5fC-rich CGI promoters corresponding to higher expression levels and presence 
of H3K4me3. 
Intriguing findings regarding the putative function of the oxidized derivatives 
of 5mC have recently been published 52,53. These studies attempted to identify 
specific readers of 5hmC, 5fC and 5caC in various cell types, including mESCs, 
neuronal progenitors and adult mouse brain tissue, through MS-based proteomic 
approaches. Several striking observations were reported. There was little overlap 
between the readers of the individual modifications in different cell types and 
tissues, indicating that these epigenetic marks may serve distinct cell-type- 
dependent roles. Few specific readers of 5hmC were detected, and those 
seemed to further confirm the role of DNA hydroxymethylation as an active DNA 
demethylation intermediate. Surprisingly however, a number of proteins, more than 
initially anticipated, were bound to 5fC and 5caC 52,53. Apart from proteins involved 
in DNA damage response and base-excision repair pathways, 5fC recruited a 
considerable amount of transcriptional regulators and proteins, which are unlikely 
to be a part of the DNA demethylation pathway. 
Further studies are required to clarify as to what extent, and if at all, the oxidized 
intermediates of 5mC function as stand-alone epigenetic marks.
2.4 TET2 in hematopoiesis: lessons from mice 
Upon the discovery of TET2 mutations in a multitude of hematological cancers, the 
question remained how the dysfunction of the protein deregulates hematopoiesis. 
Initially, Ko et al. demonstrated that genomic DNA obtained from bone marrow 
of patients carrying a TET2 mutation displayed consistently lower 5hmC levels as 
compared to bone marrow samples of healthy individuals 54,55. Overexpression of 
mutant TET2 proteins in cell lines further confirmed that TET2 defects perturb its 
catalytic activity 54,55. In addition, it was shown that shRNA-mediated depletion 
of Tet2 in mouse hematopoietic precursors skewed differentiation towards the 
monocyte/macrophage lineage in cultures 54.
To address the issue in vivo, several groups engineered Tet2 knock out (KO) 
mouse models. The group of Bernard 56 used two independent approaches, 
a gene-trap model inactivating tet2 at the ES cell level, and mice bearing a 
conditional Tet2 allele. A marked reduction of 5hmC levels was detected in cells 
where Tet2 was absent. Analysis of the hematopoietic compartments of the affected 
mice revealed an amplification of the Lin-Sca+Kit+ (LSK; hematopoietic stem cell) 
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pool. Compared to control animals, conditional Tet2 KO mice had increased 
absolute numbers of common myeloid progenitors (CMPs) and megakaryocyte-
erythrocyte progenitors (MEPs), but the granulocyte-macrophage progenitor 
(GMP) population remained stable. When transplanted, total bone marrow or 
purified LSK cells from the Tet2-deficient mice, were both able to reconstitute all 
hematopoietic lineages in wild-type recipient mice. Over time, the contribution of 
Tet2-depleted cells increased in both the myeloid and the lymphoid lineages, and 
an amplification of the LSK compartment was observed in some recipient animals. 
Eventually, the gene-trap animals developed bona fide myeloid tumors displaying 
CMML-like disease features which were transplantable to secondary recipients. In 
line with these data, Li et al. 57 also showed that the bone marrow of tet2-null mice 
had an enriched LSK population and diminished 5hmC levels. Moreover, within 
2-4 months these animals developed a CMML-resembling phenotype featuring 
persistent monocytosis, hepato- and splenomegaly and myeloproliferation. 
A  significant percentage of Tet2+/- and Tet2-/- animals progressed to lethal 
myeloid malignancies, such as CMML, MPN-like myeloid leukemia, myeloid 
leukemia with maturation and MDS. In addition, Tet2-depleted cells demonstrated 
an obvious proliferative capacity in serial transplantation assays. Similar results 
were also reported by Ko et al. 58 whose conditional Tet2 KO mouse model further 
strengthened the evidence that bone marrow of mice lacking Tet2 showed a clear 
expansion of the hematopoietic stem cell pool. Tet2-/- cells had an enhanced 
ability to reconstitute hematopoiesis in vivo relative to tet2 wild type cells. Finally, 
Tet2 posed a constraint on cells from undergoing differentiation as shown by 
expression of lineage specific markers. All studies also uniformly proved that 
although expressed, Tet1 and Tet3 are unable to compensate for the loss of Tet2, 
neither by overexpression (mRNA), nor by maintaining normal 5hmC levels in the 
affected cells. 
2.5 “Take your vitamins!” 
Vitamin C (= L-ascorbic acid) is a water-soluble compound with essential nutritional 
properties. Among other animal species, primates have lost the capability to 
synthesize vitamin C, and require its intake through diet. 
Although mainly popular for its antioxidant activity, vitamin C also serves as an 
electron donor to a number of enzymes, including DNA- and histone-modifying Fe 
(iron)-dependent oxidoreductases. Since most cell culture media do not contain 
vitamin C, the pivotal role of this compound in active DNA demethylation remained 
unacknowledged until a report appeared in 2010 showing that ascorbate can 
induce widespread demethylation in the epigenome of human ESCs 59. Yet, it took 
a few more years to establish a clear link between the TET enzymes and vitamin C.
Several reports appeared in 2013 60-62 demonstrating the direct role of vitamin C as 
an important co-factor of the TET proteins. As stated earlier in this introduction (2.1), TET 
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enzymes belong to the group of 2-oxoglutarate and Fe(II)-dependent dioxygenases 
(2OGFeDO). To convert 5mC into 5hmC, TETs utilize Fe(II) (also frequently denoted as 
Fe2+), as a co-factor, and 2-oxoglutarate (2-OG) as a co-substrate. Shortly, molecular 
oxygen (O2) is used for the oxidative decarboxylation of 2-OG into succinate and CO2, 
leading to the formation of intermediate Fe(IV)-oxo species that enable hydroxylation 
of the methyl group of the substrate. If that occurs, Fe(IV) is reduced back to Fe(II) 
after release of the succinate. However, in the absence of a substrate succinate is 
released without reduction of iron to Fe(II), resulting in the generation of catalytically 
inactive oxidized iron species and enzyme inactivation. Minor et al. 60 hypothesized 
that to maintain the enzyme fully active, ascorbate is required, to serve as an electron 
donor for the reduction of oxidized iron species. They showed that the addition of 
vitamin C, time- and dose- dependently, enhanced the formation of 5hmC in mouse 
embryonic fibroblasts, without affecting the expression of the Tet genes.
Simultaneously, Blaschke et al. 61 made the serendipitous discovery that 
knockout serum replacement (KSR: a defined, serum-free formulation optimized 
to grow and maintain undifferentiated ESCs in culture) promoted TET-dependent 
demethylation, accompanied by an increase in 5hmC levels in mESCs and 
upregulated expression of germ-line genes. A small molecule screen identified 
vitamin C as the component responsible for this effect. 
The relevance of vitamin C in the modulation of TET function and 5hmC 
levels should remain the subject of further exploration, more so in the light of the 
possibility to design vitamin C-based therapies for TET/5hmC-deficient cancers. 
3. acute myeloid leukemia (aml)
3.1 Definition and classification of AML
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous clonal 
hematopoietic malignancy which arises in precursor cells produced in the bone 
marrow. As a consequence of cytogenetic and molecular lesions, the affected cells 
lose their ability to differentiate into mature blood cells of the myeloid lineage but 
have increased proliferative and self-renewal properties. The immature leukemic 
cells, i.e. blasts, expand and eventually completely overwhelm the bone marrow and 
blood, suppressing normal hematopoiesis. Due to the lack of mature erythrocytes, 
monocytes, granulocytes and thrombocytes, AML patients suffer from anemia, 
and an increased risk of infection and bleeding. AML is among the most common 
forms of acute leukemia in adults, and its incidence generally increases with age 
with ~70 years being the median age of onset. In elderly patients, the disease often 
presents as an evolution from MDS, whereas in younger patients de novo AML is 
more common. AML affects males more often than females.
In the past three decades, major advances have been made in understanding 
the genetic origins of AML and implementing this knowledge in the diagnosis, 
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prognosis and treatment of patients. The revised World Health Organization (WHO) 
classification of acute myeloid leukemias from 2008 accordingly recognizes subtypes 
of AML as unique disease entities based on specific recurrent genetic abnormalities 
that predict prognosis and response to therapy. Approximately 50-60% of the 
AML patients have an abnormal karyotype. Cytogenetic abnormalities have been 
extensively investigated and their prognostic value has been determined by several 
independent studies 63. The most frequently observed karyotypic lesions and their 
impact on prognosis are listed in table 1.
table 1.  Prognostic classification of AML based on recurrent cytogenetic abnormalities
Favorable  prognosis Intermediate prognosis Unfavorable prognosis
t(15;17) Entities not classified as abn(3q) excluding t(3;5)
t(8;21) favorable or unfavorable inv(3)/ t(3;3)
inv(16) add(5q)/ del(5q)/ -5q
add(7q)/ del(7q)/ -7q
t(6;10)
t(10;11)
t(11q23) excluding t(9;11) 
and t(11;19)
t(9;22)
abn(17p)/ -17
Monosomal karyotype*
Adapted from Grimwade et al. 63 
* at least two autosomal monosomies, or a single monosomy accompanied by at least one other structural 
chromosomal abnormality 64
3.2 Common genetic mutations in AML
Nonetheless, AML patients with normal cytogenetics (CN-AML) still comprise the 
largest subgroup of AML patients (~45%) 65 which poses a particular complication in 
terms of prognostication and taking optimal treatment steps. Attempts to resolve 
this have resulted in the rapid identification of a myriad of new molecular markers in 
AML allowing for a more genetically-oriented risk stratification of patients, deeper 
understanding of the basic biology of AML, and the development of new targeted 
forms of therapy. Among the most frequently affected genes are FLT3 (25%), NPM1 
(25-35%) CEBPa (10-15%), and RAS (10-15%) (Table 2). 
The fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase which plays an 
important role in governing normal hematopoiesis. Flt-3 alterations include internal 
tandem duplication (ITD) of the juxtamembrane domain, as well as mutations in the 
tyrosine kinase domain (TKD) of the protein. AML patients who carry a FLT3-ITD 
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have a worse prognosis 66,67 and the significance of FLT3-ITD as an independent 
poor prognostic factor has been established by multiple studies 67,68. Unlike ITD, 
FLT3-TKD mutations are rarer and do not appear to have an adverse effect on 
prognosis 69. The flt-3 pathway is an obvious target for the development of small 
molecule inhibitors that block the constitutive activation of the mutant protein and 
some are already in clinical and preclinical development 70. For instance, quizartinib 
(AC-220) and midostaurin (PKC412) have shown promise in certain AML subgroups 
in phase II/III clinical trials, and sorafenib has been reported to show a prominent 
activity against FLT3-ITD positive AML 71. 
Nucleophosmin 1 (NPM1) mutations, despite being among the most frequent 
genetic aberrations in AML (25-35% in AML; 50-60% within the subgroup of 
cytogenetically normal CN-AML), were discovered no earlier than 2005 72. Albeit 
rare, NPM1 was already known to be a translocation partner of several proteins, 
among which RARa 73 in acute promyelocytic leukemia (APL). This prompted further 
research which led to the key publication by Falini and colleagues 72, describing 
the aberrant cytoplasmic, instead of nuclear, localization of NPM1 in patients with 
table 2. Prognostic significance of recurrent genetic mutations in AML
Gene Incidence Prognostic impact Gene function
NPM1 25-35% Favorable Nuclear import, apoptosis
FLT3-ITD 20-25% Unfavorable Growth factor receptor
DNMT3a 20-23% Unfavorable Epigenetic regulation
MLL 10-15% Unfavorable Epigenetic regulation
N/K-RAS 10-15% Intermediate Signal transduction
CEBPa 10-15% Favorable 
(bi-allelic mutations)
Transcription factor
CBFB-MYH11 Inv(16)(p13q22) 10% Favorable Transcription factor
AML1-ETO t(8;21)(q22;q22) 10% Favorable Transcription factor
TET2 8-13% Unfavorable Epigenetic regulation
IDH2 6-10% Unclear Metabolism
PML-RAR  t(15;17)(q22;q21) 5-10% Favorable Transcription factor
ASXL1 5-10% Unfavorable Epigenetic regulation
RUNX1 5-10% Unfavorable Transcription factor
FLT3-TKD 5-7% Intermediate Growth factor receptor
WT1 3-10% Unclear/unfavorable Transcription factor
IDH1 3-9% Unclear Metabolism
PTPN11 3-5% Intermediate Signal transduction
C-KIT 2-6% 
(high in CBF leukemia)
Unfavorable 
in CBF leukemia
Growth factor receptor
CBL <2% (16% in inv16) Unclear Signal transduction
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AML caused by mutations affecting exon 12 of the gene. The presence of NPM1 
mutations is generally considered a favorable prognostic factor, in the absence 
of FLT3-ITD 74. 
CCAAT/enhancer-binding protein alpha (CEBPa) is a transcription factor which 
plays a critical role in myeloid development. Mutations of CEBPa are associated with 
significantly better outcome in CN-AMLs, only in the case of biallelic aberrations 75. 
Like NPM1, the group of CEBPa mutated AML patients, is now defined as a 
provisional entity with unique genetic characteristics in the refined version of the 
2008 WHO classification of myeloid neoplasms and acute leukemias 76. 
Activating mutations in the N- and K-RAS proto-oncogenes occur in 10-15% 
of AML and do not appear to significantly affect survival 65, although one study 
has shown that RAS positive leukemic cells may be more sensitive to high-dose 
cytarabine treatment 77.
4. epigenetic deregulation in aml
For over a decade, the classical two-hit model of leukemogenesis dominated 
the hemato-oncology field 78. Essentially, it stated that at least two genetic 
events affecting different classes of proteins were required to drive malignant 
transformation of the hematopoietic progenitors. Class I genes, affecting 
proliferation, provide the transformed clone with growth advantage, whereas class 
II genes, involved in differentiation, alter the execution of normal myelopoiesis. 
Although useful, this model is likely oversimplified and has been challenged 
over the years through the discovery of novel classes of mutations in myeloid 
neoplasia 79, such as mutations affecting RNA splicing, which have recently been 
discovered in MDS 80. Another distinct group are genetic defects perturbing 
epigenetic regulation, either at the DNA level (DNA (de)methylation), or at the 
histone level (various histone modifiers). 
4.1 DNA-methyltransferases (DNMTs) in AML
Aberrant DNA methylation profiles are a hallmark of leukemia. Promoter 
hypermethylation inactivates a number of tumor suppressor genes involved 
in a variety of cellular processes and signaling pathways to promote cancer 
proliferation. Of note, methylation state is not only useful as a biomarker, but it 
has also been associated with prognosis and treatment response. For instance, 
hypermethylation of the Wilms tumour (WT)1 gene in AML has been shown to 
correlate with a chemotherapy resistant phenotype 81. Furthermore, AML patients 
display heterogeneous patterns of methylation of the cyclin-dependent kinase 
(CDKN)2B 82. The methylation signature of CDKN2B marks disease progression 83. 
In 2001 Mizuno et al. 84 showed that DNMT1, DNMT3a and DNMT3b are all 
overexpressed in AML patients, as well as in cells of patients in acute phase chronic 
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myeloid leukemia (CML). DNMT1 and DNMT3b are specifically overexpressed in 
AMLs with CDKN2B hypermethylation suggesting involvement of these proteins in 
the aberrant repression of the cyclin kinase. In CML, overexpression of the DNMTs 
seems to correlate with disease evolution, as normal levels of the DNMTs are 
present in chronic phase CML, which increase upon progression to blast crisis CML.
Interestingly, following deep sequencing of the genomes of two AML patients 
with normal karyotype, the group of Ley 85 discovered a frameshift mutation in 
the DNMT3a gene. Sanger sequencing of a cohort of 281 AML patients identified 
DNMT3a defects in 22,1% of the cases. The most commonly affected amino acid 
was R882, although nonsense, missense, frameshift and splices-site aberrations 
were found in other portions of the protein as well. Moreover, DNMT3a mutations 
represented an independent poor prognostic factor in AML; they were significantly 
correlated with FLT3 and NPM1, and cytogenetically normal AML, as well as 
AML- M4 and AML-M5 FAB subtype. DNA methylation was measured by liquid 
chromatography (LC) - tandem mass spectrometry (MS) but revealed no differences 
between wild type and DNMT3a mutant cells. MeDIP analysis showed decreased 
DNA methylation at 182 loci but there was no consistent correlation with the 
expression of the respective neighboring genes.
Shortly after, Yan et al. 86 reported the identification of somatic mutations 
in DNMT3a upon exome sequencing of acute monocytic leukemia (AML-M5) in 
20,5% of the cases. Additional screening of other AML FAB subtypes affirmed the 
presence of DNMT3a mutations in AML-M4 as well. Patients with aberrant DNMT3a 
had inferior overall survival. In vitro data suggested reduced enzymatic activity of 
the mutant DNMT3a protein and reduced affinity to histone H3. Of note, DNA 
methylation and gene expression patterns were altered (e.g HOXB genes) in cases 
bearing a mutation as compared to wild type counterparts. 
At present, the precise mechanism(s) through which DNMT3a mutations 
contribute to leukemogenesis remains unclear. Most aberrations found in 
patients are heterozygous suggesting that haploinsufficiency is capable of driving 
myeloid transformation. However, in vitro studies using purified protein do not 
properly reflect the in vivo situation where the wild type allele is still present. 
Studies assessing the effect of DNMT3a mutations on genome 5mC levels are 
conflicting 85-87. Several scenarios seem plausible. DNMT3a mutations may inhibit 
the unaffected allele in a dominant negative fashion, since DNMT3a is known to 
form oligomers. Alternatively, they may disturb interactions with other proteins, 
such as DNMT3L. DNMT3L is a shorter form which lacks methyltransferase activity, 
but increases the binding of DNMT3a to certain loci 88,89. 
Surprisingly, conditional disruption of either DNMT3a or DNMT3b in mouse 
CD34- LSK cells did not affect hematopoiesis. Nevertheless, conditional 
depletion of both DNMT3a and DNMT3b did. The de novo methyltransferases 
were essential for self-renewal, but not for differentiation, in hematopoietic 
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cells. Cells lacking both DNMT3a and DNMT3b retained myeloid and lymphoid 
lineage differentiation potential but were incapable of long-term reconstitution 
in transplantation assays 90. More recently, Goodell and colleagues showed that 
conditional ablation of DNMT3a in the hematopoietic system impaired HSC 
differentiation over serial transplantations and resulted in an expansion of the 
stem cell population in the bone marrow 91. In this model, both hypomethylation 
and hypermethylation of CpG islands were found. DNMT3a-null animals showed 
an upregulation of multipotency genes whereas transcription factors were 
downregulated. 
Provided the role of DNMT3a mutations in AML, as well as the combined 
contribution of both de novo methyltransferases in leukemia mouse models, it came 
as no surprise when a role for DNMT3b in AML was established. Sequence analysis 
showed the absence of acquired mutations in DNMT3b. However, overexpression 
of DNMT3b in 192 de novo AML patients was an independent indicator of poor 
survival 92,93. 
4.2 The metabolic enzymes connection 
In 1924 Otto Warburg postulated his famous hypothesis, stating that metabolic 
insults are the fundamental cause of cancer. Nowadays, deregulation of multiple 
oncogenes and tumor suppressors is known to alter metabolism and induce aerobic 
glycolysis 94. Little did Warburg know at the time, that mutations in metabolic 
enzymes themselves would turn out to be more multifaceted than expected. 
Two key publications appeared in 2009, showing the frequent involvement of 
the isocitrate dehydrogenase 1 (IDH1) and IDH2 in cancer. Yan et al. 95 reported 
hotspot mutations affecting IDH1 in 70% of glioma patients and to a lesser extent 
IDH2. Mardis et al. 96 found IDH1 mutations in 8,5% of AML patients. The overall 
prevalence of IDH1 and IDH2 mutations in AML was ~20%. In contrast to gliomas 
where IDH1 mutations were more frequent, in AML IDH2 mutations were more 
common suggesting a potentially different oncogenic effect of IDH in gliomas 
versus AML 97.
The IDH1 and IDH2 are NADP(+)-dependent metabolic enzymes which catalyze 
the oxidative decarboxylation of isocitrate into alpha-ketoglutarate (α-KG, also 
2-oxoglutarate 2-OG). IDH1 is located in the cytoplasm and peroxisomes, whereas 
IDH2 is a mitochondrial component of the Krebs cycle (TCA cycle). Initially, thought 
to have a dominant-negative effect, IDH mutations turned out to have a neomorphic 
activity instead. The defective proteins gain the novel function of converting α-KG 
into the R(-) enantiomer of 2-hydroxyglutarate (further on referred to as simply 
2-HG). The build-up of the onco-metabolite 2-HG was not restricted to cell extracts 
but was also found to rapidly accumulate in the medium of cells expressing the 
mutant forms 98. Elevated 2-HG has been found both in cells and serum of AML 
patients 97,99,100. 
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The most common IDH1 mutation affects amino acid 132, an arginine residue 
(R132) in the active site of the enzyme. The mitochondrial homolog, IDH2, bears two 
hotspot substitutions affecting the analogous R172 residue, and R140 which has also 
been predicted to bind and orient α-KG in the active site 81. IDH aberrations are always 
heterozygous retaining one healthy allele. Since IDH proteins exist as homodimers, 
the mutant allele promotes NADPH-dependent reduction of α-KG provided by the 
wild type allele to generate 2-HG 98. Elevated 2-HG however, is not exclusive to IDH 
transformed tumors. Toxic accumulation of the R(-), as well as the S(-) stereoisomers 
of 2-HG have also been observed in patients carrying rare germ-line mutations in the 
D(R)- and L(S) -2 hydroxyglatarate dehydrogenases, D- and L- 2HGDH respectively. 
Interestingly, some L-2HG aciduria patients develop brain tumors. Although brain 
cancer has not been reported in D-2HG aciduria individuals, D-2HG aciduria follows 
a more severe clinical course and patients likely succumb before gliomas can form 
101-103. This explanation may also be a valid reason why hematological disorders have 
never been reported in patients suffering from this inborn error of metabolism. Of 
note, in previously unexplained D-2HG aciduria patients lacking mutations in the 
D-2HGDH enzyme, IDH2 mutations appeared to be causative 104.
In 2010 Figueroa et al. 105 showed that the dominant feature of bone marrow 
CD34+ AML cells with mutated IDH1/2 was hypermethylation of a subset of 
promoters. The DNA hypermethylation signature was similar between IDH1 and 
IDH2 mutant AMLs suggesting a shared pathogenic mechanism in the epigenetic 
deregulation of gene expression. Ectopic expression of IDH1 R132 and IDH2 
R172 mutants in HEK293T cells led to a significant increase in 5mC levels. As the 
TET proteins utilize α-KG (= 2-OG), Fe(II) and molecular oxygen as co-factors in 
the generation of 5-hmC, the potential link between IDH mutations and TET2 
mutations soon became evident (Fig. 5). Moreover, TET2 and IDH aberrations 
mutually exclusive, yet again alluding that alterations in these proteins perturb 
a common biological pathway 105. Co-transfection of TET2 with mutant IDH1/2, 
but not the wild type proteins, inhibited the formation of 5hmC in HEK293T cells. 
In addition, TET2 and IDH1/2 hypermethylation signatures in AML overlapped.
Later, a conditional knock-in (KI) IDH1 (R132H) mouse model was generated by 
Sasaki et al. 106. The mutant form was inserted either in all hematopoietic cells or in cells 
of the myeloid lineage specifically. Analogous to the phenotype of TET2 KO mice (see 
section 2.4), the bone marrow of IDH1 KI animals was eventually overgrown by immature 
hematopoietic progenitors (LSK cells and lineage-restricted progenitors, LRK cells). 
Expression arrays performed on sorted LSK cells from KI and control animals, showed 
alterations in a set of genes related to cellular growth and proliferation. A significant 
amount of CpG sites was aberrantly methylated demonstrating the hypermethylator 
activity of the IDH1 R132 mutant in vivo. The WNT, Notch, and TGF-β pathways which 
are all targeted by promoter and intragenic hypermethylation in IDH1/2 mutant AML 
cells were also implicated in the IDH1 KI mouse model. 
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Notwithstanding, the proof-of-principle studies linking the production of 2-HG 
with the functional inhibition of the TET enzymes, placed IDH mutations in a much 
broader context. 
TET proteins, as mentioned in section 2.1, belong to the superfamily of 
2-oxoglutarate and Fe(II)-dependent dioxygenases (note 2). 
Note 2
2-oxoglutarate and Fe(II)-dependent dioxygenases are a class of enzymes that are 
conserved in eukaryotes and bacteria. They catalyze a variety of reactions typically 
involving the oxidation of an organic substrate using a dioxygen molecule, mostly 
using ferrous iron Fe(II) as the active site co-factor and 2-OG as a co-substrate which 
is decarboxylated to succinate and CO2.
Mammalian cells express over 60 dioxygenases that utilize α-KG (= 2-OG) as a co-
substrate among which the TET enzymes, and JmjC-domain containing histone 
demethylases (JHDMs) 107-109. The JmjC demethylases demethylate mono-, di-, 
and tri- methylated lysine residues on histone H3 110,111. 2-HG produced by IDH 
mutants does not only inhibit the TETs but also multiple histone demethylases in vitro 
and in vivo 112. Overexpression of IDH1 R132 in a glioma cell line led to the visible 
Figure 5. 2-HG is a competitive inhibitor of the TET proteins. IDH1 and IDH2 convert 
isocitrate into α-KG (= 2-OG), either in the cytosol (IDH1) or in the mitochondria during the 
Krebs cycle (IDH2). Whereas the wild type IDH proteins supply α-KG to the TET enzymes, 
the mutants gain the novel function of further processing α-KG into 2-hydroxyglutarate 
(2HG). 2-HG accumulates in the affected cells, as well as their surrounding environment, 
and competes with α-KG for binding at the same active sites
DNMTs TETs 
IDH1/2 mut IDH1/2 wt 
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increase in H3K4me1, H3K27me2, H3K4me3, H3K9me2, and H3K79me2 levels which 
was reversible upon the addition of cell permeable α-KG. Furthermore, a panel 
of human glioma samples with or without IDH1 mutation was tested. H3K79me2 
was significantly elevated in tumors carrying an IDH1 defect. Later, Lu et al. 113 
investigated the effects of IDH mutants and 2-HG on differentiation using 3T3-L1 
cells as a model. Upon stimulation with a differentiation cocktail, immortalized 
murine 3T3-L1 cells undergo extensive chromatin remodelling leading to their 
maturation into adipocytes. Transduction of these cells with either IDH2 R172 or IDH2 
R140 mutant resulted in a block in differentiation, which was not the case for cells 
transduced with wild type IDH2. Furthermore, cell permeable 2-HG alone was able 
to induce the same phenotype. Gene expression analysis of cells transduced with 
IDH or treated with 2-HG showed a profound defect in the expression of transcription 
factors essential for adipocyte-lineage commitment. Biochemical data revealed an 
increase in H3K27me3 and H3K9me3. In addition, the authors tested normal human 
astrocytes transduced with IDH1 R132 and demonstrated that long-term cultures 
displayed a profound elevation of H3K9me3 and CpG DNA methylation. 
Taken together, a body of evidence has been compiled examining the wide-
range defects induced by IDH mutations in cancer cells. Given that 2-HG not only 
accumulates in cells but also in the surrounding environment, an important question 
still remains to be addressed. It would be of tremendous interest to determine 
whether 2-HG excreted by the leukemic cells is able to penetrate nearby healthy 
cells and tissues thus modifying their transcriptional program. Notably, both in 
MDS and AML local changes in the hematopoietic niche are present and complex 
interactions between the transformed cells and their microenvironment exist 114.
4.3 Histone modifiers in AML
Epigenetic deregulation due to mutations in histone modifiers is not a rare event. 
Mixed-lineage Leukemia (MLL)-rearranged leukemias bearing chromosomal 
translocations involving chromosome 11q23 represent ~10% of the adult AML 
cases. There are over 60 known fusion partners of MLL (among which TET1, see 
section 2.1) which correlate with disease phenotype and prognosis albeit the 
presence of MLL defects generally confers poor prognosis 115. MLL belongs to 
the trithorax group (TrxG) of chromatin modifiers and it regulates the expression 
of Hox genes which play a critical role in hematopoiesis 116,117. The MLL protein 
contains an N-terminal DNA binding domain, and a C-terminal SET domain with 
H3K4 methyltransferase activity 118,119. Biochemical studies have identified MLL as a 
member of a large multiprotein complex that contains other chromatin remodelling 
proteins, such as histone deacetylases (HDACs) and components of the Swi/Snf 
chromatin-remodelling complex 103. All translocations involving MLL appear to 
produce a fusion protein possessing the N-terminal portion of MLL fused in frame 
to the C-terminus of the fusion partner120. Essentially, MLL retains its DNA binding 
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capability but is bereft of its methyltransferase activity. Pathways targeted by MLL 
fusions include DNA methylation, histone acetylation and histone methylation 115.
A member of the PRC2 complex (see box 4, section 2.3) has recently been 
implicated in myeloid malignancies. The Enhancer of Zeste Homologue 2 (EZH2) 
is an H3K27 methyltransferase. Mutations and overexpression of EZH2 have both 
been reported in AML. Alterations of wild type EZH2 expression in MDS/AML 
have in addition been associated with inferior outcome 121. Intriguingly, EZH2 
harbors both activating and loss-of-function mutations suggesting its transforming 
contribution as both an oncogene and a tumor suppressor. Initially, the gain-of-
function Y641 mutation was detected in patients with germinal-centre diffuse 
large-B cell lymphoma 122 and it was further demonstrated that indeed both di- and 
tri- methylation of H3K27 were increased 123. Later, recurrent nonsense, missense 
and frameshift aberrations were identified in patients with MDS 124, CMML and 
primary myelofibrosis (PMF) 125. In-vitro data have shown that those are likely 
inactivating126. Mutations of EZH2 in AML are in fact rare 127,128. 
Although infrequent mutations and/or chromosomal rearrangements involving 
other histone (de)methylases, such as NSD1 (H3K36 methyltransferase), JARID1A 
(KDM5a, lysine demethylase) and UTX (KDM6b, H3K27 demethylase) have also 
been reported 129.
4.4 Epigenetic therapies in MDS and AML
As more and more whole AML genomes are being sequenced, a few progressive 
concepts have emerged: 1) The list of the recurrent “culprits” is now (almost) 
complete; 2) Leukemia arises as a multistep process following the evolution 
of a single transformed clone which expands, but despite what was initially 
believed, this clone carries only a few driver mutations and a snapshot of multiple 
“by-standers”. This essentially means that mutations are accumulated in the 
hematopoietic cells of healthy individuals as a result of aging. The AML genome 
thus already contains a number of mutations that were present before the initiating 
pathogenic event. The transformed clone(s) accumulates additional insults 
yielding subclones that can contribute to disease progression and/or relapse 130. 
Pappaemmanuil et al. even suggest the possibility of genetic “predestination”, 
meaning that early genetic insults set cancer clones on a certain path of clonal 
evolution by limiting the repertoire of cooperating lesions. Moreover, the number 
of driver mutations correlates with the outcome of patients 131; 3) A necessity 
arises to translate our knowledge of the genetic background of AML into targeted 
forms of therapy. 
The reversible nature of epigenetic marks makes them a very promising target 
for the development of novel therapies, especially within the group of elderly 
patients, where aggressive treatment regimens and hematopoietic stem cell 
transplantation (HSCT) are not advisory and treatment options remain limited. 
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Several drugs aimed at both DNA methylation and histone modifications have 
been approved for use in patients, and many are currently undergoing assessment 
stages in clinical trials. The first three epigenetic therapeutics included two DNMT 
inhibitors (DNMTi), namely azacitidine (5-aza = Vidaza) and its deoxy- derivative 
decitabine (5-aza-2’ deoxycitidine), as well as the histone deacetylase (HDAC) 
inhibitor (vorinostat). Both 5-aza and decitabine are analogues of the naturally 
occurring pyrimidine cytidine. They are believed to exert their anti-neoplastic 
effect through two mechanisms: cytotoxicity through incorporation into DNA 
and/or RNA, and DNA hypomethylation through covalent binding to the DNMT1 
protein resulting in its inhibition 132,133. Whereas 5-aza incorporates to a larger extent 
into RNA rather than DNA, decitabine can only incorporate into DNA. Although 
the precise mechanism of action of DNMT and HDAC inhibitors remains elusive, 
they have shown promising clinical response in high-risk MDS and AML patients 134. 
Due to their lower toxicity, as compared to traditional chemotherapeutics, DNA 
hypomethylating agents are often a preferred and safer alternative for frail patients. 
Considering the implications of TET2 mutations in myeloid malignancies on 
DNA methylation, it has been hypothesized that treatment of patients carrying TET2 
aberrations with hypomethylating agents may be beneficial. A small retrospective 
study from Itzykson et al. 135 conducted in 86 patients with high-risk MDS and 
low blast count AML, showed that TET2 mutated cases had an 82% improved 
response rate versus 45% in TET2 wild type patients. However, response duration 
and overall survival were comparable between the two groups. In contrast, another 
study reported that TET2 alterations rather predicted decreased responsiveness 
to hypomethylating agents in MDS 136. Sekeres et al. 137 assessed the efficacy of a 
treatment regimen combining lenalidomide and azacitidine in a cohort of 36 MDS 
patients. The authors claimed that patients with mutations affecting the methylation 
pathway achieved complete remission (CR) more often than patients without 
these mutations. However, such a claim is an overstatement, considering only 
4 of the 36 patients carried a mutation in a gene involved in DNA (de)methylation 
(TET2, DNMT3a, IDH1/2). The small numbers of patients and the incomplete 
characterization of patient characteristics must be taken into account regarding 
the aforementioned reports. Larger studies with well-defined parameters and 
homogeneous patient groups will prove to be much more informative in assessing 
the potential benefits of DNA hypomethylating agents in patients carrying not only 
TET2, but also IDH1/2 and DNMT3a mutations. 
Hypermethylation of various histone lysine residues as a consequence of 
mutations in histone methyltransferases, histone demethylases and IDH1/2, have 
prompted attempts to target histone methylation in myeloid cancers. Among the 
most auspicious therapeutic compounds currently undergoing clinical assessment 
is EPZ-5676, a DOT1L inhibitor targeting MLL-rearranged leukemias. The four most 
frequent MLL translocations (MLL-AF4, MLL-AF9, MLL-AF10 and MLL-ENL) result 
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in the recruitment of the disruptor of telomeric silencing 1 (DOT1L) to the fusion 
protein and consequentially an increase in H3K79 methyltransferase activity. 
EPZ-5676 is the first histone methyltransferase (HMT) inhibitor to enter clinical 
development. A phase I trial has been initiated in September 2012 (Epizyme). 
EZH2 mutations result in gain- or loss-of-function affecting H3K27 methylation. 
Moreover, the H3K27 demethylase, UTX, has also been implicated in some of 
the same disorders as EZH2, providing a strong rationale for the development 
of targeted therapies aiming at H3K27 methylation. In fact, compounds able to 
pharmacologically inhibit EZH2 are already being explored 138-140.
outline of this thesis
The main objective of this thesis was to investigate in-depth the clinical significance, 
as well as the biological (dys)function of the novel epigenetic regulator TET2. As 
30% of MDS patients eventually progress to AML, the first aim of this project was to 
determine the significance of TET2 mutations on survival of AML patients, and how 
these abrogate the function of the TET2 protein. Chapter 2 describes the study 
of TET2 mutations in 357 de novo AML patients who were enrolled in the EORTC/
GIMEMA 06991 clinical trial. We show that TET2 mutation is an independent factor 
of poor prognosis in AML. Aberrant TET2 expression may also negatively affect 
overall survival of AML patients. Furthermore, we demonstrate that TET2 defects 
result in a loss of its DNA hydroxymethylation activity. Finally, we hypothesize 
that mutations affecting DNA hydroxymethylation (TET2, IDH1, IDH2) and DNA 
methylation (DNMT3a) likely cooperate during leukemogensis, based on their 
significant co- occurrence in patients. 
In Chapter 3, the levels of 5-hydroxymethylcytosine in the same cohort of 
patients were determined (whenever possible), and correlated to clinical outcome. 
A highly quantitative HPLC-tandem MS method was developed and employed 
to measure 5hmC in genomic DNA. TET2 and IDH1/2 mutations clearly caused 
a significant decrease in DNA hydroxymethylation. Of note, 5hmC levels varied 
within a wide range. To exclude the effect of TET2 and IDH1/2 defects on overall 
survival, the study further focused on AML patients who were wild type for these 
aberrations. Unlike patients with intermediate levels, patients with high 5hmC levels 
had an inferior prognosis. In addition, high 5hmC content was strongly associated 
with the presence of AML1-ETO and MLL1 translocations.
Chapter 4 of this manuscript poses the question whether 5hmC, like its preceding 
mark, 5mC, is maintained faithfully during cell division. In-depth analysis of TET 
(TET1, TET2, TET3) mRNA and protein expression in G0/G1, S (early, mid, late) and 
G2/M phases of the cell cycle, showed no significant changes. However, HLPC-MS-
based measurements indicated that unlike 5mC levels, which remained stable due 
to the activity of DNMT1, 5hmC levels declined in late S and G2/M phases of the 
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cell cycle. This means that 5hmC is not copied immediately during DNA replication. 
We hypothesize that 5hmC, unlike 5mC, is not a stand-alone epigenetic mark, but 
a mere intermediate along the DNA demethylation pathway, and its formation is 
a consequence of pre-exisiting conditions, such as DNA methylation and histone 
modifications, rather than faithful maintenance during cell cycle. 
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abstract
We assessed the prognostic impact of TET2 mutations and mRNA expression 
in a prospective cohort of 357 adult AML patients <60 years of age enrolled in 
the EORTC/GIMEMA AML-12 06991 clinical trial. In addition the co-occurrence 
with other genetic defects and the functional consequences of TET2 mutations 
were investigated. TET2 mutations occurred in 7.6% of the patients and were an 
independent marker of poor prognosis (p=0.024). TET2 and IDH1/2 mutations 
strongly associated with aberrations in the DNA methyltransferase DNMT3A. 
Functional studies confirmed previous work that neither nonsense truncations, 
nor missense TET2 mutations induced 5-hydroxymethylcytosine formation. In 
addition, we now show that mutant TET2 forms did not act in a dominant-negative 
manner when co-expressed with the wild-type protein. Finally, as loss-of-function 
TET2 mutations predicted poor outcome, we questioned whether low TET2 mRNA 
expression in cases of AML without TET2 mutations would affect overall survival. 
Notably, also AML patients with low TET2 mRNA expression levels showed inferior 
overall survival.
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introduction 
Recently, a number of novel recurrent alterations have been described in adult 
AML, among which a group of epigenetic modifiers including TET2, ASXL1, BCOR, 
DNMT3A, IDH1 and IDH2 [1,2]. Verifying the relevance of these new genes as 
prognostic markers is crucial before they can be implemented into clinical practice 
to improve risk-adapted treatment. Understanding the molecular biological 
consequences of genetic mutations allows the development and application 
of targeted forms of therapy, aiming at the impaired proteins or the biological 
pathways they are involved in. TET2 aberrations occur in various myeloid neoplasms. 
Mutations were found in 20-25% of myelodysplastic syndromes [3,4], 10-15% of 
myeloproliferative neoplasms [5], and up to 50% of chronic myelomonocytic 
leukemias [6]. In AML, TET2 mutations affect 7-10% of the adulthood cases [3-5] and 
1.5-4% of pediatric cases [7,8]. The impact of TET2 mutations on clinical outcome in 
AML is still controversial. In some studies, TET2 mutations correlated with inferior 
survival, particularly in the subgroup of cytogenetically normal AML, whereas in 
other studies no prognostic impact of TET2 mutations was observed [9-15]. So 
far, few prospectively collected cohorts have been analyzed for the impact of 
TET2 mutations using multivariate analysis, and including the currently established 
genetic and other prognostic parameters [10-12, 14].
Several studies based on mouse models have shown that inactivation of 
TET2 in myeloid cells induces a myeloproliferative syndrome, confirming the 
role of TET2 mutations in the pathogenesis of myeloid malignancies [16-18]. The 
TET protein family comprising TET1, TET2 and TET3, belongs to the group of 
2 oxoglutarate (2OG)-and Fe(II)-dependent dioxygenases, and is involved in a 
novel epigenetic modification, namely the conversion of 5-methylcytosine (5mC) 
into 5-hydroxymethylcytosine (5hmC) [19]. TET proteins further oxidize 5hmC to 
formyl- and carboxylcytosine (5fC and 5caC). 5fC and 5caC are recognized by the 
thymine-DNA glycosylase (TDG), and replaced by unmodified cytosines through 
the DNA repair machinery [20,21]. Mapping of TET protein binding sites and 5hmC 
on the genome has shown that they localize to the transcription start sites of 
genes, suggesting a role for the TETs in the regulation of gene expression through 
modification of chromatin at promoter regions [22-24]. 
In this study, we assessed the incidence and clinical impact of TET2 mutations 
in a prospective cohort of 357 AML patients who were treated uniformly according 
to the EORTC/GIMEMA AML-12 06991 clinical trial protocol. We determined the 
co-occurrence of TET2 mutations with other molecular markers. In addition, the 
function of different TET2 isoforms and TET2 mutants was tested in cell line models. 
Finally, mRNA levels of TET2 were measured and correlated to survival.
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materials and methods 
Patients
Bone marrow samples from 357 patients included in the EORTC/GIMEMA 06991 
AML-12 [25] clinical trial NCT0004128 (1999- 2009) were obtained at diagnosis. 
Informed consent was obtained from all patients included in the study. To avoid 
bias, consecutive patients from the larger participating centers were included in 
the analysis. Median age was 46 years (range 15-60 years) and median follow-up 
was 5.63 years. The study was approved by the Institutional Review Board of the 
Radboud University Nijmegen Medical Centre and all aspects of this study abided 
by the principles laid out in the declaration of Helsinki. All patients had untreated 
newly diagnosed AML, ≥ 30% blast cells in bone marrow smears, and represented 
all AML FAB subtypes, except AML-M3. Briefly, the AML-12 trial assessed the value 
of high vs. standard dose Ara-C during induction, as well as IL-2 after intensive 
consolidation/auto-SCT. 
Q-PCR and mutational analysis 
For Q-PCR analysis RNA was isolated from healthy donor-derived G-SCF-mobilized 
CD34+ cells, or patient-derived bone marrow or peripheral blood mononuclear cells. 
mRNA levels of TET2 isoform 1 and isoform 2, TET1 and TET3 were determined as 
previously described [3,4]. DNA sequencing of TET2 isoform 1 (NM_001127208.2) was 
performed as described [3]. cDNA sequencing primers are listed in Supplementary 
Table S1. EVI1, IDH1 R132, IDH2 R140 and R172 detection was performed as 
described [26,27]. Direct DNA sequencing of DNMT3A (ENST00000264709) was 
performed on exons 7-23 either by Sanger sequencing (primer sequences listed 
in Supplementary Table S2) or 454-based next generation sequencing (454 Life 
Sciences, Branford, CT, USA) [28].NGS data were analyzed using R453Plus1Toolbox, 
GS Variant Analyzer Software 2.6 (454 Life Sciences, Branford, CT) and Sequence 
Pilot version 3.5.2 (JSI Medical Systems, Kippenheim, Germany)[29]. NPM1 and FLT3 
mutation analyses were developed previously [30,31].
Statistical analysis 
Overall survival (OS) was computed from the date of registration in the EORTC 06991 
study until death (whatever the cause) or until last follow-up (censored observation). 
Survival distribution of OS was estimated according to the Kaplan-Meier technique. 
The Cox Proportional Hazards Model was used to determine the prognostic 
importance of each factor analyzed and to obtain hazard ratio (HR) estimates as 
well as corresponding 95% confidence intervals (95% CI). All statistical analyses 
were performed according to the intention-to-treat principle. Being a prognostic 
factor analysis, only eligible patients were included. For contingency tables, the 
significance of a relationship between categorical 2 variables, the Fisher exact test 
was used. Statistical analyses were performed by using SAS® (Cary, USA). 
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Plasmids used for overexpression in cell line models
N-terminally tagged eGFP-TET2 isoform 1 plasmid was kindly provided by 
Dr. O. Bernard. TET2 isoform 1 (NM_001127208.2), TET2 isoform 2 (NM_017628.4), 
TET2 catalytic domain (a.a. 1104 – a.a. 2002), TET2 box 2 (a.a. 1789-a.a. 2002) 
sequences were cloned into pDONR201 using the Gateway cloning technology 
(Life technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
The entry vectors were further transferred into a Gateway based pDest733 [32] 
{Relaix, 2004 #374}destination vector to create N-terminal mRFP fusion proteins. 
TET2 mutant sequences were generated using the QuikChange XL site-directed 
mutagenesis kit (Stratagene, Agilent technologies, CA, USA) as recommended by 
the manufacturers and cloned into pDONR201. The entry vectors were used for 
transfer into pDest733 and pDest501 Gateway-based expression plasmids [35] to 
create N-terminal mRFP and eCFP fusions, respectively. 
Cell culture, transfection and immunofluorescence 
COS-1 cells were grown in Iscove’s Modified Dulbecco’s Media (IMDM) (Life 
technologies) supplemented with 10% fetal calf serum and penicillin and 
streptomycin. Cells were transfected with Lipofectamin 2000 reagent (Life 
technologies). Proteins were expressed for 20-24h. Subsequently, cells were fixed 
with 4% PFA for 20 min, washed extensively with PBS and permeabilized with 
0.5% Triton X-100 in PBS for 5 min. To allow detection of 5hmC, cells were treated 
with 2M HCl for 20-25 min. HCl was neutralized with 100mM Tris-HCl for 10 min 
(pH=8), followed by extensive washing with PBS. A blocking step was performed 
with 5%BSA in PBS/Tween for 30 min. Afterwards, samples were incubated with 
a primary antibody against 5hmC (Active motif, CA, USA; 1:500 dilution) for 2h at 
RT, and subsequently washed with PBS. To allow primary antibody detection, the 
following secondary antibodies were used: Alexa 488 (Life technologies; 1:500 
dilution) or Alexa 350 (Life technologies; 1:50 dilution). Samples were mounted with 
Vectashield with DAPI or Antifade Prolong Gold (in the case of Alexa 350). Samples 
were analyzed with a Leica DMBRE (type 301-371.011) microscope. Images were 
taken at 40x or 100x magnification using a DC350F (10447116) camera and Leica 
FW4000 acquisition software (Leica Microsystems, Wetzlar, Germany). 
results
TET2 mutations correlate with poor overall survival in AML in univariate 
analysis 
Bidirectional Sanger sequencing of the entire TET2 coding region, and the splice 
donor and acceptor sites, revealed mutations in 27/357 (7.6%) of the patients (for 
detailed patient characteristics see Table 1; localization of mutations is depicted in 
Supplementary Fig. S1). In 19 of the cases, mutations affected one allele, whereas 
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table 1. Clinical and molecular characteristics according to TET2 mutation status in 357 adult AML 
patients (Continued)
TET2 mutation Correlation 
to TET2 
mutation
(p-value)
Hazard ratio
(95% CI)
p-value 
(Wald test)No (N=330) Yes (N=27)
N (%) N (%)
Type of AML de novo
secondary
311 (94.2) 27 (100) 0.38
19 (5.8) 0 (0.0)
Sex Male 160 (48.5) 13 (48.1) 0.97
Female 170 (51.5) 14 (51.9)
Age (years) at 
diagnosis
Median 45.0 54.0
Range 15.0 - 60.0 24.0 - 59.0
15-25 36 (10.9) 1 (3.7) 0.015 1.0 0.05 
26-45 133 (40.3) 6 (22.2) 1.33 (0.79, 2.25)
46-60 161 (48.8) 20 (74.1) 1.71 (1.03, 2.85)
WHO-ECOG 
performance 
status
PS 0 181 (54.8) 13 (48.1) 0.65 1.0 0.11
PS 1 119 (36.1) 12 (44.4) 0.89 (0.66, 1.19)
PS 2 22 (6.7) 1 (3.7) 1.30 (0.76, 2.23)
PS 3-4 8 (2.4) 1 (3.7) 2.03 (0.99, 4.17)
WBC (x109/l) at 
diagnosis
Median 21.5 32.1
Range 0.5 - 319.6 1.1 - 240.8
< 25 183 (55.5) 13 (48.1) 0.69 1.0 0.44
25-99.9 105 (31.8) 10 (37.0) 1.16 (0.86, 1.56) 
>= 100 42 (12.7) 4 (14.8) 1.09 (0.72, 1.64)
FAB subtype M0 13 (3.9) 1 (3.7) 0.06 1.0 0.16
M1 87 (26.4) 2 (7.4) 1.21 (0.55, 2.65)
M2 93 (28.2) 9 (33.3) 1.18 (0.54, 2.59)
M4 60 (18.2) 3 (11.1) 0.91 (0.40, 2.08)
M5 65 (19.7) 11 (40.7) 1.53 (0.69, 3.37)
M6 6 (1.8) 1 (3.7) 2.23 (0.75, 6.64)
M7 1 (0.3) 0 (0.0) 4.72 (0.58, 
38.64)
Unknown 5 (1.5) 0 (0.0) -
Cytogenetic 
risk group
Good 41 (12.4) 0 (0.0) 0.004 1.0 <0.0001
Intermediate 
(NN,-Y) 
111 (33.6) 15 (55.6) 2.63 (1.40, 4.97)
Others 73 (22.1) 1 (3.7) 3.17 (1.65, 6.11)
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table 1. Clinical and molecular characteristics according to TET2 mutation status in 357 adult AML 
patients (Continued)
TET2 mutation Correlation 
to TET2 
mutation
(p-value)
Hazard ratio
(95% CI)
p-value 
(Wald test)No (N=330) Yes (N=27)
N (%) N (%)
Poor (-5/5q-,-
7/7q-, Complex)
29 (8.8) 1 (3.7) 6.16 (3.01, 
12.60)
UNK/ND/Failure 76 (23.0) 10 (37.0) -
NPM1mutation No 224 (67.9) 13 (48.1) 0.03 1.0 0.67
Yes 102 (30.9) 14 (51.9) 0.94 (0.70, 1.25)
Unknown 4 (1.2) 0 (0.0) -
FLT3-ITD No 254 (77.0) 19 (70.4) 0.48 1.0 <0.0001
Yes 73 (22.1) 8 (29.6) 2.39 (1.78, 3.20)
Unknown 3 (0.9) 0 (0.0) -
FLT3-TKD No 294 (89.1) 22 (81.5) 0.31 1.0 0.19
Yes 30 (9.1) 4 (14.8) 0.73 (0.46, 1.17)
Unknown 6 (1.8) 1 (3.7) -
IDH1 mutation No 288 (87.3) 24 (88.9) 0.24 1.0 0.08
Yes 28 (8.5) 0 (0.0) 1.50 (0.96, 2.36)
Unknown 14 (4.2) 3 (11.1) -
IDH2 mutation No 278 (84.2) 22 (81.5) 1.0 1.0 0.49
Yes 36 (10.9) 2 (7.4) 0.86 (0.55, 1.33)
Unknown 16 (4.8) 3 (11.1) -
IDH mutation No 254 (77.0) 22 (81.5) 0.28 1.0
Yes 62 (18.8) 2 (7.4) 1.07 (0.76, 1.51) 0.69
Unknown 14 (4.2) 3 (11.1) -
EVI1 
overexpression
No 103 (31.2) 7 (25.9) 1.0 1.0 0.0004
Yes 7 (2.1) 0 (0.0) 3.94 (1.75, 8.88)
Unknown 220 (66.7) 20 (74.1) -
DNMT3A 
mutation
No 50 (15.2) 6 (22.2) 0.02 1.0 0.04
Yes 18 (5.5) 9 (33.3) 1.73 (1.01, 2.99)
Unknown 262 (79.4) 12 (44.4) -
Abbreviations: CI, confidence interval; WBC, white blood cell count; PS, performance status;
ITD, internal tandem duplication; TKD, tyrosine kinase domain
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in 8 patients two TET2 aberrations co-existed, suggesting bi-allelic inactivation (for 
detailed patient characteristics of TET2 mutated patients see Table 2). In univariate 
analysis, the various cytogenetic subtypes showed the expected correlations 
with overall survival, with the t(8;21) and inv(16) translocations correlating with 
a good prognosis, and -5, -7 and complex karyotypes signifying poor outcome 
(Supplementary Fig. S2A). NPM1 mutations did however not have prognostic 
impact (Supplementary Fig. S2B). In line with published data, the presence of a 
FLT3-ITD mutation correlated with inferior clinical outcome (p<0.0001), whereas 
a FLT3-TKD mutation associated with intermediate or slightly better survival 
(Supplementary Fig. S2C and S2D). Furthermore, EVI1 overexpression was strongly 
associated with inferior prognosis (Supplementary Fig. S2E, p=0.0004). 
The presence of a TET2 mutation correlated with poor overall survival (Fig. 1A, 
p=0.025). IDH2 mutations did not show a significant effect on overall survival 
(Fig. 1C), whereas a trend towards poor prognosis was present in patients with 
an IDH1 mutation (Fig. 1D, p=0.075). Finally, DNMT3A mutations also predicted 
unfavorable outcome (Fig. 1B, p=0.04).
table 2. Characteristics of TET2 mutated patients. Additional molecular markers that were assessed are: 
FLT3-ITD, FLT3-TKD, IDH1, IDH2, DNMT3A, NPM1 mutation, and EVI-1 overexpression. (Continued)
UPN1 TET2 mutation by sequencing Cytogenetics
FLT3-ITD, FLT3-TKD, IDH1, 
IDH2, DNMT3A, NPM1, 
EVI1 overexpression
Nonsense
Frameshift/
In-frame deletion
Missense/
Splice site
36 p.S1039L 46,XX IDH2 R172L, DNMT3A 
p.F640Y
98 p.R1359H 46,XY NPM1
171 p.A31T 46,XX -
329 p.P1115LfsX2 46,XX NPM1, FLT3-ITD, DNMT3A 
IVS9-1G>T
356 p.N275IfsX18 46,XX FLT3-ITD, DNMT3A 
p.R882C
3622 p.R1896M 46,XX,t(4;7)(q24;q21) 
[19]/ 46,XX [1] 
NPM1, FLT3-TKD
379 p.Q255X Failure -
404 p.Q414X Unknown -
729 p.S358R 46,XY NPM1
791 p.I1873N 45,XY,-7,del(20)(q11) -
8062 p.P929LfsX24
p.S137VfsX8
46,XY NPM1, FLT3-ITD, DNMT3A 
p.D252X
858 p.L956V Failure NPM1, FLT3-ITD
879 p.Q742K Unknown NPM1, FLT3-ITD
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Association of TET2 mutations with other prognostic features including 
molecular and cytogenetic markers
TET2 mutations correlated with older age, and were almost exclusively present 
in the group of cytogenetically normal AML (Table 1). We found no association 
between TET2 mutations and performance status or WBC at diagnosis. There 
was, however, an association between TET2 mutations and FAB subtype (p=0.06). 
TET2 mutations were less frequent in AML-M1, and enriched in AML-M5 patients. 
NPM1 and TET2 defects were significantly correlated (p=0.03), whereas FLT3-ITD 
table 2. Characteristics of TET2 mutated patients. Additional molecular markers that were assessed are: 
FLT3-ITD, FLT3-TKD, IDH1, IDH2, DNMT3A, NPM1 mutation, and EVI-1 overexpression. (Continued)
UPN1 TET2 mutation by sequencing Cytogenetics
FLT3-ITD, FLT3-TKD, IDH1, 
IDH2, DNMT3A, NPM1, 
EVI1 overexpression
Nonsense
Frameshift/
In-frame deletion
Missense/
Splice site
893 p.I750_K753 46,XY -
1062 p.I1873N 46,XY -
12662 p.G1869E
IVS2-2A>G
46,XX NPM1, FLT3-TKD, DNMT3A 
(p.N501S; p.R882H)
1398 p.H850R 46,XY NPM1, FLT3-ITD, DNMT3A 
p.R882H
1456 p.Q831TfsX15 46,XX FLT3-ITD, DNMT3A 
p.R882H
15522 p.Q917X Failure -
16122 p.C1378R
p.P1419R
Failure -
1744 p.R1572W Failure -
1832 p.T621SfsX13 46,XX NPM1, FLT3-TKD
1879 p.T1397I 46,XX NPM1
19152 p.S1758X p.T1554SfsX16 Failure NPM1, FLT3-TKD
19282 p.Q749X p.D1384N 46,XY NPM1, DNMT3A IVS9del 
-18_+1
1965 p.S1246L Failure NPM1, FLT3-ITD, DNMT3A 
p.R882H, IDH2 R140Q
21122 p.R1261H
p.R1359S
Failure -> FISH:
MLL (11q23) 
rearrangement negative; 
1 extra MLL signal 
[44/150] and 2 extra MLL 
signals [74/150]
-
1 UPN indicates unique patient number
2 indicates patients with more than one affected TET2 allele, based on the occurrence of two separate TET2 
mutations, or a homozygous mutation as observed in the Sanger sequencing results, pointing to LOH by 
(micro) deletions or uniparental disomy.
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2 Sep 2011    14:49
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TET2wt 
TET2mut 
p= 0.025 
TET2 
and FLT3-TKD aberrations were often present together with TET2 mutations but 
their co-occurrence did not reach statistical significance. TET2 and IDH mutations 
seldom co-existed in the same patient as may be expected since IDH mutations 
abrogate the activity of TET2 [33]. Notably, both TET2 and IDH mutations strongly 
correlated with the presence of a DNMT3A mutation (p=0.02 and p=0.004 
respectively). Patients who carried DNMT3A aberrations together with either a 
TET2 or an IDH mutation, very frequently had an additional FLT3-ITD.
TET2 mutations represent an independent marker of poor prognosis in 
AML
Cox regression analysis was performed to determine whether TET2 mutations 
represent an independent marker of poor prognosis. In multivariate analysis, 
adjusting for age, cytogenetic/FLT3-ITD risk group, NPM1 mutation, AML type, 
institution, and stratifying by treatment arm, TET2 mutations remained an 
independent predictor of inferior survival (p=0.01, HR = 1.86, 95% CI: 1.15 – 3.00. 
Within the poor-risk group of patients carrying a FLT3-ITD and/or a high-risk 
cytogenetic profile (-5, -7, complex), which conferred the expected poor overall 
survival, the presence of an additional TET2 mutation defined a subgroup of 
patients with an even more dismal prognosis (Fig. 2A, p=0.033). NPM1 mutations 
had only a minor effect towards favorable outcome in the cytogenetically normal 
Figure 1. Univariate analysis assessing the effect of mutations in genes implicated in the 
DNA (hydroxy)methylation pathway. TET2 (A) DNMT3A (B) IDH1 (C) and IDH2 (D).
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O N Number of patients at risk : TET2_mutation
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Overall Logrank test: p=0.061
TET2wt 
TET2mut 
p= 0.061 
TET2 
subgroup without FLT3-ITD (Supplementary Fig. 2B). Also within the NPM1 
mutated group, TET2 mutations conferred a trend towards worse survival (Fig. 2B, 
p=0.061). Finally, as DNMT3A and TET2 mutations frequently co-occurred (Table 1), 
and DNMT3A mutations correlated with inferior survival (Fig. 1B), we tested what 
the effect of TET2 mutations would be in the context of a concomitant DNMT3A 
mutation. Also in the DNMT3A mutated subgroup, the presence of a TET2 mutation 
further exacerbated the poor prognosis of patients (Fig. 2C, p=0.066). Treatment 
with standard or high dose Ara-C did not alter the effect of TET2 mutation, as 
these mutations remained a poor indicator of prognosis in both patient groups 
(Supplementary Fig. S3).
Functionality of different TET2 splice- and truncation variants
Although studies so far have always focused on the longest isoform of TET2 
(isoform 1), there are three major TET2 transcripts that may be expressed in cells, 
as we previously showed [3] (Supplementary Fig. S4A). The shorter isoforms lack 
the catalytic domain and their function remains unknown. The expression levels of 
isoform 1, and of the shorter form, isoform 2, are comparable. Furthermore, isoform 
2 is reminiscent of some of the truncation mutants found in patients [3]. To investigate 
whether isoform 2 exhibits dominant-negative features, we tested its effect on 
the capacity of isoform 1 to generate 5hmC. Several expression constructs were 
created that contained TET2 isoform 1, TET2 isoform 2, the catalytic domain (CD), 
and the second conserved region of the catalytic domain (box 2) (Supplementary 
A
C
Figure 2. Kaplan-Meier survival 
curves of cytogenetic and genetic 
subgroups. An unfavorable effect of 
TET2 mutations on overall survival was 
observed within the (A) cytogenetic 
high risk and/or FLT3-ITD positive 
patients (B) NPM1 mutated and (C) 
DNMT3A mutated patients. 
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Fig. S4B). To monitor expression, all proteins were N-terminally fused to mRFP 
(monomeric red fluorescent protein). COS-1 cells were transiently transfected 
with each of the expression vectors and immunostaining was performed using 
an antibody specific for 5-hydroxymethylcytosine. Expression of isoform 1 and 
the isolated catalytic domain resulted in a clear formation of 5hmC. Isoform 2 
and the isolated, conserved box 2 showed no enzymatic activity (Supplementary 
Fig. S4C). Importantly, co-expression of isoform 2 with isoform 1 did not inhibit 
the generation of 5hmC (Supplementary Fig. S4D), implying that isoform 2 does 
not exhibit dominant-negative properties.
TET2 mutations result in loss of function and are not dominant-negative
Mutations in TET2 are scattered throughout the entire coding region of the gene 
and may result in the production of truncated proteins, as well as single amino acid 
substitutions. In-vitro studies and mouse models have suggested that likely all TET2 
mutations lead to loss of function. Moreover, in patients, despite the presence of 
a wild type allele, DNA hydroxymethylation is strongly reduced [34]. It remains 
however possible that the mutant protein inhibits the function of the wild-type 
allele in a dominant-negative fashion. To test this, six mutant TET2 sequences were 
cloned into expression vectors, each N-terminally fused to mRFP. Two nonsense 
mutations were selected that delete either both conserved boxes (R506X)—hence 
the whole catalytic domain—or yield a protein containing only the first conserved 
box (box 1), causing a partial deletion of the catalytic domain (S1758X). Additionally, 
four missense substitutions were generated, two in box 1 (R1214W and R1261L) 
and two in box 2 (I1873T and H1881Q) (Fig. 3A). All six mutants, including the 
single amino acid substitutions, lost the capability to generate 5hmC (Fig. 3B). 
Furthermore, co-expression of GFP-tagged wild-type TET2 with each of the mutant 
proteins did not result in loss of hydroxymethylation, indicating that, with respect 
to the formation of 5hmC, the mutants are not dominant negative (Fig. 3C).
Effect of wild-type TET2 on survival of AML patients
As diminished TET2 function appears to be the mechanism through which 
mutations in this gene contribute to oncogenesis, and patients who carry TET2 
mutations show a significantly worse overall survival, we tested whether the 
Figure 3. TET2 mutant proteins show impaired catalytic activity, but do not exhibit dominant-
negative features when co-expressed with wild-type protein. (A) Localization of TET2 
mutations found in patients with myeloid malignancies used for functional testing. Two 
of the mutants result in truncated proteins lacking either both conserved boxes within the 
catalytic region, or only the second conserved box, whereas the rest of the mutants result in 
missense substitutions in the conserved boxes. All aberrations leading to amino acid changes 
have been confirmed either by us or other as true acquired somatic mutations. The H1881Q 
mutation targets an Fe (II)-binding site in the catalytic domain of TET2. (B) Mutant forms of 
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-2002 AA TET2 isoform 1 box1 box2 
conserved box 1: AA 1104-1447  
conserved box 2: AA 1844-1950 
R506X S1758X R1214W 
R1261L 
I1873T 
H1881Q 
Catalytic domain 
A
B C
TET2 found in patients are unable to produce 5hmC unlike wild-type protein. Constructs 
contain an N-terminal mRFP tag. Images were taken at 40x magnification. (C) mRFP-tagged 
mutant forms of TET2 do not act in a dominant-negative manner over wild-type GFP-TET2. 
Images were taken at 100x magnification
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expression levels of isoforms 1 and 2 of TET2 may impact clinical outcome in 
patients without a TET2 or IDH mutation. The mRNA levels of both isoforms 
varied between different patients. No significant differences in expression were 
observed between patients with and without a TET2 mutation (Supplementary 
Fig. S5A). When compared to mRNA levels of TET2 in CD34+ cells, AML patients 
showed expression levels that were distributed in a wider range (Supplementary 
Fig. S5B). The median levels of TET2 expression in patients were similar to those 
measured in healthy CD34+ control cells. There was no difference in overall 
survival when TET2 isoform 2 expression was considered (Fig. 4B). In contrast, 
overall survival analysis showed that low TET2 isoform 1 expressers had an inferior 
clinical outcome (Fig. 4A p= 0.05). 
discussion 
The prognostic significance of TET2 mutations in AML patients has been 
controversial. Initially, Abdel-Wahab et al.[9] showed an association with poor OS in 
a smaller, retrospective study, whereas Nibourel et al. [13] reported no correlation 
between TET2 mutational status and clinical outcome, albeit in a pre-selected 
group of de novo AML patients achieving complete remission. Consequently, 
studies involving larger cohorts of patients were explored. Shen et al. [14] found 
no prognostic significance for TET2 mutations in 605 de novo AML patients who 
had no other recognizable karyotypic abnormalities except 11q23, and Metzeler 
et al. [12] identified TET2 mutations as a predictor of inferior survival in favorable-
risk cytogenetically normal primary AML patients, as defined by the European 
LeukemiaNet (ELN) guidelines. Chou et al. [10] defined TET2 aberrations as a 
marker of poor prognosis in AML patients of intermediate risk, and Weismann et al. 
[15] also showed a negative impact of TET2 mutations on survival in favorable-risk 
Figure 4. Aberrant expression of the wild-type TET2 isoform 1 has a negative impact on 
overall survival (A), whereas the TET2 isoform 2 expression has no effect on survival (B).
A B
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AML patients with normal cytogenetics. Most recently, [11] Gaidzik et al. did not find 
a prognostic impact of TET2 mutations in 330 cytogenetically normal AML patients. 
In the current study, we show a negative prognostic impact of TET2 mutations in 
a sizeable, prospectively studied cohort of adult AML patients <60 years of age. 
The negative effect of TET2 mutation on overall survival was present in various 
risk groups. In accordance with previous reports, TET2 mutations were significantly 
associated with older age. In addition, TET2 alterations were reported in normal 
elderly individuals with clonal hematopoiesis [35] and TET2 mutations were shown 
to be present in a pre-leukemic stage of leukemia evolution [36]. Furthermore, 
TET2 mutations are found in many different subtypes of myeloid malignancies. This 
suggests that cells carrying TET2 defects may clonally expand, but that additionally 
acquired mutations mostly determine the subtype and severity of the disease that 
eventually causes clinical problems. 
It has previously been noted that TET2 and DNMT3A mutations co-occur in 
T-cell lymphomas [37]. In AML, a correlation between IDH and DNMT3A has been 
observed in AML [14]. In the present study, we show that both TET2 and IDH 
mutations were enriched in patients who also carried a DNMT3A defect. Although 
DNMT3A mutations conferred poor prognosis (in line with previous work [38]), the 
additional presence of TET2 alterations in these patients defined a subgroup with a 
particularly unfavorable outcome. As established earlier, TET2 and IDH mutations 
were mutually exclusive since both groups of mutations perturb a common 
biological pathway [33,39,40]. The high incidence of DNMT3A mutations in both 
of these groups is highly indicative of a cooperative mechanism through which 
mutations impairing DNA hydroxymethylation and DNA methylation contribute to 
leukemogenesis. Further functional characterization of this interaction in in vivo 
models is necessary and may provide important insights into targeted therapies 
aimed at the DNA (de)methylation pathway within patients with this particular 
genetic profile. 
Testing of TET2 mutations in vitro [34], as well as in mouse models consistently 
points to a loss-of-function phenotype [16-18,41]. This is further supported in this 
manuscript. In addition, we show that TET2 mutants do not suppress the function 
of the wild-type protein, and hence do not show dominant-negative traits. As 
mRNA levels of TET2 in AML patients varied over a wide range compared to 
normal hematopoietic cells, this raised the possibility that the level of TET2 mRNA 
expression could be relevant in patients who do not carry loss-of-function mutations 
of the TET2 gene. Analysis of the effect of wild-type TET2 expression on clinical 
outcome in patients without TET2 or IDH mutations demonstrated that patients 
with low levels of TET2 expression had a worse overall survival. We conclude that 
both loss-of-function mutations and low expression of TET2 are markers in of poor 
prognosis in AML indicating that the development of therapies targeting the DNA 
hydroxymethylation pathway could be beneficial for these patients. 
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Supplementary methods
table s1. Primers used for cDNA sequencing of TET2
Exon Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
3 CAGTTTGCTATGTCTAGGTATTCCGA TGTGCGTTTTATTCCTCCATTTT
3 CAGAATAGTCGTGTGAGTCCTGAC GCAATGGAAACACAATCTGGA
3 GAACACACACATGGTGAACTCC AATTGTGATGGTGGTGGTGG
3 TCCAGGGAACCACAAAGCTAG GCTTGAGGTGTTCTGACATTGG
3 ACATGTATGCAGCCCTTCTCC GGGAATCTGCTCTTTGTTGAAA
3 ACCAACATCTCCAGTTCCAA ATGCACTTGATTTCATGGTCT
3 CAAATGGGACTGGAGGAAGT GTTTGCTGCTGTTCTTGCTT
3 CAGAAGGACACTCAAAAGCATG TTGCTGCTCTAAAGCTGGG
3 GAGAATCCACCTGCAAGCTG TTTCACAAGACACAAGCATCG
3- 6 GAGCAGGTCCTAA TAAGCTGCTTGGGGATGACC
6- 9 TGTACTACAATGGATGTAAGTTTGCC GACTTGCCGACAAAGGAAACTAGA
9-10 AAGTCAGGATGTTAGCAGAGCCA GGCTTTTGAATCAGAATACCCAA
10 CCAGCCCTATGAACTTCTATTC CCATAACTACAGTGCAGCTCCG
10 CAAACATGGACTATAAAAATGGTGAAC CACCAGGATCTCCCTCGTCTT
10 GCCGTGGCTCCAACTCAT GGCAGTGGGGAAAGGTCAC
table s2. Primers used for Sanger sequencing of DNMT3A exon 7 till 23
Exon Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
7 CTAATTCCTGGAGAGGTCAAGGTG AGATGGAGAGAGGAGAGCAGGAC
8 TCTTGCCTCATTCAGATGGAGC CCTGGGATCAAGAACCTTCCC
9 GTGCTTGCAAGTGTAAGCCTCG CCTGCACTCCAACTTCCAGG
10 GCCTTCCAGCCTGTCCTGA CCAACTCTACGGTTCTAGCCAAC
10- 11 GCCTTCCAGCCTGTCCTGA GTACACCAGCCGCTCTGCA
11- 12 GTTGGCTAGAACCGTAGAGTTGG CTAAGTGCCTCTGCTACTCTGCC
13 GTTCGAGACTGGGGTCACAGT AGAAGCGGTGGACACAGTCAG
14 GGTCATGTCTTCAGGGCTTAGG TGCTACCTGGAATGGAAAGACC
15 TTTCCATTCCAGGTAGCACACC AGGCTCCTAGACCCACACACC
16 AGGGTGTGTGGGTCTAGGAGC GCTGTGAAGCTAACCATCATTTCG
17 GTGGGGTAGAATTGTAGCAGGA ATGAACAAAATGAAAGGAGGCAA
18- 19 TTCCTGTCTGCCTCTGTCCCT CAGCAGTCCAAGGTAGAAGCCA
20 ATTAACCATTCAGCTCCTCAATCAC TGCAGTCCCAGCCCACAG
21 GTTATGACGTGTGTGCGTGATT CCTGCACCGTCTCCTAAATTG
22 GTTTGGCGAGTACCTGGCATATT GGAAAACAAGTCAGGTGGGAAAG
23 CTGCTGTGTGGTTAGACGGCTT TGCAATAACCTTCTTGTTTCAGTCA
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nonsense & frameshift mutations 
missense & in-frame deletions  UPN 
   UPN 
conserved box 1: AA 1104-1447
conserved box 2: AA 1844-1950
-2002 AA TET2 isoform 1 box1 
356 329 36 
box2 
1928 1879 
806 1915 
171 
1928 1456 
1266 791 362 1398 1965 
1915 
893 467 
806 
1266 
404 
879 
1552 1832 
858 
379 
2112 
1612 
729 1744 
1062 98 
2112 
Catalytic domain 
Underlined UPNs indicate more than one TET2 mutation 
Supplementary results
Figure S1. Schematic representation of the position of TET2 mutations found in 357 patients 
with AML. A total of 33 mutations was found in 27 patients. Indicated are missense mutations 
leading to amino acid substitutions (dark boxes) and nonsense and frameshift mutations 
leading to STOP codons (light boxes). The splice site defect in subject 1266 is shown in 
the beginning of the protein since it affects the first coding exon of the gene (exon3). The 
catalytic domain of TET2, including the highly, cross-species conserved domains (box 1 
and 2), is indicated. Ruler denotes amino acid number, UPN=unique patient number.
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Figure S2. Univariate analysis indicating the effect of various cytogenetic (A) and molecular 
markers (B-E) on overall survival in 357 patients with AML. FLT3-ITD and overexpression 
of EVI1 correlated with significantly inferior overall survival, whereas FLT3-TKD and NPM1 
mutations did not significantly affect clinical outcome.
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abstract
Patients with acute myeloid leukemia (AML) frequently harbor mutations in genes 
involved in the DNA (hydroxy)methylation pathway (DNMT3A, TET2, IDH1 and 
IDH2). In this study, we measured 5-hydroxymethylcytosine (5hmC) levels in 206 
clinically and molecularly well-characterized younger adult AML patients (≤60 years) 
included in the EORTC/GIMEMA AML-12 06991 clinical trial, and correlated the 
5hmC levels with mutational status and overall survival (OS). In healthy control cells, 
5hmC levels were confined to a narrow range (1.5 fold difference), whereas in AML 
cells, a much wider range was detected (15 fold difference). We identified three 
5hmC subpopulations in our patient cohort (low, intermediate and high). The low 
5hmC group consisted almost entirely of patients with TET2 or IDH mutations. As 
expected, TET2 and IDH mutated patients had significantly lower levels of 5hmC 
compared to patients without mutated TET2 and IDH1/2 (both P<.001). Interestingly, 
high 5hmC levels correlated with inferior OS (high vs intermediate 5hmC: P=.047, 
HR=1.81). Multivariate analysis revealed that high 5hmC is an independent poor 
prognostic indicator for OS (high vs intermediate 5hmC: P=.01, HR=2.10). 
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introduction 
Alterations in DNA methylation occur in many types of cancer, including 
hematological malignancies. Global hypomethylation, as well as promoter 
hypermethylation leading to silencing of various tumor suppressor genes, have 
been described.1,2 Since DNA methylation is reversible, it represents a promising 
target for therapy. In several clinical trials the effect of hypomethylating agents 
(Azacitidine and Decitabine) on the treatment of patients with myelodysplastic 
syndromes (MDS) and acute myeloid leukemia (AML) has been assessed,3-6 which 
may result in the reactivation of silenced genes. These trials showed promising 
results for intermediate-1 to high-risk MDS and elderly AML patients by improving 
complete remission rates, event-free survival and overall survival. 
In the last few years our knowledge of DNA (de)methylation has grown 
extensively. It has been known for a few decades that DNA methyltransferases 
(DNMT) are responsible for the conversion of cytosine into methylcytosine. 
DNMT3A and DNMT3B are de novo DNA methyltransferases, while DNMT1 is 
mainly implicated in maintaining methylcytosine marks during DNA replication.7 
DNA demethylation can take place as a passive process when the 5mC mark is 
not sustained during DNA replication. Only recently, evidence for an active DNA 
demethylation process has been presented. In 2009 it was discovered that the 
Ten-Eleven-Translocation (TET) protein family, consisting of TET1, TET2 and TET3, 
mediates the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine 
(5hmC).8 5hmC can be further oxidized by TET proteins to 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC), which are both recognized by thymine DNA 
glycosylase (TDG). Subsequently, TDG activates the base excision repair pathway 
which replaces the modified cytosine with an unmodified cytosine, thereby 
completing the active demethylation process.9-11 Neuronal cells and stem cells 
display remarkably high levels of 5hmC, suggesting that 5hmC may be a rather 
stable mark with a more versatile function besides being an intermediate in 
the active DNA demethylation process.8,12 TET proteins belong to the group of 
α-ketoglutarate (α-KG) and iron (Fe(II))-dependent dioxygenases. The co-substrate 
α-KG is produced by the isocitrate dehydrogenase (IDH) proteins, which catalyze 
the conversion of isocitrate into α-ketoglutarate.13 
Intriguingly, four genes (TET2, IDH1, IDH2 and DNMT3A) important for regulating 
DNA (hydroxy)methylation are frequently mutated in myeloid malignancies 
(Figure S1). Loss-of-function mutations in TET2 have been described in various 
hematological malignancies,14-17 including 7-10% of AML patients.18-20 Heterozygous 
mutations in IDH1 and IDH2 occur in 10-20% of AML patients and are mutually 
exclusive with TET2 mutations.19 Mutant IDH proteins are unable to catalyze the 
formation of α-KG but gain the function to convert α-KG into the oncometabolite 
2-hydroxyglutarate (2HG).21 In vitro studies have shown that 2HG is a competitive 
inhibitor of the TET proteins.22,23 This implies that both TET2 and IDH1/2 mutations 
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can impair 5hmC generation, which may explain why mutations in these genes 
are mutually exclusive. Indeed, AML patients with TET2 or IDH mutations showed 
decreased 5hmC levels.24-27 Recently, mutations affecting the methyltransferase 
DNMT3A were described in 20-25% of AML patients.19,28,29 Interestingly, DNMT3A 
mutations frequently co-occurred with TET2 or IDH1/2 mutations,18 suggesting that 
an additive effect may result from the combination of these mutations. In most AML 
studies DNMT3A mutations have been associated with a poor prognosis18,19,28-30 
except for a recent study by Gaidzik et al.31 Also TET2 mutations were associated 
with a poor prognosis in most studies,18,19,32-34 whereas the effect of IDH mutations 
is less clear. In several studies IDH1 mutations correlated with a poor survival 
in cytogenetically normal AML patients, while the impact of IDH2 mutations on 
survival remains inconclusive.18,35-37 
Several studies have assessed the effect of these mutations on DNA methylation. 
AML patients harboring IDH1/2 mutations showed a promoter hypermethylation 
phenotype and clustered together based on their common DNA methylation 
profile.38 The effect of TET2 mutations on overall DNA methylation remains 
controversial. In some studies TET2 mutated patients displayed a hypermethylation 
signature overlapping with IDH1/2 mutated patients,23 while others described no 
major effect on global methylation or even hypomethylation.24,39 In vitro, most 
DNMT3A mutations led to a decreased capability of the protein to produce 
5mC,29,40 although global 5mC levels in patients with DNMT3A mutations were not 
decreased.28 Methylated DNA immunoprecipitation (Me-DIP) experiments showed 
several differentially methylated regions between patients with and without 
DNMT3A mutations.28,29 No information is available concerning the consequences 
of DNMT3A mutations on 5hmC levels. 
The impact of 5hmC levels on survival of AML patients has not been addressed 
so far. In this study, we measured 5(h)mC levels in a prospectively collected cohort 
of 206 AML patients included in the EORTC/GIMEMA AML-12 clinical trial, and 
assessed whether 5hmC levels in AML correlated with clinical and molecular 
parameters.
materials and methods
Patient samples
Bone marrow (BM) and peripheral blood (PB) from AML patients (n=206) included 
in the EORTC/GIMEMA AML-12 06991 clinical trial (NCT0004128, 1999-2009)41 were 
obtained after informed consent. To avoid bias, only patients from participating 
centers where DNA was collected from all consecutive cases were included. In total 
we obtained DNA from 206 AML patients. After DNA collection, we performed 
the 5hmC analysis. A consort diagram of the trial and an overview of the patients 
included and excluded in our study are enclosed in the Supplementary material 
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(Table S1-2, Figure S2-3). The observed overall survival (OS) rate was slightly lower 
in the included cohort of patients compared to the non-included group (38.6% 
vs 41.9% 5-year OS rate, P=.22).The study was conducted in accordance with the 
Declaration of Helsinki, and was approved by the Institutional Review Board of the 
Radboud University Nijmegen Medical Centre. The cohort of AML patients (age 
16 to 60 years) contained samples of all French-American-British classification 
subtypes, except for AML M3. The median follow-up at the time of analysis was 
6.4 years. PB and BM mononuclear cells, as well as G-CSF-mobilized CD34 positive 
cells, were obtained from healthy donors (age 18 to 60 years for PB and BM donors 
and 44 to 67 years for donors of CD34 positive cells).
DNA and RNA isolation
For genomic sequencing and 5(h)mC measurements, DNA was isolated from whole 
PB or BM of AML patients (at diagnosis or in remission) using salt extraction. We 
compared the 5hmC values in PB and BM and observed that the levels were 
comparable (Figure S4). RNA for expression analysis was isolated using RNA-Bee 
(Tel-Test, inc., Friendswood, TX, USA). DNA from G-CSF-mobilized CD34 positive 
cells was isolated using salt extraction and DNA from PB and BM mononuclear 
cells of healthy donors was isolated using the NucleoSpin Blood QuickPure kit 
(Macherey Nagel, Düren, Germany).
Sequence analysis 
Sanger sequencing was performed on PCR-amplified genomic DNA fragments 
spanning the entire coding region of TET2 (NM_001127208.2), as previously 
described.14 For IDH1 (ENST00000345146) and IDH2 (ENST00000330062) 
the mutational hotspot regions were sequenced. DNMT3A exons 7-23 
(ENST00000264709) were sequenced using Sanger sequencing or Roche 
454-based next generation sequencing (NGS, 454 Life Sciences, Branford, CT, 
USA). Primers used for IDH1, IDH2 and DNMT3A Sanger sequencing can be found 
in supplementary tables 3 and 4. DNMT3A NGS was performed as previously 
described.42 In short, this encompasses PCR-based amplicon-library preparation 
followed by emulsion PCR and pyrosequencing. NGS data were analyzed using 
R453Plus1Toolbox,43 GS Variant Analyzer Software 2.6 (454 Life Sciences), and 
Sequence Pilot version 3.5.2 (JSI Medical Systems, Kippenheim, Germany). For 
TET2 and DNMT3A, all intron-exon boundaries were included to identify possible 
splice site mutations. The variations were compared with the dbSNP database to 
determine whether they represented known SNPs. 
TET expression analysis
mRNA levels of TET2 isoform 1 and isoform 2, TET1 and TET3 were determined 
using quantitative PCR. Specific PCR primers and probes were designed to 
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discriminate between the different TET2 isoforms (Table S5). Taqman assays 
Hs00286756_m1 and Hs00379125_m1 (Life Technologies, Carlsbad, CA, USA) were 
used to determine TET1 and TET3 expression. Quantitative PCR was conducted 
using an Applied Biosystems Taqman 7900HT Fast Real-Time PCR system (Life 
Technologies). Expression levels were normalized to GAPDH and calculated using 
the 2ΔCT method.
5mC and 5hmC HPLC-MS/MS measurement
For each patient, 2 µg of DNA (isolated from approximately 1 x 106 cells) was 
degraded into individual nucleosides using DNA degradase plus (Zymo Research, 
Irvine, CA, USA). The individual nucleosides were measured using a high-
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 
system consisting of an Acquity UPLC (Waters, Milford, MA, USA) containing 
a Waters Atlantis Hilic column (2.1mm*100mm 3µ) connected to a Micromass 
Quattro Premier XE (Waters). Quantification was performed using area-based linear 
regression curves derived from calibration standards containing internal standard 
solutions. The 5mC and 5hmC levels were calculated as a concentration percentage 
ratio of %mdC/dG and %hmdC/dG, respectively. The inter-assay coefficient of 
variation (CV) over a one-year period was 2% for 5mC and 5% for 5hmC (n=49). 
A detailed description is presented in the supplementary material.
2HG HPLC-MS/MS measurement
A detailed description is presented in the supplementary material.
Bisulfite sequencing
Bisulfite conversion of 500 ng of DNA was performed using the Methyldetector 
kit (Active motif, Carlsbad, CA, USA), according to the manufacturers protocol. 
A semi-nested PCR on the converted DNA was carried out to amplify a CpG-rich 
promoter region in 2 genes frequently hypermethylated in AML; P15 and MyoD. 
Primer sequences are listed in Table S6. PCR products were cloned into the pDrive 
vector (Qiagen, Valencia, CA, USA), transformed in competent DH12α cells, and 
plated on a LB agar plate containing 50 µg/ml ampicillin. Per patient, DNA was 
isolated from 10 colonies and sequenced using Sanger sequencing.
Statistical analysis
5(h)mC differences between two patient groups were statistically tested by 
performing unpaired T-tests or Mann-Whitney U tests. More than two groups 
were compared using a One-way ANOVA or Kruskal Wallis test. Pearson and 
Spearman correlation coefficients were used to calculate correlations between two 
continuous variables. Two-sided p-values are reported. For negative results that 
may be scientifically relevant, we determined minimal detectable differences with 
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a power of 80% (http://biomath.info/power/ttest.htm). To divide the AML patients 
in subgroups based on their 5hmC level, we fitted a normal mixture model to the 
data using the mixtools R package.44 The optimal number of components was 
determined using the Akaike information criterion (AIC).45 The results of the OS 
analysis have been presented in a Kaplan-Meier curve. OS was computed from the 
date of registration in the EORTC 06991 study until death (by any cause) or until 
last follow-up (censored observation). The Cox Proportional Hazards Model was 
used to determine the prognostic importance of each factor analyzed and to obtain 
hazard ratio (HR) estimates as well as corresponding 95% confidence intervals 
(95% CI). The following variables were considered: 5hmC levels as continuous 
or categorical variable, cytogenetic/FLT3-ITD risk group (good = inv16, t(8;21); 
poor = -5/5q-, -7/7q-, complex, FLT3-ITD; Intermediate = NN, -Y; others = other 
cytogenetic abnormalities), white blood cell count (< 25, 25-<100, > 100), % of 
bone marrow blasts (20-<40%, 40-<60%, 60-<80%, >80%) and age (<30, 30-<40, 
40-<50, 50-60 years). Statistical analyses were performed using SAS® (SAS, Cary, 
NC, USA), R (R Development Core Team, www.r-project.org), and SPSS software 
(IBM Corporation, Armonk, NY, USA). 
results
Wide distribution of 5hmC levels in AML patients
5hmC levels were measured in 206 AML patients (see Table 1 for patient 
characteristics), in healthy purified CD34 positive progenitor cells, as well as 
healthy BM and PB cells using HPLC-MS/MS. In CD34 positive cells (Figure 1A, 
range 0.037-0.045%; mean 0.041%), and in healthy control cells from BM and PB 
(Figure 1B, range 0.024-0.033%; mean 0.029%) 5hmC levels were tightly clustered, 
whereas in AML cells a wide range of 5hmC levels was detected (Figure 1A, range 
0.006-0.091%; mean 0.039%). To determine whether these aberrant 5hmC levels 
were normalized in remission, we measured 5hmC levels in paired samples at 
diagnosis and remission from 25 AML patients. For 19/25 patients the type of 
material (BM or PB) at remission was matched to the material used at diagnosis. In 
all cases, the remission samples showed 5hmC levels comparable to the levels in 
healthy BM and PB (Figure 1B). In addition, from 5 patients 5hmC was measured 
at diagnosis, during remission, and at relapse. For all 5 patients, 5hmC levels in 
remission were comparable to healthy controls (Figure 1C). At relapse, 5hmC 
returned to the levels obtained at diagnosis in all but one patient (UPN128). 
We found that this patient harbored an IDH1 mutation at diagnosis which was 
absent at relapse, which may explain the difference in 5hmC levels between 
diagnosis and relapse (see next paragraph). For patients with similar 5hmC levels 
at diagnosis and relapse, the same mutations were present at both time points 
(Table S7). 
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table 1. Patient characteristics
Overall population (n=206)
No. %
Age (years) at diagnosis
Median (range) 48.0 (16.0-60.0)
<30 21 10.2
30-<40 36 17.5
40-<50 59 28.6
50-60 90 43.7
Sex
Male 101 49.0
Female 105 51.0
WHO-ECOG performance status (PS)
PS 0 122 59.2
PS 1 74 35.9
PS 2 7 3.4
PS 3-4 3 1.5
WBC (x109/l) at diagnosis
Median (range) 24.7 (0.5-312.5)
< 25 104 50.5
25-99.9 69 33.5
>= 100 33 16.0
FAB subtype
M0 11 5.3
M1 45 21.8
M2 65 31.6
M4 25 12.1
M5 48 23.3
M6 6 2.9
M7 1 0.5
Unknown 5 2.4
Cytogenetic/FLT3-ITD risk group
Good 24 11.7
Intermediate (NN,-Y) 62 30.1
Poor (-5/5q-,-7/7q-,complex, FLT3-ITD) 67 32.5
Others 46 22.3
UNK/ND/Failure 7 3.4
No. indicates number; WHO-ECOG, World Health Organization-Eastern Cooperative Oncology Group; WBC, 
white blood cell count; FAB, French–American–British classification; UNK, unknown; and ND, not determined.
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Decreased global 5hmC levels in patients with TET2 or IDH1/2 mutations
The entire TET2 gene and the mutational hotspot regions in IDH1 and IDH2 were 
sequenced in 206 AML patients using Sanger sequencing.18 TET2 mutations were 
present in 7% of the patients (n=15), IDH1 R132 in 10% (n=21), IDH2 R140 in 11% 
(n=22) and IDH2 R172 in 2% (n=4) of the patients. In most cases TET2, IDH1 and 
IDH2 mutations were mutually exclusive, except for one patient with an IDH1 and 
subclonal IDH2 mutation (Table S8). 
Using HPLC-MS/MS, we confirmed that patients with IDH mutations produce 
2HG, which is known to inhibit TET proteins (Figure 2A; Table S9).22,23 Patients 
with IDH mutations had up to 150 times higher plasma 2HG levels compared 
Figure 1. Aberrant 5hmC levels in AML. (A) In AML cells a broad range of 5hmC levels was 
detected at diagnosis when compared to healthy CD34 positive cells. (B) Aberrant 5hmC 
levels at diagnosis were restored to normal levels in remission. (C) For five AML patients 
5hmC levels were measured at diagnosis, remission and relapse. The 5hmC levels were in 4 
out of 5 cases comparable at diagnosis and relapse. For UPN128 the 5hmC level at relapse 
was remarkably higher than at diagnosis, due to an IDH1 mutation at diagnosis which was 
absent at relapse. Dashed lines indicate the range of 5hmC values measured in healthy bone 
marrow and healthy peripheral blood. UPN indicates unique patient number. 
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to IDH wild type patients (P=.03). Since a reduced function of TET2, either by 
mutations or by 2HG-mediated inhibition, may affect both 5mC and 5hmC levels, 
we compared these levels in patients with and without TET2 or IDH mutations. 
We observed small, but statistically significant differences in 5mC levels between 
the different patient groups (Figure 2B). Patients with IDH mutations displayed 
slightly increased 5mC values compared to TET2/IDH wild type and TET2 mutated 
patients (P=.02 and P=.001, respectively). In contrast, substantial differences in 
5hmC levels were found. Patients with TET2 mutations had significantly lower 
5hmC levels compared to patients without TET2 or IDH mutations (Figure 2C, 
P<.001). Patients with two TET2 aberrations showed a significantly lower 5hmC than 
patients with a single affected allele (Figure 2D, P=.003). Furthermore, 5hmC values 
were decreased in patients with IDH1/2 mutations compared to TET2/IDH wild 
type patients (Figure 2C, P<.001). Comparison of the 3 different IDH mutational 
hotspots revealed a slightly lower 5hmC in the subgroup of patients with IDH2 
R172 mutations (n=4, Figure 2D).
Effect of DNMT3A mutations on global 5mC and 5hmC levels
Since the DNMT3A protein forms 5-methylcytosine, we investigated whether 
mutations in DNMT3A would affect global 5mC and 5hmC levels. DNMT3A exons 
7-23 were sequenced in 79 patients (Table S8). Interestingly, DNMT3A mutations 
frequently co-occurred with TET2 or IDH mutations; 64% of TET2 mutated and 63% 
of IDH mutated patients harbored a DNMT3A mutation. The frequent co-occurrence 
suggests that an additive oncogenic effect may result from the combination of 
these mutations. When patients were divided into different subgroups based on 
co-occurring mutations, mutant DNMT3A alone had no strong effect on global 
5mC levels (Figure 2E). The detected difference between means (DNMT3A/
TET2/IDH wildtype vs DNMT3A mutant group) was 0.03, and was not significant 
(the minimal detectable difference in our cohort was 0.29 %5mC/G with a power 
of 80%). In addition, DNMT3A mutations also did not significantly affect global 
5hmC values (Figure 2F). The observed difference between means was 0.0056 
(the minimal detectable difference with a power of 80% was 0.016 %5hmC/G).     
High 5hmC levels confer poor prognosis in AML
In AML a wide range of 5hmC levels was observed when compared to healthy control 
cells (Figure 1A). As 5hmC values were not normally distributed, we used a mixture 
model analysis to divide the patient cohort in subgroups. Three subpopulations 
were identified; low 5hmC (0.006-<0.023), intermediate 5hmC (0.023-<0.070) and 
high 5hmC (0.070-0.091) (see Table S10 for patient characteristics). We questioned 
whether 5hmC levels correlated with overall survival by examining the survival of 
these three groups. Univariate analysis showed that the low and intermediate 5hmC 
groups had comparable 5-year OS rates (Figure 3, 38.3% vs 40.7%). Interestingly, 
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Figure 2. 5hmC levels are decreased in TET2 and IDH mutated patients. (A) Plasma 2HG 
levels measured by LC-MS/MS were up to 150 times higher in patients with IDH mutations 
compared to IDH wild type patients. (B) Small differences in 5mC values were present between 
AML patients. Patients with IDH mutations showed higher 5mC levels than TET2 mutated and 
TET2/IDH wild type patients. (C) Patients with TET2 or IDH1/2 mutations showed significantly 
lower 5hmC levels than TET2/IDH wild type patients. (D) Patients with two affected TET2 
alleles showed lower 5hmC values than patients with only one affected allele. All types of 
IDH mutations led to decreased 5hmC levels. The 4 patients with an IDH2 R172 mutation had 
slightly lower 5hmC values than most patients with an IDH1 R132 or IDH2 R140 mutation. (E) 
DNMT3A mutations frequently co-occurred with TET2 or IDH mutations. DNMT3A mutations 
did not significantly affect global 5mC levels. (F) Mutant DNMT3A did also not strongly affect 
5hmC values, but the levels were influenced by the presence or absence of accompanying 
TET2 or IDH mutations. Mut indicates mutated; and wt, wild type. Symbols indicate unpaired 
T-test (*), Mann-Whitney U test (†), One-way ANOVA (‡) and Kruskal Wallis test (§).
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the high 5hmC group showed a considerably lower 5-year OS rate when compared 
to the intermediate group (Figure 3, 18.9% vs 40.7%) resulting in a significant 
difference in OS (P=.047, HR=1.81, 95%CI=1.01-3.24). A similar trend was observed 
when event-free survival was analyzed (Table S11). Multivariate Cox regression 
analysis showed that, when adjusted for cytogenetic/FLT3-ITD features, high 5hmC 
levels independently predicted poor overall survival (Table 2, high vs intermediate 
5hmC: P=.01, HR=2.10, 95%CI=1.16-3.80). 
Figure 3. Overall survival according to 5hmC level. Patients were divided into three groups 
based on a mixture model analysis. Univariate analysis indicates that patients with high 
5hmC levels (0.070-0.091) showed a poor overall survival when compared to patients with 
low (<0.023) and intermediate (0.023-<0.070) 5hmC. 
Correlation of 5hmC levels with clinical and molecular parameters
As shown in figure 2C, low 5hmC levels could in many patients be explained by 
TET or IDH mutations. In patients without TET2 or IDH mutations 5hmC levels still 
varied considerably. Therefore, we examined whether the range of 5hmC values in 
patients without TET2 or IDH mutations correlated with specific clinical or molecular 
parameters. There was no significant correlation between 5hmC levels and sex, 
age, initial performance status, white blood cell count or cytogenetic categories 
(Figure S5). Furthermore, we assessed whether 5hmC levels correlated with the 
percentage of blasts at diagnosis, since it has been shown that stem cells may 
contain more 5hmC than differentiated cells.46 A positive correlation was present 
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between 5hmC levels and the percentage of blasts in BM (P=.003) and PB (P=.02) 
at diagnosis (Figure S6). The percentage of BM blasts did however not appear to be 
of prognostic importance for OS, neither in uni- nor in multivariate analysis. When 
blast percentage was included in the multivariate model (Table S12, model 2), high 
5hmC remained an independent poor prognostic factor, thereby showing that 
5hmC is not a surrogate marker for percentage of BM blasts. To investigate whether 
the level of TET expression affected the level of 5hmC in AML, we measured mRNA 
expression of TET1 (n=31), TET2 (isoform 1 and 2, n=109) and TET3 (n=31) in patients 
without TET2 or IDH mutations. For all TET family members, no strong correlation 
was found with the level of 5hmC (Figure S7). Finally, we considered whether 
5hmC levels correlated with other specific molecular aberrations. Interestingly, MLL 
aberrations and AML1-ETO translocations were enriched in patients with high levels 
of 5hmC (Figure 4). Of note, there was one patient who carried an IDH2 mutation 
together with an MLL translocation. Of all patients with MLL aberrations, this 
patient showed the lowest value of 5hmC, possibly indicating that the effect of IDH 
mutations (correlating with low 5hmC) overrides the effect of MLL translocations 
(correlating with high 5hmC).
Increased P15 promoter methylation in patients with low 5hmC levels
We examined the methylation status of 2 genes that are frequently hypermethylated 
in AML (P15 and MyoD)47 in 10 patients with low and 10 with high 5hmC levels. 
The majority of patients with low 5hmC (8/10) showed considerable methylation 
on the P15 promoter, compared to only 2/10 patients with high 5hmC levels (at 
least 1 CpG >50% methylated, Figure 5A), which suggests that demethylation of 
the P15 promoter is altered in most patients with low 5hmC. In contrast, for MyoD 
no difference in promoter methylation was observed between the low and high 
table 2. Multivariate Cox regression analysis
 
Parameter
 
P-value  Hazard ratio
95% Hazard ratio
Confidence limits
5hmC: <0.023 vs 0.023-<0.070 0.44 1.18 0.77 1.81
5hmC: >=0.070 vs 0.023-<0.070 0.01 2.10 1.16 3.80
Cytogenetics/FLT3-ITD: Good vs Intermediate 0.21 0.60 0.25 1.36
Cytogenetics/FLT3-ITD: Others vs Intermediate 0.17 1.44 0.86 2.39
Cytogenetics/FLT3-ITD: Poor vs Intermediate <0.0001 3.00 1.90 4.68
Cytogenetics/FLT3-ITD: Unknown vs Intermediate 0.02 2.96 1.21 7.21
AIC for this model=1238
Addition of age, treatment arm (data not shown) and/or percentage bone marrow blasts (Table S12) in the 
model did not improve its prognostic discrimination value. Considering 5hmC as a continuous variable in the 
model (linear and quadratic effect), and adjusting for cytogenetic/FLT3-ITD risk groups provided similar results 
as the model indicated above (see table S12). 
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5hmC groups (Figure 5B), indicating that this correlation is promoter specific. 
Therefore, genome-wide analysis should be performed to determine which genes 
are differentially methylated between the low and high 5hmC groups. 
discussion
In this study we correlated global 5(h)mC levels with various clinical and molecular 
parameters in a large prospectively collected cohort of younger adult AML patients 
(age <=60) included in the EORTC/GIMEMA AML-12 clinical trial. No major 
differences in global 5mC levels were observed between patients, but 5hmC levels 
were distributed over a wide range. In remission, 5hmC values were normalized to 
levels comparable to healthy BM and PB, indicating that the aberrant 5hmC levels 
at diagnosis were an intrinsic property of the leukemic cells. In line with previous 
reports, mutations in TET2 and IDH1/2 were mutually exclusive,19,23 and patients 
with these mutations displayed significantly decreased 5hmC levels.24-27 Among 
the patients that did not harbor TET2 or IDH mutations, a wide variation in 5hmC 
levels was still observed. 
Remarkably, IDH or TET2 mutations co-occurred frequently with mutations in 
DNMT3A, indicating that they may co-operate during malignant transformation. 
The majority of DNMT3A mutations are heterozygous missense mutations affecting 
one specific amino acid (R882), but nonsense and frameshift mutations have also 
been described.48 We did not observe significant effects of DNMT3A mutations 
on global 5mC levels, both in patients with mono- and bi-allelic mutations. This 
suggest that there is still enough remaining DNMT protein (DNMT3B, DNMT1 
Figure 4. Molecular markers in different groups of 5hmC levels. Patients are ranked from 
low to high 5hmC level, and the different 5hmC groups used for the overall survival analysis 
are indicated. Per patient all mutations are indicated with small colored boxes. Light grey 
boxes represent no mutation and dark grey boxes not determined/unknown. TET2 and IDH 
mutations are present in patients with low 5hmC, while AML1-ETO and MLL translocations 
are more frequently found in patients with high 5hmC levels. ITD indicates internal tandem 
duplication; inv, inversion; and transl, translocation.
5hmC 
TET2
IDH1
IDH2
DNMT3A
NPM1
FLT3- ITD
FLT3- 835
CBFB- MYH11
BCR- ABL1
MLL transl.
AML1- ETO
Cytogenetics
low 5hmC (<0.023) Intermediate 5hmC (0.023-<0.070) high 5hmC (>0.069)
Cytogenetics
Good
Intermediate
Others
Poor
Unknown
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methylated
CpG: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 5hmC 0 < 25%
UPN 496 0.091 25 < 50%
UPN 254 0.084 50 < 75%
UPN 75 0.081 75 - 100%
UPN 1581 0.081
UPN 528 0.078
UPN 1530 0.078
UPN 2013 0.077
UPN 1569 0.073
UPN 39 0.072
UPN 7 0.072
UPN 140 0.016
UPN 1799 0.015
UPN 328 0.013
UPN 746 0.013
UPN 438 0.013
UPN 690 0.012
UPN 500 0.011
UPN 1399 0.009
UPN 36 0.008
UPN 2112 0.006
P15 promoter methylation
H
igh 5hm
C
Low
 5hm
C
methylated
CpG: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 5hmC 0 < 25%
UPN 496 0.091 25 < 50%
UPN 254 0.084 50 < 75%
UPN 75 0.081 75 - 100%
UPN 1581 0.081
UPN 528 0.078
UPN 1530 0.078
UPN 2013 0.077
UPN 1569 0.073
UPN 39 0.072
UPN 7 0.072
UPN 140 0.016
UPN 1799 0.015
UPN 328 0.013
UPN 746 0.013
UPN 438 0.013
UPN 690 0.012
UPN 500 0.011
UPN 1399 0.009
UPN 36 0.008
UPN 2112 0.006
MyoD promoter methylation
H
igh 5hm
C
Low
 5hm
C
A
B
Figure 5. P15 and MyoD promoter methylation. P15 (A) and MyoD (B) promoter methylation 
were determined in 10 patients with low and 10 with high 5hmC levels. For each CpG the 
methylation status is indicated with shaded boxes. Patients with low 5hmC show more P15 
promoter methylation than patients with high 5hmC levels, while there is no difference in 
MyoD promoter methylation. UPN indicates unique patient number.
and in most cases a remaining DNMT3A allele) to form most of the 5mC marks. 
In addition, we did not find strong correlations between global 5mC levels and 
survival (Figure S8). This lack of correlation does not necessarily mean that 5mC 
levels are not relevant, but may rather point to the fact that global DNA methylation 
patterns obscure local effects at specific genes. In order to identify the important 
loci for (deregulated) 5mC levels, more targeted strategies, such as MeDIP, should 
be used. 
TET2 and IDH mutations both lead to defective conversion of 5mC into 5hmC, 
which may result in impaired demethylation of DNA, contributing to the malignant 
transformation of cells. Using bisulfite sequencing, we showed a high level of P15 
promoter methylation in patients with low 5hmC. However, no difference was 
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observed for the MyoD gene, indicating that the correlation is locus-specific. 
Genome-wide methylation and hydroxymethylation patterns should be determined 
to see which genes are differentially (hydroxy)methylated between patients with 
low and high 5hmC levels. Apart from affecting the methylation status of the DNA, 
other processes might be influenced by 5hmC as well. Several studies showed 
that the 5hmC mark may attract specific proteins like MECP2 and UHRF2.49,50 The 
role of these interactions is not clear yet, but protein complexes that recognize 
the 5hmC mark might serve as “readers” of the local epigenetic DNA code and 
induce further chromatin alterations.
After excluding patients with mutations in TET2 or IDH, 5hmC levels still varied 
considerably in the remaining patients. The cause of this broad range of 5hmC 
levels could not be attributed to differences in TET expression, as no strong 
correlation was found between TET1, 2 or 3 mRNA expression and 5hmC levels. 
A positive correlation was, however, observed between blast count at diagnosis 
and 5hmC levels. As it has been shown that stem cells contain more 5hmC than 
differentiated cells, this might explain the correlation.46
We assessed whether 5hmC levels correlated with OS by comparing the survival 
of the three 5hmC subpopulations present in our cohort (Figure 1A). We showed 
that high 5hmC levels conferred a poor prognosis in both uni- and multivariate 
analysis. On the other hand, low 5hmC levels did not affect survival. The low 
5hmC group mainly consists of patients with TET2 or IDH1/2 mutations (45 out of 
47 patients). TET2 mutations in AML are often associated with a poor prognosis,32-34 
as was also observed in our study.18 The impact of IDH mutations on OS was less 
pronounced, with IDH1 mutations showing a trend towards a poor prognosis, 
whereas IDH2 mutations had no effect.18 The differences in OS between these 
3 types of mutations indicates that low 5hmC is not the only variable that affects 
survival in these patients. Interestingly, AML1-ETO and MLL translocations were 
more frequently present in patient cells with high 5hmC levels. These findings 
remain to be confirmed in future studies.
Finally, it would be particularly interesting to investigate how patients with 
aberrant 5hmC respond to hypomethylating agents, such as decitabine and 
5-azacitidine, as these compounds have shown promising results in MDS and elderly 
AML.3-6 If a correlation between 5hmC levels and response to these therapeutics 
could be shown, this would allow a more tailored therapeutic approach. 
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supplementary information
Supplementary materials and methods
5mC and 5hmC HPLC-MS/MS measurement
For each patient, 2 µg of DNA was degraded into individual nucleosides by mixing 
the DNA with 1x DNA degradase reaction buffer and 5U DNA degradase plus (Zymo 
Research, Irvine, CA, USA), followed by incubation at 37°C for 5 hours and 70°C 
for 20 minutes. Hydrolyzed DNA was used for HPLC-MS/MS analysis. Nucleoside 
calibration standards corresponding to 0.025, 0.05, 0.1, 0.2, 0.5, 1 and 2 µg of DNA, 
containing 5.3% 5-methyl-2’-deoxycytidine/2’-deoxyguanosine (mdC/dG) and 0.02% 
5-hydroxymethyl-2’-deoxycytidine/2’-deoxyguanosine (hmdC/dG), were prepared 
in deionized water (dH2O). In addition, an internal standard solution was prepared 
containing 0.02 µM D2hmdC, 0.27µM 
13C4-mdC (kindly provided by Prof. Dr. H. Blom) 
and U-15N5-dG (Cambridge Isotopes Laboratories, Andover, MA, USA) in dH2O. 
25 µl dH2O was added to the 25 µl of DNA hydrolysate, and 25 µl 1x degradase 
reaction buffer to the calibration standards. Subsequently, 25 µl of internal standard 
solution, 50 µl of methanol (Merck, Darmstadt, Germany) and 500 µl acetonitrile 
(ACN, Merck) were added to both samples and calibrators. After centrifugation, 
the eluates were dried under an N2 flow and dissolved in 75 µl 95% ACN. 5 µl of 
the calibrators and samples were injected into the HPLC-MS/MS system consisting 
of an Acquity UPLC (Waters, Milford, MA, USA) containing a Waters Atlantis Hilic 
column (2.1mm*100mm 3µ) connected to a Micromass Quattro Premier XE (Waters). 
The mobile phase was made up by ACN and 20 mM ammonium acetate (Sigma-
Aldrich, St. Louis, MO, USA) in dH2O. The initial flow rate was set to 400 µl/min. The 
UPLC flow was directed to the Quattro Premier fitted with an electrospray ionization 
probe operated in positive mode at unit resolution. The capillary voltage was set at 
3 kV. The temperature settings for the source and ion block were 400 ˚C and 100 ˚C 
respectively. As a drying gas, nitrogen was used at a flow rate of 1100 L/h. The 
collision cell was operated with argon as the collision gas at a pressure of 0.8 Pa. 
The cone voltage and collision energy voltage were individually set for the different 
nucleosides to obtain a maximum response for their deoxyribose loss. Quantification 
was performed using area-based linear regression curves derived from the prepared 
calibration standards. The 5mC and 5hmC levels were calculated as a concentration 
percentage ratio of %mdC/dG and %hmdC/dG, respectively. 
In each run, granulocyte DNA, with 5mC and 5hmC levels of 3.9 and 0.027 
respectively, was included to monitor inter-assay reproducibility. The inter-assay 
CV over a one-year period was 2% for 5mC and 5% for 5hmC (n=49). To test 
the reproducibility of the 5hmC measurements at the extremes, three patient 
samples with 5hmC values of 0.014 (low), 0.044 (intermediate) and 0.096 (high) 
were measured 5 times leading to CV values of 5.7%, 2.9% and 1.1%, respectively. 
The accuracy of the assay was determined by measuring a range of 5hmC values 
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from 2% to 0.0032% with 5-fold steps, resulting in a R2 of 0.9866, see graph 
below. All measurements were performed blinded to clinical and molecular data 
of the patients. 
2HG HPLC-MS/MS measurement 
2HG (Sigma-Aldrich) calibration standards of 0.15, 0.3, 0.6, 1.2, 2.5, 5 and 10 µM, 
and an internal standard solution of 10 µM U-13C5-l-2hg (Chiralex, Nijmegen, the 
Netherlands) were prepared in dH2O. 100 µl sample was diluted with 50 µl internal 
standard solution and passed through a Microcon 30 kD ultrafilter (Millipore, 
Billerica, MA, USA). The filtrate was acidified with 10 µl 4% formic acid (Merck) and 
5 µl was injected into the HPLC-MS/MS system consisting of a 232 XL autosampler 
(Gilson, Middleton, WI, USA) connected to an HP1100 HPLC (Agilent, Palo Alto, CA, 
USA) with an PFP column (2.1mm*100mm 3µ, Phenomenex, Torrance, CA, USA), 
and a Micromass Quattro LC (Waters). The mobile phase consisted of dH2O and 
methanol (Merck) containing 0.3% formic acid (Merck) and was run at a flow rate of 
250 µl/min. By running a gradient, 2HG was eluted completely separated from its 
structural isomers 3-hydroxyglutarate and 2-hydroxy-2-methylsuccinate (the optical 
D- and L-isomers do still co-elute). The HPLC flow was directed to a Quattro LC 
tandem mass spectrometer fitted with an electrospray ionization probe operating 
in the negative mode at unit resolution. The capillary voltage was set at 3 kV, and 
a cone voltage of 20 V was used. The temperature settings for the source and ion 
block were 400 ˚C and 100 ˚C respectively. As a drying gas nitrogen was used at 
a flow rate of 650L/h. The collision cell was operated at 9 eV with argon as the 
collision gas at a pressure of 0.2 Pa. The mass spectrometer was set to monitor 
the water loss of both 2HG and U-13C5-I-2hg; recording the mass transitions of m/z 
147 to m/z 129 and m/z 152 to 134 m/z, respectively.  
Quantification was performed using an area-based linear regression curve 
derived from the prepared calibration standards containing internal standard 
solution. The inter-assay (3 months period) CV of a plasma containing 1.0 µM of 
2HG was 4% (n=20). All measurements were performed blinded to clinical and 
molecular data of the patients.
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supplementary tables and figures
table s1. Patient characteristics (Continued)
Parameter 
Patient characteristics AML-12 study
Excluded (N=1736) Included (N=206)
N (%) N (%)
Age (years) at diagnosis    
<30  290 (16.7)  21 (10.2) 
30-<40  332 (19.1)  36 (17.5) 
40-<50  476 (27.4)  59 (28.6) 
50-60  638 (36.8)  90 (43.7) 
Sex    
Male  911 (52.5)  101 (49.0) 
Female  818 (47.1)  105 (51.0) 
Missing  7 (0.4)  0 (0.0)
WHO-ECOG performance status (PS)    
PS 0  805 (46.4)  122 (59.2) 
PS 1  740 (42.6)  74 (35.9) 
PS 2  160 (9.2)  7 (3.4) 
PS 3-4  27 (1.6)  3 (1.5) 
Missing  4 (0.2)  0 (0.0) 
WBC (x109/l) at diagnosis    
< 25 1037 (59.7)  104 (50.5) 
25-99.9  499 (28.7)  69 (33.5) 
>= 100  191 (11.0)  33 (16.0) 
Missing  9 (0.5)  0 (0.0) 
FAB subtype    
M0  98 (5.6)  11 (5.3) 
M1  435 (25.1)  45 (21.8) 
M2  445 (25.6)  65 (31.6) 
M3  4 (0.2)  0 (0.0) 
M4  346 (19.9)  25 (12.1) 
M5  321 (18.5)  48 (23.3) 
M6  57 (3.3)  6 (2.9) 
M7  3 (0.2)  1 (0.5) 
Unknown  27 (1.6)  5 (2.4)
Cytogenetic/FLT3-ITD risk group 
Good  165 (9.5)  24 (11.7)
Intermediate (NN,-Y)  578 (33.3)  62 (30.1)
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table s1. Patient characteristics (Continued)
Parameter 
Patient characteristics AML-12 study
Excluded (N=1736) Included (N=206)
N (%) N (%)
Poor (-5/5q-,-7/7q-,complex,FLT3-ITD)  144 (8.3)  67 (32.5)
Others  240 (13.8)  46 (22.3)
UNK/ND/Failure  609 (35.1)  7 (3.4)
Treatment randomized    
SD-AraC  859 (49.5)  110 (53.4) 
HD-AraC  877 (50.5)  96 (46.6) 
SCT in CR    
AutoSCT  484 (27.9)  62 (30.1) 
AlloSCT  347 (20.0)  53 (25.7) 
Response after induction    
CR  1280 (73.7)  152 (73.8) 
NoCR  456 (26.3)  54 (26.2)
EFS status    
NoCR  413 (23.8)  53 (25.7) 
CCR  570 (32.8)  61 (29.6) 
Relapse  567 (32.7)  69 (33.5) 
Death in CR  143 (8.2)  22 (10.7) 
Not evaluated  43 (2.5)  1 (0.5) 
Survival Status    
Alive  752 (43.3)  76 (36.9) 
Dead  984 (56.7)  130 (63.1) 
WHO-ECOG indicates World Health Organization-Eastern Cooperative Oncology Group; WBC, white blood 
cell count; FAB, French–American–British classification; UNK, unknown; ND, not determined; SD, standard 
dose; HD, high dose; SCT, stem cell transplantation; CR, complete remission; EFS, event free survival; and 
CCR, continuous complete remission. 
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table s2. Duration of survival 
Study 
population
Patients Observed Hazard Ratio P-Value Median (95% CI) % at 5 Year(s)
(N) deaths (O) (95% CI) (Log-Rank) (Years) (95% CI)
Excluded 1736 984 1 0.2164 2.12 (1.85, 2.48) 41.91 (39.50, 44.30)
Included 206 130 1.12 (0.93, 1.35) 1.68 (1.20, 2.96) 38.57 (31.85, 45.25)
Time used Std error Min AML-12: Max AML-12:
(Years)   Duration of survival Duration of survival
4.97 1.227 0 10.91
4.35 3.437 0 11.64
95% CI indicates 95% confidence interval.
table s3. Primers used for IDH1 and IDH2 sequencing
Gene position Forward/Reverse Primer sequence (5’ to 3’)
IDH1 R132 Forward tgtaaaacgacggccagtGGCACGGTCTTCAGAGAAGC
  Reverse caggaaacagctatgaccCAAAATCACATTATTGCCAAGATG
IDH2 R140 and R172 Forward tgtaaaacgacggccagtCGTCTGGCTGTGTTGTTGCTT
  Reverse caggaaacagctatgaccAGGATGGCTAGGCGAGGAG
M13 seq primer Forward tgtaaaacgacggccagt
  Reverse caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
table s4. Primers used for sequencing DNMT3A exon 7 till 23 (Continued)
Exon Forward/Reverse Primer sequence (5’ to 3’)
7 Forward tgtaaaacgacggccagtCTAATTCCTGGAGAGGTCAAGGTG
  Reverse caggaaacagctatgaccAGATGGAGAGAGGAGAGCAGGAC
8 Forward tgtaaaacgacggccagtTCTTGCCTCATTCAGATGGAGC
  Reverse caggaaacagctatgaccCCTGGGATCAAGAACCTTCCC
9 Forward tgtaaaacgacggccagtGTGCTTGCAAGTGTAAGCCTCG
  Reverse  caggaaacagctatgaccCCTGCACTCCAACTTCCAGG 
10 Forward tgtaaaacgacggccagtGCCTTCCAGCCTGTCCTGA
  Reverse caggaaacagctatgaccCCAACTCTACGGTTCTAGCCAAC
10-11 Forward tgtaaaacgacggccagtGCCTTCCAGCCTGTCCTGA
  Reverse caggaaacagctatgaccGTACACCAGCCGCTCTGCA
11-12 Forward tgtaaaacgacggccagtGTTGGCTAGAACCGTAGAGTTGG
96
C
h
a
r
a
C
te
r
iz
a
tio
n
 o
f a
C
u
te
 m
y
e
lo
id
 le
u
k
e
m
ia
 b
a
se
d
 o
n
 5h
m
C
3
table s4. Primers used for sequencing DNMT3A exon 7 till 23 (Continued)
Exon Forward/Reverse Primer sequence (5’ to 3’)
  Reverse caggaaacagctatgaccCTAAGTGCCTCTGCTACTCTGCC
13 Forward tgtaaaacgacggccagtGTTCGAGACTGGGGTCACAGT
  Reverse caggaaacagctatgaccAGAAGCGGTGGACACAGTCAG
14 Forward tgtaaaacgacggccagtGGTCATGTCTTCAGGGCTTAGG
  Reverse caggaaacagctatgaccTGCTACCTGGAATGGAAAGACC
15 Forward tgtaaaacgacggccagtTTTCCATTCCAGGTAGCACACC
  Reverse caggaaacagctatgaccAGGCTCCTAGACCCACACACC
16 Forward tgtaaaacgacggccagtAGGGTGTGTGGGTCTAGGAGC
  Reverse caggaaacagctatgaccGCTGTGAAGCTAACCATCATTTCG
17 Forward tgtaaaacgacggccagtGTGGGGTAGAATTGTAGCAGGA
  Reverse caggaaacagctatgaccATGAACAAAATGAAAGGAGGCAA
18-19 Forward tgtaaaacgacggccagtTTCCTGTCTGCCTCTGTCCCT
  Reverse caggaaacagctatgaccCAGCAGTCCAAGGTAGAAGCCA
20 Forward tgtaaaacgacggccagtATTAACCATTCAGCTCCTCAATCAC
  Reverse caggaaacagctatgaccTGCAGTCCCAGCCCACAG
21 Forward tgtaaaacgacggccagtGTTATGACGTGTGTGCGTGATT
  Reverse caggaaacagctatgaccCCTGCACCGTCTCCTAAATTG
22 Forward tgtaaaacgacggccagtGTTTGGCGAGTACCTGGCATATT
  Reverse caggaaacagctatgaccGGAAAACAAGTCAGGTGGGAAAG
23 Forward tgtaaaacgacggccagtCTGCTGTGTGGTTAGACGGCTT
  Reverse caggaaacagctatgaccTGCAATAACCTTCTTGTTTCAGTCA
M13 seq primer Forward tgtaaaacgacggccagt
  Reverse caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
table s5. Primers and probes for quantitative PCR
Gene/isoform Primer/probe Primer/probe sequence (5’ to 3’)
TET2 Forward primer AATTTATTGGATACACCTGTCAAGACTC
TET2 isoform 1 Reverse primer ACCTGCTCCTAGATGGGTATAAAAAG 
TET2 isoform 2 Reverse primer GATAAACGCCATGTGTCTCAGTACA 
TET2 Probe TATGATTTCCCATCTTGC
TET1 Primer/probe mix Hs00286756_m1 (TaqMan)
TET3 Primer/probe mix Hs00379125_m1 (TaqMan)
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table s6. Primers bisulfite sequencing
Gene Forward/Reverse Primer sequence (5’ to 3’)
P15 Forward_1 TTTAAAATATTAGTTTTGGTTTTATTGGAT
  Forward_2 TTTTAGTATTTTTGGGTAGGTTTTTT
  Reverse_1/2 ACCTAAACTCAACTTCATTACCCTC
MyoD Forward_1 GTTTTAAGTTTTTTGTTTTTTG
  Forward_2 GGGATAGAGGAGTATTGAAAGTTAGTTTAG
  Reverse_1/2 AAAACTTCCTCACCCCTAACTTCT
M13 seq primer Forward gtaaaacgacggccagt
  Reverse caggaaacagctatgac
table s7. Mutations at diagnosis and relapse
UPN Genetic defects diagnosis Present at relapse
128 FLT3-ITD yes*
  IDH1 no
140 FLT3-ITD yes
  IDH2 yes
  DNMT3A yes
256 FLT3-ITD yes
  NPM1 yes
  DNMT3A yes
282 FLT3-ITD yes
  NPM1 yes
  IDH1 yes
1530 AML1-ETO yes
* Different FLT3-ITD variants at diagnosis and relapse
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table s8. Mutations in genes involved in DNA (hydroxy)methylation (Continued)
UPN DNMT3A TET2 IDH1 IDH2 5mC level 5hmC level
6 N/A - p.R132H - 4.0 0.018
35 p.S714C - - p.R140Q 3.9 0.019
36 p.F640Y - - p.R172L 4.1 0.008
50 p.R882H - - p.R172L 4.0 0.013
80 N/A - - p.R140Q 3.8 0.028
88 p.V563M* - - p.R140Q 4.1 0.019
98 - p.R1359H - - 3.8 0.023
128 - - p.R132H - 4.1 0.023
140 p.R882C - - p.R140Q 4.1 0.016
256 p.R882H - - - 3.7 0.035
265 N/A - - p.R140Q 4.2 0.036
282 N/A - p.R132H - 4.0 0.014
290 N/A - p.R132H - 3.4 0.026
328 N/A - p.R132L - 4.2 0.013
329 p.IVS9-1G>T p.P1115LfsX2 - - 3.9 0.035
356 p.R882C p.N275IfsX18 - - 3.5 0.021
360 N/A - p.R132H - 3.4 0.013
362 N/A p.R1896M* - - 3.6 0.013
378 N/A p.R1993W - - 3.6 0.024
397 p.R882H - p.R132H - 4.0 0.013
405 p.S714C - - - 4.0 0.050
438 N/A - p.R132C p.R140Q† 4.0 0.013
463 p.R326H - - - 4.2 0.052
484 p.R882C - - p.R140Q 4.1 0.019
566 N/A - p.R132C - 3.7 0.007
573 N/A - p.R132C - 3.8 0.006
582 N/A - p.R132C - 3.4 0.010
596 p.R882H - - - 3.9 0.050
627 p.R882H - - - 3.8 0.034
630 p.G543C - - - 4.0 0.034
671 p.R882H - p.R132H - 4.2 0.024
690 - - p.R132C - 4.2 0.012
746 N/A - - p.R140Q 4.2 0.013
791 - p.I1873N - - 3.9 0.029
806 p.D252X* p.S137VfsX8 - - 3.8 0.013
    p.P929LfsX24        
824 N/A - p.R132L - 4.0 0.016
907 N/A - p.R132H - 3.8 0.021
910 N/A - - p.R140Q 3.9 0.014
935 N/A p.L615AfsX23 - - 3.2 0.014
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table s8. Mutations in genes involved in DNA (hydroxy)methylation (Continued)
UPN DNMT3A TET2 IDH1 IDH2 5mC level 5hmC level
    p.T229NfsX25        
970 N/A - - p.R140Q 3.8 0.017
977 N/A - - p.R140Q 3.9 0.017
1012 - - - p.R140Q 4.2 0.007
1031 p.R635W - - p.R140Q 4.1 0.020
1079 p.R882H - - - 3.6 0.056
1095 N/A - - p.R140Q 4.1 0.017
1174 N/A - - p.R140Q 3.9 0.012
1176 - - p.R132H - 4.1 0.024
1178 - - - p.R140Q 3.9 0.024
1253 N/A - p.R132C - 3.7 0.013
1266 p.R882H p.IVS2-2A>G - - 3.8 0.016
  p.N501S p.G1869E        
1269 p.R882H - - p.R140Q 4.0 0.020
1398 p.R882H p.H850R - - 3.9 0.043
1399 N/A - - p.R140Q 4.0 0.013
1433 N/A - - p.R172L 3.9 0.008
1456 p.R882H p.Q831TfsX15 - - 3.7 0.031
1546 - - p.R132H - 3.9 0.023
1575 N/A - - p.R140Q 3.9 0.008
1622 N/A - p.R132G - 3.7 0.013
1626 N/A - - p.R140Q 3.9 0.021
1652 p.C517R - - - 3.8 0.054
1663 N/A - - p.R140Q 3.8 0.022
1704 N/A - p.R132H - 3.7 0.019
1763 N/A - - p.R172L 4.1 0.006
1799 N/A - p.R132H - 4.2 0.015
1879 N/A p.T1397I - - 3.8 0.032
1915 - p.S1758X - - 3.7 0.029
    p.T1554SfsX16        
1928 p.IVS9del-
18_+1
p.Q749X - - 3.9 0.021
    p.D1384N        
2085 p.R882H - - - 3.8 0.038
2111 N/A - - p.R140Q 4.2 0.015
2112 - p.R1261H - - 3.8 0.006
    p.R1359S        
UPN indicates unique patient number; N/A, not analyzed; and - , wild type.
*Homozygous mutation
 † Subclonal IDH2 mutation
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table s9. Plasma 2-hydroxyglutarate levels in IDH wild type and IDH mutant AML patients
Sample IDH mutation TET2 mutation 2HG (µM)
1 IDH1 R132H  - 3.9
2 IDH1 R132C  - 10
3 IDH1 R132C  - 14
4 IDH2 R140Q  - 11
5 IDH2 R140Q  - 32
6 IDH1 R132C + subclonal IDH2 R140Q  - 6.3
7  - Q847X+S128fsX15 0.39
8  - R1261H+R1359S 1.3
9  -  - 0.22
10  -  - 0.30
11  -  - 0.35
12  -  - 0.55
table s10. Patient characteristics per 5hmC group (Continued)
 
 
 
5hmC groups Total cohort
<0.023  
(n=47)
0.023-<0.070  
(n=142)
0.070-0.091  
(n=17) (n=206)
No. (%) No. (%) No. (%) No. (%)
Age (years) at diagnosis        
 Median (range)  53 (35-60)  46 (16-60)  42 (16-59)  48 (16-60) 
 <30  0 (0.0)  18 (12.7)  3 (17.6)  21 (10.2) 
 30-40  1 (2.1)  31 (21.8)  4 (23.5)  36 (17.5) 
 40-50  14 (29.8)  40 (28.2)  5 (29.4)  59 (28.6) 
 50-60  32 (68.1)  53 (37.3)  5 (29.4)  90 (43.7) 
Sex        
 Male  18 (38.3)  77 (54.2)  6 (35.3)  101 (49.0) 
 Female  29 (61.7)  65 (45.8)  11 (64.7)  105 (51.0) 
WHO-ECOG performance status        
 PS 0  27 (57.4)  86 (60.6)  9 (52.9)  122 (59.2) 
 PS 1  19 (40.4)  48 (33.8)  7 (41.2)  74 (35.9) 
 PS 2  1 (2.1)  5 (3.5)  1 (5.9)  7 (3.4) 
 PS 3-4  0 (0.0)  3 (2.1)  0 (0.0)  3 (1.5) 
WBC (x109/l) at diagnosis        
 Median (range) 16.9 (0.5-291.0)  25.8 (0.6-312.5)  18.2 (1.0-196.4)  24.7 (0.5-312.5)
 < 25  25 (53.2)  69 (48.6)  10 (58.8)  104 (50.5) 
 25-99.9  11 (23.4)  53 (37.3)  5 (29.4)  69 (33.5) 
 >= 100  11 (23.4)  20 (14.1)  2 (11.8)  33 (16.0) 
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table s10. Patient characteristics per 5hmC group (Continued)
 
 
 
5hmC groups Total cohort
<0.023  
(n=47)
0.023-<0.070  
(n=142)
0.070-0.091  
(n=17) (n=206)
No. (%) No. (%) No. (%) No. (%)
FAB subtype        
 M0  4 (8.5)  6 (4.2)  1 (5.9)  11 (5.3) 
 M1  14 (29.8)  25 (17.6)  6 (35.3)  45 (21.8) 
 M2  8 (17.0)  51 (35.9)  6 (35.3)  65 (31.6) 
 M4  2 (4.3)  22 (15.5)  1 (5.9)  25 (12.1) 
 M5  17 (36.2)  29 (20.4)  2 (11.8)  48 (23.3) 
 M6  1 (2.1)  5 (3.5)  0 (0.0)  6 (2.9) 
 M7  0 (0.0)  1 (0.7)  0 (0.0)  1 (0.5) 
 Unknown  1 (2.1)  3 (2.1)  1 (5.9)  5 (2.4) 
Cytogenetic/FLT3-ITD risk group        
 Good  0 (0.0)  22 (15.5)  2 (11.8)  24 (11.7) 
 Intermediate (NN,-Y)  25 (53.2)  33 (23.2)  4 (23.5)  62 (30.1) 
 Poor (-5/5q-,-7/7q-,complex, 
 FLT3-ITD) 
 11 (23.4)  28 (19.7)  7 (41.2)  46 (22.3) 
 Others  10 (21.3)  53 (37.3)  4 (23.5)  67 (32.5) 
 UNK/ND/Failure  1 (2.1)  6 (4.2)  0 (0.0)  7 (3.4) 
Percentage BM blasts        
 Median (range)  76 (30-98)  64 (20-96)  68 (33-95)  67 (20-98)
 < 40%  1 (2.1)  23 (16.2)  2 (11.8)  26 (12.6) 
 40-<60%  11 (23.4)  35 (24.6)  3 (17.6)  49 (23.8) 
 60-<80%  12 (25.5)  41 (28.9)  6 (35.3)  59 (28.6) 
 80-<=100%  23 (48.9)  43 (30.3)  6 (35.3)  72 (35.0) 
No. indicates number; WHO-ECOG, World Health Organization-Eastern Cooperative Oncology Group; WBC, 
white blood cell count; FAB, French–American–British classification; UNK, unknown; ND, not determined; and 
BM, bone marrow.
table s11. Event-free survival status according to 5hmC level
Parameter
 
Patients 
(N)
 
Observed  
events (O)
Non-parametric  Cox model
Median  
(95% CI)(Years)
% at 5 Years 
(95% CI)
P-value 
(Log-Rank)
Hazard ratio 
(95% CI)
P-Value 
(Score 
test)
5hmC: <0.023 47 33 0.83  
(0.43, 1.54)
31.9  
(19.3, 45.3)  
0.159 
(df=2)
1.00 0.197 
(df=2)
5hmC: 0.023-
<0.070
141 96 0.92  
(0.57, 1.21)
31.4  
(23.8, 39.2)  
0.96  
(0.65, 1.43)  
5hmC: >=0.070 17 15 0.44  
(0.00, 1.63)       
6.4  
(0.4, 25.2)     
1.58  
(0.85, 2.91)  
95% CI indicates 95% confidence interval
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table s12. Multivariate Cox regression analysis for overall survival
Parameter P-value Hazard ratio
95% Hazard ratio
Confidence limits
Model 1 (5hmC as categorical variable, including WBC)*
5hmC: <0.023 vs 0.023-<0.070 0.18 1.35 0.87 2.10
5hmC: >=0.070 vs 0.023-<0.070 0.004 2.50 1.35 4.17
Cytogenetics/FLT3ITD: Good vs Intermediate 0.26 0.62 0.27 1.43
Cytogenetics/FLT3ITD: Others vs Intermediate 0.13 1.48 0.89 2.47
Cytogenetics/FLT3ITD: Poor vs Intermediate <0.0001 3.51 2.18 5.65
Cytogenetics/FLT3ITD: Unknown vs Intermediate 0.05 2.96 1.01 6.22
WBC: 25-<100 vs < 25 0.04 1.51 1.01 2.24
WBC: >100 vs < 25 0.17 0.69 0.41 1.17
Model 2 (5hmC as categorical variable, including BM blasts)
5hmC: <0.023 vs 0.023-<0.070 0.39 1.21 0.79 1.87
5hmC: >=0.070 vs 0.023-<0.070 0.01 2.15 1.18 3.93
Cytogenetics/FLT3-ITD: Good vs Intermediate 0.17 0.56 0.24 1.29
Cytogenetics/FLT3-ITD: Others vs Intermediate 0.15 1.46 0.88 2.44
Cytogenetics/FLT3-ITD: Poor vs Intermediate <.0001 3.17 2.01 5.03
Cytogenetics/FLT3-ITD: Unknown vs Intermediate 0.01 3.19 1.28 7.99
BM blasts: 40-<60% vs < 40% 0.73 1.12 0.60 2.09
BM blasts: 60-<80% vs < 40% 0.35 1.33 0.74 2.41
BM blasts: 80+ % vs < 40% 0.74 0.91 0.51 1.62
Model 3 (5hmC as continuous variable)        
5hmC x100: Linear effect 0.10 0.42 0.18 0.96
5hmC100 x 5hmC100: Quadratic effect 0.06 1.10 1.01 1.18
Cytogenetics/FLT3ITD: Good vs Intermediate 0.21 0.58 0.25 1.35
Cytogenetics/FLT3ITD: Others vs Intermediate 0.19 1.41 0.84 2.36
Cytogenetics/FLT3ITD: Poor vs Intermediate <0.0001 2.96 1.89 4.64
Cytogenetics/FLT3ITD: Unknown vs Intermediate 0.02 2.94 1.21 7.14
Model 1: AIC=1234
Model 2: AIC=1241
Model 3: AIC=1240
*WBC was excluded from table 2 (main manuscript) because the HR corresponding to the comparison in OS 
between WBC 25-<100 and WBC < 25 is around 1.5, whereas the HR for the comparison in OS between WBC 
>=100 and WBC < 25 is 0.7, which is unexpected as outcome generally decreases with increasing WBC. Since 
more patients in the WBC>=100 have poor cytogenetic/FLT3-ITD features than in the other WBC groups, such 
a low HR (+/- 0.7) counterbalances the HR of 3.51 (model 1 above) corresponding to the comparison poor 
cytogenetic/FLT3-ITD features vs intermediate risk group. 
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Figure S1. DNA (hydroxy)methylation pathway. Schematic overview of the DNA (hydroxy)methylation pathway,
showing the link between DNMT proteins, TET proteins and wild-type and mutated IDH proteins. 
Figure S2. Consort diagram
89
Figure S1. DNA (hydroxy)methylation pathway. Schematic overview of the DNA (hydroxy)
methylation pathway, showing the link between DNMT proteins, TET proteins and wild-type 
and mutated IDH proteins. 
Figure S2. Consort diagram
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Figure S3. Overall survival AML-12 cohort. The OS rate for the 206 AML-12 patients included 
in our study was slightly lower than for the non-included AML-12 patients.
Figure S4. 5hmC levels in peripheral blood and bone marrow are comparable. For 15 
patients 5hmC levels were measured in peripheral blood (PB) and bone marrow (BM). These 
measurements showed comparable levels using both sources. The Pearson correlation 
coefficient (r) was determined. UPN indicates unique patient number.
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Figure S5. Correlation of 5hmC levels with clinical and molecular parameters in TET2/IDH 
wild type patients. No significant correlation was found between 5hmC levels and (A) sex, 
(B) age, (C) initial performance status (PS), (D) WBC or (E) cytogenetics (FLT3-ITD status not 
considered). WBC indicates white blood cell count and Int, intermediate. Symbols indicate 
Mann-Whitney U test (*), Kruskal Wallis test (†), and Spearman correlation coefficient (rs, ‡).
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Figure S6. Blast count correlates with 5hmC levels in TET2/IDH wild type patients. 5hmC 
values in TET2/IDH wild type patients correlated with the percentage of blasts in (A) peripheral 
blood (PB) and (B) bone marrow (BM). Pearson correlation coefficients (r) were determined. 
Figure S7. Correlation between TET expression and global 5hmC values. 5hmC levels in AML 
patients without TET2 or IDH mutations were correlated with the mRNA levels of (A) TET1, 
(B) TET2 isoform 1, (C) TET2 isoform 2 and (D) TET3. Expression levels were normalized to 
GAPDH. No significant correlation could be observed between TET expression and 5hmC 
levels. Spearman correlation coefficients were determined. Iso indicates isoform. 
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Figure S8. Overall survival according to 5mC level. No strong correlation could be observed 
between global 5mC levels and overall survival. 
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abstract
Accurate propagation of DNA methylation patterns during replication is fundamental 
to cells. Recently the biological significance of DNA hydroxymethylation has 
become evident. It remains, however, unknown whether DNA hydroxymethylation 
is inherited during cell cycle. To address this question, we investigated global 
5-hydroxymethylcytosine levels during various phases of the cell cycle.
Endogenous TET (ten-eleven-translocation) mRNA and protein, as well as global 
5-hydroxymethylcytosine levels, were determined in G0/G1, S (early, mid, late), and 
G2/M phases of the cell cycle. TET mRNA and protein levels did not change. While 
5-methylcytosine content remained stable, 5-hydroxymethylcytosine declined to 
approximately 80% during late S and G2/M phases.
We conclude that, unlike 5-methylcytosine, 5-hydroxymethylcytosine is not 
sustained during cell cycle progression i.e. the 5hmC mark is not copied immediately 
during DNA synthesis. 
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introduction
DNA methylation is an epigenetic modification with a crucial role in the regulation 
of gene expression. It is mediated by the DNA-methyltransferase (DNMT) proteins 
and represents the covalent transfer of a methyl group to the 5th position of cytosine 
on DNA. 5-methylcytosine (5mC) is associated with transcriptional repression, 
playing a key role in processes such as genomic imprinting, X-chromosome 
inactivation and suppression of repetitive elements and transposons 1. Germ cell 
and early embryonic development are also accompanied by dynamic changes in 
DNA methylation patterns 2. To ensure their normal development, cells faithfully 
propagate the 5mC mark during DNA replication through the activity of the 
DNMT1 protein, the maintenance DNA-methyltransferase. During the S-phase of 
the cell cycle, DNMT1 is recruited to replication foci, where it preferentially binds 
hemi-methylated DNA and is thus responsible for copying 5mC onto the daughter 
strands simultaneously with the ongoing DNA replication 3.
The TET protein family (comprising of TET1, TET2 and TET3) first came into 
the spotlight when two landmark papers 4, 5 reported frequent TET2 mutations in 
myelodysplastic syndromes and myeloproliferative neoplasms. Defects in TET2 
occur in other myeloid cancers as well 6. Concurrently, the involvement of the 
TET proteins in the active DNA demethylation pathway was proven. TET enzymes 
convert 5mC to 5-hydroxymethylcytosine (5hmC), and further to 5-formyl (5fC) 
and 5-carboxyl (5caC) cytosine 7-9. 5fC and 5caC are recognized and excised by 
the thymine DNA glycosylase (TDG) and replaced by unmethylated cytosines. 
The TET enzymes have the potential to oxidize all three modifications, but for 
unclear reasons the process seems to halt at the stage of 5hmC. Compared to 
5fC and 5caC, 5hmC is significantly more prevalent in the genome 10. 5hmC levels 
are highest in neuronal cells and increase during brain development, suggesting 
the mark may be more than a mere DNA demethylation intermediate 11, 12. The 
existence of 5hmC-specific readers has further stregthened that notion, showing 
that apart from DNA repair enzymes, a number of transcriptional and chromatin 
regulators bind 5hmC, as well 13, 14. In addition, 5hmC levels also have prognostic 
value in cancer 15, 16. These data point to the possibility that 5hmC may indeed be 
a stable epigenetic mark with regulatory functions. 
We investigated the levels of all three TET proteins and 5hmC during different 
phases of the cell cycle, as the question arises whether DNA hydroxymethylation 
follows a similar pattern of transmission during DNA replication, as does its stable 
predecessor, 5mC. 
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materials and methods
Sorting of cells in different phases of the cell cycle
THP1, OCI-AML3 and HL60 cells were resuspended in fresh medium (37°C) to a 
concentration of approximately 1*106 cells /ml. Hoechst 33342 was added to a 
final concentration of either 10 µg/mL (OCI-AML3 and HL60), or 5µg/ml (THP1). 
Subsequently, cells were incubated at 37 °C for 45 minutes. Afterwards, cells were 
harvested and resuspended in PBS supplied with 1%FCS. 
Sorting was performed on a FACS ARIA SORP (BD Biosciences, NJ, USA) using 
a UV laser and a 450/50 filter. Doublets were discriminated using FSC area vs. 
width, SSC area vs. width, and Hoechst area vs. height. Sorting was performed 
based on Hoechst intensity into the following cell populations: G0/G1,S (early, mid 
and late), and G2/M. 
QPCR
THP1, OCI-AML3 and HL60 cells were cultured with 50µg/ml sodium L-ascorbate 
(Sigma - Aldrich, MO, USA) 17. Cells from G0/G1, S (early, mid and late) and G2/M 
phases of the cell cycle were sorted after incubation with Hoechst 33342. 
RNA was isolated using a Quick-RNA miniprep kit (Zymo Research, CA, USA). 
QPCR was performed using the following primer/probe mixes (Applied Biosystems, 
USA): TET1 (Hs00286756_m1 FAM-MGB), TET2 (Hs00289469_m1 FAM-MGB), TET3 
(Hs00379125_m1 FAM-MGB), and β-actin (4310881E VIC-TAMRA). 
5mC and 5hmC measurements
Global 5mC and 5hmC measurements were performed using an in-house developed 
HPLC tandem-MS method (for a detailed description of the entire protocol see 16)
Western blotting
THP1, OCI-AML3 and HL60 cells were cultured with 50µg/ml sodium L-ascorbate 
(Sigma-Aldrich). Cells from G0/G1, S (early, mid and late) and G2/M phases of the 
cell cycle were sorted after incubation with Hoechst 33342. In the cases of TET2 
and TET3 stainings, cell pellets were lysed in RIPA supplemented with benzonase 
(Novagen, Merck Millipore, Germany) and Complete Inhibitor of Proteases CIP (Roche, 
Basel, Switzerland) for 30min. For TET1 staining, nuclear extracts were prepared 
using the Episeeker nuclear extraction kit (Abcam, Cambridge, UK) according to 
the manufacturer’s instructions. Nuclei were subsequently lysed directly in sample 
buffer. SDS-PAGE was performed on a 6% PAA gel. Nitrocellulose membranes were 
used for Western blotting. The following primary antibodies and concentrations were 
used: TET1 antibody (1:500, Abcam, ab156993); TET2 antibody (1:1000, Diagenode, 
Liege, Belgium, c15200179); TET3 antibody (1:500, Abcam, ab139321); β-actin 
(1: 500, Sigma-Aldrich, A5441); cyclin A (1:500, Millipore, MA, USA, D5-375); cyclin 
B1 (1: 2500, Cell Signaling, MA, USA); GAPDH (1: 5000, Abcam, ab8425). 
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Cyclin A 
 
 Cyclin B1 
GAPDH 
UV 450/50 x1000 
THP1 
results and discussion
Sorting strategy 
Shortly, cells were incubated with Hoechst 33342 and immediately sorted into 
5 sub-populations: G0/G1, S (early, mid, late), G2/M (fig.1A). To ensure that the 
appropriate sub-populations were selected, cyclin A and cyclin B1 stainings were 
performed on THP1 cell lysates (fig.1B). As expected, both cyclins were absent in 
G0/G1. Cyclin A levels were highest in mid and late S phase. Cyclin B1 levels peaked 
during G2/M phase. Altogether, this proves that cells from different phases of the 
cell cycle were correctly sorted.
TET mRNA and protein levels remain stable during cell cycle
5hmC is derived from 5mC via the enzymatic activity of the TET proteins. To 
determine whether TET levels vary during cell cycle, both mRNA and protein levels 
were determined in THP1, OCI-AML3 and HL60 cells. Three different cell lines were 
used in order to ensure specific and exclude cell-line specific effects. Q-PCR of TET1, 
TET2 and TET3 was performed after sorting, and mRNA levels were normalized to 
β-actin. No significant changes in TET expression were detected (fig.2). In all three 
cell lines TET3 was most abundant, whereas TET1 levels were lowest. To check 
whether mRNA levels adequately reflect protein levels, endogenous TET1, TET2 
Figure 1. Sorting strategy (A) FACS plot of THP1 cells. A representative FACS plot of THP1 
cells is shown as an example of the sorting strategy we have utilized. Cells from G1, S (early, 
mid and late), and G2/M were sorted based on Hoechst 33342 intensity; (B) WB stainings 
of cyclin A and cyclin B1. THP1 cells were sorted into G1, S (early, mid and late), and G2M 
phases of the cell cycle. WB staining of cyclin A and cyclin B1 showed the expected patterns 
of expression, with both proteins being absent in G0/G1 and peaking around mid to late S, 
and G2/M phases. GAPDH was used as a loading control.
A B
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and TET3 protein levels were determined by Western blotting (WB). The protein 
levels of TET1, TET2 and TET3 remained stable during cell cycle (fig.3). 
Figure 2. TET mRNA expression levels do not vary during cell cycle. TET1, TET2 and TET3 
mRNA levels were measured in THP1, OCI-AML3 and HL60 (A, B and C) cells in different 
phases of the cell cycle. Data were normalized to b-actin. There was no significant variation 
in TET mRNA levels during G0/G1, S (early, mid, late) and G2/M. 
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Figure 3. TET protein levels remain stable during cell cycle. Either nuclear extracts (TET1) 
(A), or whole-cell lysate (TET2 and TET3) (B and C) from G0/G1, S (early, mid, late) and G2/M 
phases of the cell cycle, were used for WB. TET1 protein levels were normalized based on 
equal cell number input. The levels of all three TET proteins remained stable during cell cycle. 
*Two different anti-TET3 antibodies consistently recognized this band, which could be a 
shorter TET3 isoform (ENSP00000307803 according to ensembl database), or a breakdown 
product. The band indicated with an arrow corresponds to the full-length TET3 protein.
A
B
C
117
4C
y
to
sin
e
 h
y
d
r
o
x
y
m
e
th
y
la
tio
n
 d
u
r
in
g
 C
e
ll C
yC
le
 p
r
o
g
r
e
ssio
n
5hmC levels decline during S and G2/M phases of the cell cycle
To determine global levels of DNA (hydroxy)methylation, we made use of an HPLC-
MS-MS. In addition, 5mC levels were measured as a control. DNA was isolated 
from populations of THP1, OCI-AML3 and HL60 cells in G0/G1, S (early, mid and 
late), and G2/M phases of the cell cycle. 5mC and 5hmC were measured in each 
population. Each measurement was performed in a biological triplicate (fig.4).
Our results indicate that DNA hydroxymethylation does not follow the same 
pattern of inheritance as its preceding mark, DNA methylation. Global 5mC levels 
remained stable during replication since the methyl mark is immediately copied 
onto the daughter DNA strand, whereas 5hmC levels gradually decreased to 80 
-85% during late S and G2/M phases in all three cell lines and were restored to 100% 
during G0/G1. It would be very interesting to determine whether reinstallment of 
5hmC during G0/G1 occurs at the same loci. 
A
C
B
Figure 4. 5hmC levels decline during 
S and G2/M phases of the cell cycle. 
Global levels of 5mC and 5hmC were 
determined by HPLC-MS-MS in THP1, 
OCI-AML3 and HL60 cells. Cells were 
sorted into G0/G1, S (early, mid, late) 
and G2/M phases of the cell cycle prior 
to DNA isolation. Whereas 5mC levels 
remained stable during DNA replication, 
that was not the case for 5hmC. 5hmC 
levels in all three cell lines were reduced 
to approximately 80 -85% in late S and 
G2/M phases of the cell cycle. G0/G1 
was set at a 100%.
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5hmC appears to be secondary to the pre-exisiting 5mC mark, i.e no 5hmC can 
be generated without the prior existence of 5mC. Recently Otani et al, who also 
showed a decrease of 5hmC levels during DNA replication, demonstrated that the 
5mC required by the TET enzymes is generated by the de-novo methyltransferases, 
DNMT3a and DNMT3b 18. A possible scenario, therefore, might involve the de 
novo methylation of sites by the DNMT3 proteins, followed by the recruitment 
of additional factors, which trigger hydroxymethylation. Further studies are 
required to elucidate the precise mechanism that initiates the formation of 5hmC 
at specific sites. 
Altogether, our data suggest that the 5hmC mark has a different manner of 
regulation compared to 5mC. This could be logical, as 5mC is essential to a number 
of fundamental processes, such as genomic imprinting, X-chromosome inactivation 
and repression of retrotransposons, and this requires a faithful mechanism for 
maintenance.
We propose that 5hmC, unlike 5mC, is not a template for its own propagation 
during DNA replication and its formation throughout the cell cycle is dependent 
on the local epigenetic environment (DNA methylation, as well as histone 
modifications), rather than a meticulous mechanism for inheritance.
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1. what this thesis has achieved - conclusions
At the commence of this project, in September 2008, little was known about the 
TET2 gene and protein. Our group had recently identified a mutation in TET2 in 
an index MDS patient, and upon sequencing a cohort of MDS patients, discovered 
that, in fact, TET2 defects are a common event in MDS (25% of the patients). The 
objective of this thesis was to not only expand upon the clinical involvement of 
TET2 in AML (a frequent outcome/complication of MDS), but also study the (dys)
function of the protein in cells. Chapter 2 of this thesis shows that TET2 mutations 
are an independent marker of poor prognosis in AML patients. This emphasizes the 
importance of testing for TET2 mutations following a diagnosis of AML, because 
often the prognosis of a patient based on their genetic background influences the 
course of treatment. Given the size of the gene, PCR-based sequencing of TET2 
remains cumbersome, but I believe that within the near future next-generation 
sequencing technologies will prove valuable. In addition, this chapter proves that 
perhaps most, if not all, TET2 defects result in loss-of-function. TET2 mutants 
overexpressed in cell line systems failed to produce 5hmC, unlike the wild type 
protein. As 5hmC levels are influenced by a number of factors, besides the TET 
proteins, Chapter 3 was dedicated to studying the levels of 5hmC in AML patients 
and their potential association with patient survival. Interestingly, we identified high 
5hmC levels as a marker of poor prognosis. 
It remains unclear as to what extent 5hmC can be considered a stable DNA base. 
An important aspect of 5mC, the precursor of 5hmC, is its manner of transmission 
during DNA replication. DNA methylation is crucial to the normal development 
of cells. To ensure its proper distribution through generations, the DNMT1 
protein is recruited to replication foci during cell division, where it methylates the 
newly synthesized DNA strand. In Chapter 4, we reveal that unlike 5mC which 
is maintained during replication, 5hmC levels decrease during late S and G2/M 
phases of the cell cycle. This indicates that, likely, DNA hydroxymethylation does 
not serve as a template for its own propagation, but is rather a consequence of 
the pre-existing DNA methylation mark.
2. discussion points and future directions
Cooperative effect of genetic mutations affecting DNA methylation 
and DNA hydroxymethylation in leukemogenesis
An interesting observation was reported in Chapter 2 of this thesis. Upon analyzing 
co-existence of mutations in AML patients, we noticed that both TET2 and IDH1/2 
aberrations were frequently accompanied by a mutation in the DNMT3a gene (p= 
0.02 and p= 0.004, respectively). This is a somewhat puzzling notion given that 
these proteins have conflicting functions within the same biological pathway. While 
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TET2 and IDH defects perturb DNA hydroxymethylation (i.e. DNA demethylation), 
DNMT3a aberrations affect the DNA methylation pathway. (fig 1)
Inactivating TET2 mutations lead to decreased 5hmC levels. IDH mutations 
result in the production of the oncometabolite 2-hydroxyglutarate (2-HG), which 
also inhibits the TET proteins, thus indirectly contributing to lowering DNA 
hydroxymethylation levels. Assuming that TET2 and IDH1/2 mutations have, to some 
extent, overlapping effects, they could be considered a common entity. Therefore, 
the fact that 67% of AML patients with a DNMT3a mutation carry in addition either 
a TET2 or and IDH1/2 defect, cannot be ignored, and is strongly suggestive of 
a cooperative effect between DNA methylation and DNA hydroxymethylation 
defects in driving leukemogenic transformation (fig 2).
This hypothesis has been supported by a study published shortly after completion 
of this thesis. Zhang et al. (Zhang, Combined Effect of Dnmt3a Loss-Of-Function 
and Idh2 neomorphic mutation Promotes Hematopoietic Malignancy, 2013, ASH 
abstract) employed a mouse model carrying a double knock-out of the DNMT3a 
gene and an IDH2 R140Q mutation: DNMT3a (-/-)/ IDH2 R140Q. Mice developed an 
MDS/MPN-like disease with frequent progression towards AML. Strikingly, serum 
Figure 1. Leukemia-associated proteins in the DNA methylation and active DNA 
demethylation pathways  
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from these mice showed levels of 2-HG (2-hydroxyglutarate) which were higher 
than 2-HG levels measured in mice carrying the IDH2 R140Q mutation alone. This 
suggests that DNMT3a loss-of-function defects further stimulate the synthesis of 
2-HG. It is not yet clear how, but the authors of the study indicate a clear synergistic 
effect on the metabolome between the two genetic backgrounds. If the DNMT3a 
protein regulates promoters of genes involved in metabolic processes, that may 
explain why DNMT3a mutations further exacerbate metabolic deregulation, when 
combined with IDH defects.
Although this study provides an excellent first step towards unraveling the 
cooperative effect between mutations affecting DNA methylation and DNA 
hydroxymethylation, a lot remains to be discovered. It would be particularly 
interesting to create models which bear a DNMT3a mutation together with either a 
TET2, an IDH1 or an IDH2 defect and compare them to cells carrying the individual 
mutations, especially in terms of alterations affecting 5mC and its oxidized 
derivatives (5hmC, 5fC and 5caC). If, indeed, DNMT3a mutations co-occurring with 
IDH2 R140Q stimulate further metabolic changes, is that also true in the context 
of IDH1 mutations, and what is the precise mechanism of this cooperation? IDH1/2 
mutations induce rather pleiotropic epigenetic alterations, affecting not only DNA 
(hydroxy)methylation, but the histone code as well. How do DNMT3a and TET2 
mutations, on the other hand, contribute to a shared leukemogenic potential? It is 
reasonable to hypothesize that the combinations of these mutations would have 
a significant effect on gene expression. Should a particular biological pathway be 
affected, that would provide a strong rationale for the development of treatments 
targeting specific subgroups of AML patients carrying DNMT3a together with 
either TET2 or DNMT3a mutations.
Figure 2. Frequent co-occurrence of DNMT3a mutations together with TET2 or IDH 
mutations in AML patients
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5hmC levels in cancer and their association with cancer progression 
and prognosis
Aberrancies in 5hmC levels may be not only an important factor in cancer initiation/
progression, but also affect patient survival. As indicated in Chapter 3, high levels 
of 5hmC are an independent marker of inferior survival in AML patients. Multiple 
studies have shown that the prognostic significance of abnormal 5hmC levels 
extends beyond leukemia and may be a characteristic feature of cancer in general. 
Yang et al. 1 reported reduced 5hmC levels in human breast, liver, lung, pancreatic 
and prostate cancer and suggested that decreased TET expression caused the drop 
in 5hmC levels. Although our own data did not demonstrate a correlation between 
TET expression and 5hmC levels, we do not exclude the possibility that a reduction 
of TET levels would be obvious in a particular hematopoietic subtype. The authors 
propose the implementation of 5hmC levels measurement as a biomarker in cancer. 
In breast cancer, the leucin zipper LZTS1 had lower levels of 5hmC and TET1 
at the promoter region 2. In addition, this decrease correlated with unfavorable 
histopathologic parameters, such as lymph node involvement. Furthermore, down-
regulation of LZTS1 in breast cancer is associated with metastasis. Jawert et al. 3 
showed that TET2 and 5hmC levels are significantly reduced in oral squamous 
cell carcinoma. Orr et al. 4 reported that decreased 5hmC levels correlated with 
inferior survival in malignant glioma, and furthermore were associated with tumor 
progression and aggressiveness. Gambichler et al. 5 also demonstrated reduced 
5hmC levels in advanced melanomas. Gastric cancer patients with reduced 5hmC 
levels had significantly lower survival rate 6. Low 5hmC also correlated with inferior 
OS and more aggressive tumor behavior in hepatocellcular carcinoma 7. 
The majority of these studies are based on immunohistochemical stainings. If 
5hmC levels are to be used as a biomarker in cancer in the future, it is of utmost 
importance to implement more precise and quantitative methods for 5hmC 
determination.
Our study showed that most AML cases with low 5hmC could be explained 
by either a TET2 or/and IDH mutation. The precise contribution of low 5hmC 
to OS of patients in the context of these mutations needs to be explored in 
larger patient groups. There were, nonetheless, several unexplained cases in 
our cohort. It would be interesting to determine what causes the drop of 5hmC 
in these patients. Several scenarios could be envisaged. In 2013, the group of 
Rao showed that the CXXC domain protein IDAX (CXXC4) modulates TET2 
expression, hence DNA hydroxymethylation 8. Bioinformatic analysis has shown 
that IDAX was initially encoded by an ancestral TET2 gene, which underwent a 
chromosomal re-arrangement during evolution resulting in gene inversion which 
split the CXXC domain from the catalytic portion of TET2. IDAX recruits TET2 to 
DNA and subsequently activates a caspase reaction leading to the degradation, 
hence downmodulation, of the TET2 protein. In addition, it has been previously 
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demonstrated that IDAX is an inhibitor of the Wnt signalling pathway and has 
been implicated in malignant renal cell carcinoma and colonic villous adenoma 9. 
Therefore, it is likely that mutations or de-regulated expression of IDAX could 
also contribute to disturbances in 5hmC levels. In the past few years several 
AML genomes have been sequenced. As no study thus far has reported putative 
mutations of IDAX (CXXC4) in AML, and decreased expression of the gene has 
previously been associated with renal carcinoma, the expression levels of IDAX 
should be investigated in the context of AML.
Alternatively, TET2/5hmC levels may be downregulated by miRNAs. microRNAs 
are small non-coding RNAs which bind to 3‘UTRs of mRNA molecules and infuence 
their stability. Up to date, several miRNA have been shown to affect TET2 levels. 
miRNA- 29a levels inversely correlate with TET levels 10. mi-RNA22 is upregulated 
in MDS and leukemia and its expression confers poor OS of patients. TET2 is key 
target of mi-RNA22 11. mi-RNA22 downregulates TET2 expression in patients, 
hence decreases 5hmC levels. Most recently, Cheng et al. 12 reported that mi-
RNA125b, mi-RNA29b, mi-RNA29c, mi-RNA101 and mi-RNA7 target TET2, and 
are exclusively overexpressed in TET2 wild type AML.
Despite the afore-mentioned hypotheses, the possibility remains that some 
case will remain unexplained. The best way to approach those would be the 
utilization of next-generation sequencing technologies.
Not only low, but also high 5hmC levels, affect patient outcome. Chapter 3 
of this thesis shows that high 5hmC levels are an independent indicator of poor 
prognosis in AML. In addition, AML1-ETO and MLL translocations were found more 
frequently in patients with high 5hmC. Huang et al. 13 established a link between 
TET1 and MLL demonstrating that TET1 is a direct target of MLL-fusion proteins. 
Furthermore, TET1 was found to be up-regulated in MLL-rearranged leukemias, 
resulting in a global increase of 5hmC levels. Generally, the AML-ETO translocation 
is associated with relatively good prognosis, unless c-kit mutations are present. 
It would therefore be very valuable to determine whether high 5hmC occurs in 
patients carrying AML-ETO in combination with c-kit abnormalities.
Based on the fact that TET mutations alone are unable to cause leukemia, 
the group of Helin (Rasmussen, TET Proteins and Histone Modifications in 
Hematopoiesis, 2013, ASH abstract) set out to determine which additional 
aberrations might cooperate with the TETs in the initiation of leukemia. The 
study suggests that AML1-ETO fusion together with TET2 mutations synergize 
causing an aggressive AML-like disease in mice. DNA methylation was indeed 
altered displaying progressive hypermethylation of gene regulatory elements. 
However, the authors make no mention of global 5hmC levels in mice carrying 
both defects. Moreover, in patients, TET2 mutations and AML1-ETO co-occur only 
rarely. It remains therefore unclear how, and whether, the AML1-ETO fusion protein 
alters DNA hydroxymethylation levels. ETO is known to interact with HDACs and 
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co-repressors, such as Sin3a 14, 15, and the fusion protein can recruit DNMT1 to 
target genes 16. The substantial involvement of AML1-ETO in epigenetic processes 
gives a strong rationale to investigate in-depth the link between high 5hmC and 
AML1-ETO fusion.
Since AML1-ETO, in the absence of secondary events 17 is also insufficient for 
leukemogenesis, possibly additional factor(s) contribute to the increase of 5hmC 
levels in AML patients. 
5hmC – the “sixth base”?
Despite our growing knowledge of DNA (de)methylation and the proteins involved 
in these epigenetic processes, the precise mechanisms that govern and regulate 
them, need to be defined. The discovery of the TET proteins and their role in the 
formation of 5hmC marked a new era in the area of DNA demethylation - a pathway 
that had remained controversial for many years. The TET proteins oxidize 5mC 
consecutively to 5hmC, 5fC and finally 5caC; 5fC and 5caC are recognized and 
excised by the TDG protein and replaced by an unmethylated C. This process could 
have been construed as simple and straightforward, were it not for the puzzling 
fact that the TET proteins seem to halt at the stage of 5hmC. The explanation for 
this is presently unknown and has evoked discussion as to the function(s) of DNA 
hydroxymethylation. Initially, researchers expected that as a DNA demethylation 
intermediate 5hmC would simply counteract the consequences of 5mC and reverse 
gene silencing. Surprisingly, the group of Helin showed that a number of Tet1-
bound genes were downregulated. This implies that 5hmC does nor per se indicate 
activation of gene expression and may be subject to more complex regulation 
than anticipated 18. Moreover, a recent study claims that despite their overlapping 
functions, the TET proteins in fact have different roles in the demethylation cascade, 
with TET2 and TET3 being primarily responsible for the further oxidation of 5hmC 
into 5fC and 5caC 19. Based on this study, one could hypothesize that while TET1 
is responsible for a poised state i.e. a halt at the level of 5hmC, TET2 and TET3 
may indeed be associated with upregulation of gene expression.
The presence of 5hmC varies across different tissues and cell types. Highest 
levels of 5hmC have been measured in the brain, especially in the brain cortex 20. This 
is an extremely interesting observation, not only in terms of 5hmC function, but also 
evolution of the brain. The cerebral cortex is associated with higher brain function 
- cognition, reasoning, decision-making, problem-solving, visual processing to 
name a few. One can envisage that such complex processes require an adaptable 
cellular machinery, one equipped to quickly translate input into gene expression. 
In this context, 5hmC, even 5fC and 5caC, could be viewed as an additional layer 
to the complexity of DNA methylation regulation in mammals 21 – a step in the 
evolutionary process. It would therefore be very important to determine how the 
distribution of the TET proteins and 5hmC has changed throughout evolution.
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While 5hmC levels are high, 5fC and 5caC have not been found to accumulate 
in brain tissues 22. They are present in much lower levels in the genome and are 
believed to be only transient, short-lived intermediates in the DNA methylation 
cascade. 5hmC, but also 5fC, attracts specific “readers” 23, 24. Those include DNA 
repair enzymes, but also transcriptional and chromatin regulators. 
Altogether the data discussed so far neither prove, nor invalidate, the premise 
that 5hmC is a stable epigenetic mark with functions beyond DNA demethylation.
In Chapter 3 we hypothesized that based on its lack of a clear inheritance 
pattern during cell cycle, 5hmC should not be viewed as a stand-alone mark. 
Global 5mC levels remained stable during DNA replication, since the methyl 
mark is immediately copied onto the daughter DNA strand by DNMT1. However, 
5hmC levels declined to 80 -85% during late S and G2/M phases in all three cell 
lines that we tested. Albeit not seemingly dramatic, the consequences of this 
decrease should be considered in the context of the asymmetric distribution of 
5hmC. Following base-resolution sequencing of 5hmC in the mammalian genome, 
Yu et al. 25 showed that although ~92% of 5mC was symmetrically modified, 
that was true for only 21% of 5hmC sites. The major implication of this finding 
would be the complete loss of 5hmC on a number of daughter DNA strands post 
replication. Nonetheless, according to our data 5hmC levels are restored in G0/G1. 
It remains unclear whether 5hmC is re-established at the same genomic positions, 
or deposited at different sites. It would be particularly interesting to gain more 
insight into DNA hydroxymethylation changes occurring both globally and at 
local promoters during various phases of the cell cycle, using base-resolution 
sequencing technologies.
5hmC is dependent on 5mC generated by the de-novo methyltransferases, 
DNMT3a and DNMT3b 26. DNMT3a and DNMT3b, unlike DNMT1, can recognize 
and methylate cytosine in the context of hemi-hydoxymethylated DNA 27, 
suggesting that 5hmC could by itself trigger local epigenetic changes. At sites 
where 5hmC is completely lost, however, there must be other factors responsible 
for restoring the mark at these positions. IDAX has been shown to regulate the 
activity of the TET proteins 8. Direct interactions exist between TET1 and EZH2, 
a member of the PRC2 complex involved in histone methylation 28. Nevertheless, 
the first step in generating 5hmC is the recruitment of the DNMT3 proteins and 
the establishment of the DNA methylation signature. Although not a definitive 
proof, our study clearly supports the notion that 5hmC, and likely 5fC and 5caC, 
add to the complexity of DNA methylation regulation, but do not rank equal with 
it. The oxidized derivatives of 5mC could be merely intermediates in the DNA 
deymethylation pathway. Unravelling the intricate mechanisms that govern this 
pathway remain a fascinating challenge that will certainly inspire a number of 
researchers in the foreseeable future. 
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3. concluding remarks
Undeniably research, much like fashion, is driven by trends. There is no doubt that 
the current “sweethearts”, the TET proteins and 5hmC, have taken the limelight and 
attracted the attention of scientist from both the hematology and the epigenetics 
fields, and are slowly expanding their influence to include cancer research and 
neurobiology, among others. This has resulted in a number of crucial discoveries in 
a short time. It is my belief, that the following years will witness significant progress 
on several fronts. Firstly, scientists need to unveil the precise mechanism governing 
the DNA demethylation cascade. Despite their seemingly overlapping functions, 
it is clear that the TET proteins likely have unique activities too 21. Establishing 
what those are will thus contribute to understanding better the dynamics of 5mC, 
5hmC, 5fC and 5caC. Secondly, as the TETs and 5hmC represent just a piece of 
the bigger epigenetic puzzle, deciphering the interplay between DNA methylation, 
DNA hydroxymethylation and histone modifications, is crucial to understanding the 
processes that ultimately drive or suppress gene expression. And finally, but most 
importantly, the knowledge we gather along the way should be translated into the 
development of “smarter”, more sophisticated (epigenetic) treatments, than the 
ones we can currently offer to patients with myeloid malignancies.
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In 2009 novel mutations in the TET2 gene were reported in myelodysplastic 
syndromes (MDS) and myeloproliferative neoplasms (MPN). TET2 belongs to a 
family of proteins, including also TET1 and TET3. The TETs belong to the group 
of 2-oxoglutarate and Fe-dependent dioxygenases and catalyze the sequential 
oxidation of 5-methylcytosine 5mC) into 5-hydroxymethyl- (5hmC), 5-formyl- (5fC) 
and finally 5-carboxyl-cytosine (5caC). 5caC is recognized by the cell’s base-
excision repair machinery and replaced by an unmethylated cytosine. Essentially, 
the discovery of the TET proteins marked a new era in the area of active DNA 
demethylation, a process that had previously remained controversial and elusive. 
Since epigenetic deregulation is a hallmark of cancer, we wanted to further 
investigate the significance of TET2 mutations, both clinically and functionally. 
Approximately 30% of MDS patients eventually progress to acute myeloid leukemia 
(AML). In Chapter 2 of this thesis, we determined the clinical and biological 
significance of TET2 aberrations in a well-characterized cohort of younger AML 
patients (age ≤60). We found that TET2 mutations affect approximately 8% of 
the patients, but more importantly, that they are a marker of poor prognosis. 
TET2 mutations are mutually exclusive of IDH defects, but frequently co-occur 
with both NPM1 and DNMT3a mutations. In addition, patients who carry both 
TET2 and NPM1, and TET2 and DNMT3a aberrations have a worse overall survival 
compared to NPM1 or DNMT3a single mutations. Our next goal was to determine 
what the biological effect of TET2 mutations was. Overexpression of six mutant 
TET2 sequences in cell lines showed that all TET2 mutations are loss-of-function, 
but are not dominant negative. Given that loss-of-function TET2 aberrations had 
a negative impact on OS of patients we further investigated whether low TET2 
expression in TET2 wild type AML patients would affect outcome. We found that 
low TET2 expression, which is not caused by TET2 defects, may indeed result in 
inferior survival in AML. 
Following up on this study, in Chapter 3, we measured 5hmC levels in the same 
cohort of AML patients as to find out whether 5hmC levels have prognostic value. 
First we compared levels of 5hmC in healthy vs. AML patient cells. Notably, healthy 
cells showed a narrow range of 5hmC values, whereas patient cells had a much 
wider distribution of 5hmC levels, already suggesting that deregulation of DNA 
hydroxymethylation may be a distinct feature of AML. Within the patient group, we 
identified three subpopulations based on 5hmC levels, namely low, intermediate 
and high. TET2 and IDH1/2 mutations both result in reduced levels of 5hmC. Most 
of the patients with low 5hmC in our study did in fact carry either a TET2, or an 
IDH aberration. TET2 mutations are known to have a negative impact on survival, 
but the effect of IDH defects remains unclear. The significance of low 5hmC levels 
on OS in the context of TET2 and IDH mutations should be investigated in larger 
patient cohorts. Interestingly, high 5hmC levels were an independent indicator 
of poor prognosis in AML. In addition, they correlated with MLL and AML1-ETO 
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aberrations. Altogether, this study suggests that aberrant 5hmC levels can be 
independent of TET2 and IDH mutations, but still have a significant impact on OS 
of AML patients. 
Although it is clear that 5hmC is an intermediate along the DNA demethylation 
pathway, many questions regarding its function(s) remain unanswered at present. 
The high levels of 5hmC in some tissues, such as the brain, as well as the existence 
of 5hmC-specific readers, have led to the hypothesis that the “sixth” DNA base may 
in fact be a functional mark, and not simply a demethylation by-product. However, 
the evidence presented in Chapter 4 of this thesis does not support this hypothesis. 
Unlike DNA methylation levels which remained stable during DNA replication, 
DNA hydroxymethylation levels dropped to approximately 80% in late S and G2/M 
phases of the cell cycle and were restored during G0/G1. The reduction of 5hmC 
levels was not related to TET, as neither mRNA, nor protein levels of TET1, TET2 
and TET3, changed during various stages of the cell cycle. Since 5hmC can only 
be formed based on the pre-existence of 5mC in the genome, we conclude that 
DNA hydroxymethylation is secondary to DNA methylation. 
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Blood is a highly specialized tissue consisting of different types of cells, namely 
erythrocytes (red blood cells), leukocytes (white blood cells) and thrombocytes 
(platelets), suspended in plasma. Red blood cells are the most abundant and 
their function is to transport oxygen in the body. White blood cells represent 
the immune system and defend the body against infections and foreign material, 
whereas platelets are responsible for blood clotting. All mature blood cells originate 
from pluripotent hematopoietic stem cells - special cells, which are capable of 
differentiating (maturing) into multiple cell types. Hematopoiesis (from Ancient 
Greek: haima blood and poiesis to make), or the formation of all mature blood 
cells, before they enter the bloodstream, is a complex process, which takes place 
in the bone marrow. 
Sometimes, due to mistakes in the DNA sequence, hematopoiesis is impaired. 
Immature blood cells become blocked at a certain stage in their maturation and 
cannot progress further. In addition, they lose their ability to control cell division 
and start expanding uncontrollably. As a result, the bone marrow and/or blood 
become overpopulated by non-functioning, immature blood cells - a cancer of 
the blood (leukemia). Generally, depending on the blood cell type, and stage at 
which cell differentiation is arrested, different types of leukemia exist. Patients with 
leukemia suffer from anemia, susceptibility to infections and inability to clot, due 
to the lack of red and white blood cells, and platelets.
In the past 50 years, especially after the discovery of DNA structure in 1953, 
researchers have made significant progress in understanding the human genome 
- the genetic material of an organism. Every cell in our body contains DNA in its 
nucleus. DNA consists of 4 building blocks: A (adenine), (G) guanine, C (cytosine) 
and T (thymine). A gene is a short stretch of DNA, which contains the instructions 
for the synthesis of a protein. Proteins are essential to the proper functioning of 
cells, tissues and ultimately the whole organism.
Mistakes in a particular DNA sequence, for instance the substitution of an A for 
a G, are called mutations. Leukemia is caused by various genetic mutations. Our 
increasing knowledge of how these mutations affect the corresponding proteins 
and disrupt cellular processes has led to more refined leukemia classifications, 
more precise diagnosis and prognostic scoring of patients, and will eventually 
translate into better treatment strategies. Genetic testing already gives physicians 
the opportunity to offer more tailored treatment, based on the specific set of 
mutations that a patient carries. Certain mutations give a better prognosis and can 
be approached with less intensive cures, whereas others have a worse prognosis. 
Patients with a poorer prognosis and increased risk of relapse are treated more 
aggressively. 
In 2009, our group found a novel mutation in a gene that had never been 
described before. The gene is called TET2, and although at the time we didn’t know 
that, it functions as an epigenetic regulator. Since every single cell in our bodies 
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carries that same genetic information, there have to be mechanisms which regulate 
gene expression. Essentially this means that certain genes, which are active in 
liver cells for instance, should not be expressed in neurons, and vice versa. These 
highly specific patterns of gene expression are possible due to the existence of 
the “above genetic” code, i.e. the epi-genetic code. The most famous epigenetic 
modification is DNA methylation, which entails the addition of a methyl group to 
cytosine (C => 5mC), one of the building blocks of DNA. Stretches of DNA which 
contain methylated cytosines signify repression of gene expression. The TET2 
gene converts 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), and 
further to 5-formyl and 5 carboxyl-cytosine. The formyl and carboxyl derivatives 
are then excised by specific enzymes and replaced by C (cytosine), thus reverting 
gene silencing. Regulation of gene expression is an extremely complex process, 
and the TET2 protein turned out to be very important player in it. 
In Chapter 2 of this thesis, we determined the prognostic and biological 
significance of TET2 mutations in a specific type of leukemia, called acute myeloid 
leukemia (AML). AML is the most common type of acute leukemia in adults, and its 
incidence increases with age. We wanted to determine how TET2 mutations affect 
prognosis of AML patients. Our study included 357 AML patients and mutations 
were found in 8% of the patients. Moreover, TET2 mutations were a marker of 
poor prognosis. We also measured the levels of expression of the TET2 gene in 
patients and discovered that lower levels of TET2 in AML patients who do not carry 
a mutation in the gene, also signify worse overall survival. It remains unknown what 
causes the decrease of TET2 in these cases. 
Although this information already makes a difference for diagnosing and treating 
a patient with a TET2 mutation, it still does not explain how the mistake in the gene 
causes the disease. To answer that question, we made use of a cell line model. Cell 
lines are immortalized cells which can grow indefinitely in laboratory conditions 
and are often used in research. Making use of molecular cloning technology, the 
TET2 gene was artificially introduced in different cell lines. 5hmC, the product of 
TET2 activity, was used as readout. Wild type (non-mutated) TET2 was compared 
to 6 different mutant TET2 proteins. Unlike wild type TET2, which was able to 
produce 5hmC, none of the 6 mutants did. This shows that TET2 mutations cause 
loss-of-function in AML cells which carry the mutation, i.e. mutations found in AML 
inactivate TET2 function and likely cause disturbances in gene expression. 
5hmC is a direct product of the activity of TET2, but it certainly depends on more 
factors. Some proteins are part of large protein complexes, with each component 
being responsible for a particular task. Others regulate the expression of proteins 
by marking them for degradation. This means that proteins, other than TET2, could 
cause a similar phenotype, i.e. a reduction in 5hmC levels, when they mis-function. 
For instance mutations in another gene, called IDH, lead to the production of a 
metabolite, 2-hydroxyglutarate, which inhibits the function of TET2. Patients who 
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have IDH mutations, but an intact TET2, also present with decreased 5hmC levels. 
TET2 and IDH mutations are therefore mutually exclusive - they affect the same 
biological pathway, so they almost never occur together in the same patient. The 
reason for this is that even if cancer cells do acquire both mutations, that does not 
provide them bigger growth advantage.
In Chapter 3, we investigated the levels and prognostic value of 5hmC levels 
in 206 AML patients. 5hmC levels in healthy blood cells varied only in a narrow 
range, however, 5hmC in AML cells was distributed in a much wider range. Some 
patients had levels which were in the same scope as healthy cells. Others had lower 
or higher 5hmC levels. Most of the low 5hmC cases could be explained be the 
presence of a mutation either in TET2, or in IDH. There were, nonetheless, patients 
with unexplained low 5hmC levels. It would be very interesting to find out what the 
cause for that is. More importantly, this study showed that high 5hmC levels are 
a marker of poor prognosis. Research performed on 5hmC levels in other types 
of cancer has also indicated that 5hmC levels may be an important biomarker in 
cancer. Even though, we do see that certain mutations are more prevalent in AML 
patients with high 5hmC levels, it remains unknown what the precise mechanism is. 
Whereas Chapters 2 and 3 focused more on the clinical relevance of TET2 and 
5hmC, Chapter 4 explored aspects of their basic biology.
DNA methylation (5mC), the mark that silences gene expression, is fundamental 
to cells. It ensures that certain regions of DNA, which need to remain repressed, 
will be. It is also crucial for genomic imprinting and X-chromosome inactivation. 
Genomic imprinting is an interesting epigenetic phenomenon leading the parent-
of-origin-specific gene expression. We always get one copy of DNA from our 
mother, and one from our father, meaning that we get two sets of genes. Certain 
genes are “imprinted” - the copy that is expressed always comes from the same 
parent, whereas the other always remains silent. DNA methylation mediates that 
process. X-chromosome inactivation is another fascinating event taking place in 
the cells of females. Females inherit two copies of the X-chromosome, but to 
function normally they only need the set of genes located on one X-chromosome. 
To compensate for that, one X chromosome in the cell is always inactive, or silent. 
The choice which X-chromosome will be inactivated in any given cell in the body is 
random. DNA methylation makes sure that one X-chromosome in each cell remains 
silent and that effect lasts over the next cell generations, the effect is heritable. 
When cells divide, the need to first double, i.e. replicate, their DNA, so that each 
daughter cells gets an identical set of genetic information. During DNA replication, 
the DNA double helix unwraps and each strand is used as a template, so that 
after completion of cell division one strand comes from the mother cell and one 
strand, which is identical, is newly synthesized. In theory, DNA replication poses 
a problem for DNA methylation, as the daughter DNA strand would contain a 
normal cytosine, instead of a methylated one (C instead of 5mC) at the end of 
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the process. This would be detrimental to the cell. The examples in the previous 
paragraph demonstrate the importance of epigenetic memory. Therefore, cells 
have developed a mechanism to prevent that from happening. A specific enzyme 
called DNA-methyltransferase 1, DNMT1, makes sure that cytosines on the newly 
synthesized DNA get methylated already during DNA replication. 
In Chaper 4 of this thesis we asked whether 5hmC, like 5mC, is inherited 
during DNA replication. This study not only aimed at answering a basic scientific 
question about 5hmC, but also at shedding light on the discussion whether DNA 
hydroxymethylation is a stable epigenetic mark, or simply an intermediate in the 
pathway that reverses gene silencing caused by DNA methylation. We measured 
both 5mC (as a control) and 5hmC. Due to the mechanism for 5mC transmission 
during DNA replication, its levels remained unchanged at different phases of 
the cell cycle. In contrast, the levels of 5hmC decreased during DNA replication, 
showing that this epigenetic mark is not sustained in a similar manner, as 5mC. 
This leads us to believe that, although 5hmC is an important component of the 
DNA (de)methylation pathway, it is not a stand-alone epigenetic mark, but rather 
an intermediate in the process. It would be extremely interesting to investigate 
in depth what factors dictate the formation of 5hmC at given DNA sites and how 
that relates to the life cycle of the cell. 
It is my hope that future research will unravel the many yet unanswered questions 
about TET2 and 5hmC, but most of all, that this will result in the development of 
targeted epigenetic therapies for patients with defects in the DNA (de)methylation 
pathway.
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Bloed is een zeer gespecialiseerd weefsel dat bestaat uit verschillende soorten 
cellen, namelijk erythrocyten (rode bloedcellen), leukocyten (witte bloedcellen) 
en thrombocyten (bloedplaatjes). Deze zijn opgelost in bloedplasma. Rode 
bloedcellen zijn het meest aanwezig en hun functie is het vervoeren van zuurstof 
in het lichaam. Witte bloedcellen vertegenwoordigen het immuunsysteem en 
verdedigen het lichaam tegen infecties en vreemd materiaal. Bloedplaatjes 
zijn betrokken bij bloedstolling. Alle volwassen bloedcellen zijn afkomstig uit 
pluripotente hematopoëtische stamcellen. Dit zijn speciale cellen die in staat zijn 
te differentieren (groeien) naar verschillende soorten cellen. Hematopoëse (uit het 
oud-grieks: haima is bloed en poiesis is maken), of het vormen van alle soorten 
bloedcellen, voordat ze het bloedsomloop toetreden, is een complex proces dat 
plaats vindt in het beenmerg. 
Er zijn voorvallen waarbij hematopoëse verzwakt door fouten in de DNA 
sequentie. Onvolgroeide bloedcellen worden geblokkeerd in een van hun 
groeifases en zijn niet in staat verder te ontwikkelen. Verder zijn ze niet meer in 
staat hun celdeling te controleren en breiden zich ongeremd uit. Als resultaat 
wordt het beenmerg en/of bloed overvloed door niet-functionerende onvolgroeide 
bloed cellen – er is sprake van bloedkanker (leukemie). In het algemeen, afhankelijk 
van het type bloedcel en de groeifase waar het differentiëren gestopt is, bestaan 
er verschillende soorten leukemie. Patiënten met leukemie lijden aan anemie, 
kwetsbaarheid voor infecties en het onvermogen tot bloedstolling. Dit komt door 
het tekort aan rode bloedcellen, witte bloedcellen en bloedplaatjes. 
In de afgelopen 50 jaar, vooral na de ontdekking van de DNA structuur in 1953, 
hebben onderzoekers aanzienlijke vooruitgang geboekt in het begrijpen van het 
humaan genoom – het genetisch materiaal van het menselijk organisme. Elke cel in 
ons lichaam bevat DNA in de celkern. DNA bestaat uit 4 bouwstenen: A (adenine), 
G (guanine), C (cytosine) en T (thymine). Een gen is een kort stukje DNA dat de 
instructies bevat voor de synthese van een eiwit. Eiwitten zijn essentieel voor het 
functioneren van cellen, weefsels en uiteindelijk het hele organisme.
Fouten in een DNA sequentie, bijvoorbeeld het vervangen van een A door een 
G, worden mutaties genoemd. Leukemie wordt veroorzaakt door verschillende 
genetische mutaties. Onze groeiende kennis van hoe deze mutaties hun 
bijbehorende eiwitten beïnvloeden en cellulaire processen verstoren heeft geleid 
tot verfijnde leukemie classificaties en preciezere diagnoses van patiënten. Dit zal 
uiteindelijk ook leiden tot betere strategiën voor behandeling. Genetische tests 
helpen artsen behandelingen op maat te bereiden, gebaseerd op de specifieke 
set van mutaties die een patiënt draagt. Bepaalde mutaties geven een betere 
prognose en kunnen benaderd worden met minder intensieve behandelingen. 
Patiënten met een slechtere prognose en verhoogde kans op terugval worden 
agressievere therapiën behandeld.
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In 2009 vond onze groep een niewe mutatie in een gen dat nog niet eerder 
beschreven was. Dit gen is genaamd TET2 en het functioneert als een epigenetische 
regulator. Aangezien elke cel in onze lichamen dezelfde genetische informatie 
draagt moeten er mechanismen zijn die genexpressie reguleren. Dit betekent 
bijvoorbeeld, dat genen die geactiveerd worden in levercellen niet actief moeten 
worden in neuronen, en vice versa. Deze zeer gespecialiseerde patronen van 
genexpressie zijn mogelijk door het bestaan van de hogere genetische code, 
ofwel de epigenetische code. De meest bekende epigenetische modificatie is DNA 
methylatie. Deze voegt een methyl groep aan cytosine (C -> 5mC), een van de 
bouwstenen van DNA. Stukken DNA die gemethyleerde cytosines bevatten duiden 
op onderdrukking van genexpressie. Het TET2 eiwit converteert 5-methylcytosine 
(5mC) naar 5-hydromethylcytosine (5hmC), en verder naar 5-formyl- en 5-carboxyl-
cytosine. De formyl en carboxyl toevoegingen worden dan met behulp van 
enzymen weggesneden en weer door cytosine vervangen. Dit brengt het gen 
dus weer tot expressie/activatie. Regulatie van genepressie is een complex proces 
en het TET2 eiwit is daar zeer bij betrokken.
In Hoofdstuk 2 van deze scriptie hebben we de prognostische en biologische 
significantie van TET2 bepaald. Dit is gedaan voor een specifieke vorm van leukemie, 
genaamd acute myeloïde leukemie (AML). AML is de meest voorkomende soort 
leukemie in volwassenen en de incidentie ervan neemt toe met de leeftijd. Wij 
wilden bepalen hoe TET2 mutaties de prognose van AML patiënten beïnvloeden. 
Onze studie besloeg 357 AML patiënten en mutaties werden gevonden in 8% van 
deze groep. Het vinden van een TET2 mutatie duidt aan op een slechte prognose. 
We hebben de hoeveelheden van het TET2 gen gemeten in de patiënten en 
vonden dat lagere hoeveelheden van TET2 zonder een mutatie van het gen ook 
duiden op een slechtere overlevingskans. Het is onbekend wat de verminderde 
hoeveelheid van TET2 in deze voorvallen veroorzaakt. 
Deze informatie is nuttig voor de diagnose en behandeling van een patiënt met 
de TET2 mutatie. Het legt echter niet uit hoe de fout in het gen de aandoening 
veroorzaakt. Om deze vraag te beantwoorden maken we gebruik van een cellijn 
model. Cellijnen zijn onsterfelijke cellen die oneindig lang kunnen doorgroeien 
in een laboratorioum. Ze worden vaak gebruikt in onderzoek. Met moleculaire 
kloon technologie was het TET2 gen kunstmatig toegevoegd aan verschillende 
cellijnen. 5hmC, het product van TET2 activiteit werd uitgelezen. Wild-type (niet-
gemuteerde) TET2 werd vergeleken met 6 TET2 mutanten. Het wild-type TET2 was 
in staat 5hmC te produceren, alle 6 mutanten konden dat niet. Dit toont aan dat 
AML cellen met TET2 mutaties deactiveren de TET2 functionaliteit en veroorzaken 
warschijnlijk verstoringen in genexpressie. 
5hmC is een directe product van TET2 activiteit, maar het is zeker afhankelijk 
van meerdere factoren. Sommige eiwitten zijn onderdeel van grote eiwitstructuren, 
met elke onderdeel verantwoordelijk voor een bepaalde taak. Anderen reguleren 
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de expressie van eiwitten door ze te markeren voor degradatie. Dit betekent dat 
naast TET2 ook andere misfunctionerende eiwitten een vergeiljkbaar fenotype 
kunnen veroorzaken, namelijk een verminderde hoeveelheid van 5hmC. Ter 
voorbeeld: mutaties in een ander gen, genaamd IDH, leiden to de productie van 
een metaboliet, 2-hydroxyglutaraat, deze remt het functioneren van TET2. Patiënten 
met IDH mutaties, maar een intact TET2 tonen ook verminderde hoeveelheden 
5mhC. TET2 en IDH muaties zijn dus wederzijds exclusief. Ze beïnvloeden dezelfde 
biologische pathway, dus ze komen bijna nooit allebei voor in een patiënt. De 
reden hiervoor is dat kankercellen geen groeivoordeel krijgen zelfs als ze alle twee 
mutaties bevatten. 
In Hoofdstuk 3 hebben we de hoeveelheden en prognostische waardes van 
5hmC onderzocht in 206 AML patiënten. De hoeveelheid 5hmC varieerde minimaal 
in gezonde bloedcellen. In AML cellen was de variate aan hoeveelheid 5hmC echter 
veel breder. Sommige patiënten hadden een vergelijkbaar 5hmC niveau als dat van 
gezonde cellen. Anderen hadden hogere of lagere 5hmC niveaus. De meeste van 
de lage 5hmC gevallen konden verklaard worden met de aanwezigheid van een 
mutatie in TET2 of IDH. Er waren echter toch patiënten met een onverklaarbaar laag 
5hmC gehalte. Het zou erg interessant zijn om de oorzaak hiervan te achterhalen. 
Belangrijker is echter dat het onderzoek aanwees dat een hoger 5hmC gehalte 
een marker is van een slechte prognose. Onderzoek naar 5hmC gehaltes in andere 
soorten kanker heeft ook aangetoond dat 5hmC een belangrijke biomarker kan 
zijn in kanker. Ook al zien we dat bepaalde mutaties vaker voorkomen in AML 
patiënten met hogere 5hmC hoeveelheden, het blijft onbekend wat het precieze 
mechanisme daaracher is.
Waar Hoofdstuk 2 en 3 meer gefocused waren op de klinische relevantie van 
TET2 en 5hmC, doet Hoofdstuk 4 verder kijken op aspecten van hun basale 
biologie.
DNA methylatie (5mC), het teken dat genexpressie stillegt, is fundamenteel 
voor cellen. Het zorgt ervoor dat bepaalde gebieden van DNA die onderdrukt 
moeten worden dat ook daadwerkelijk blijven. Het is ook cruciaal voor genomische 
inprenting en X-chromosoom inactivatie. Genomische inprenting is een interessant 
epigenetisch fenomeen. Het houdt in dat genexpressie specifiek behouden blijft 
volgens het oorspronkelijk gen van de ouder. Wij krijgen altijd een DNA kopie van 
onze moeder en een van onze vader. We hebben dus twee sets aan genen. Bepaalde 
genen zijn “imprinted” – de kopie die expressie vertoont komt altijd van dezelfde 
ouder vandaan, de andere blijft altijd onderdrukt. DNA methylatie fungeert als 
mediator in dat proces. X-chromosoom inactivatie is nog een fascinerend voorval 
dat plaats vindt in cellen van vrouwen. Vrouwen erven twee kopiën van van het 
X-chromosoom. Om daarvoor te compenseren is een X-chromosoom in elke cel 
altijd inactief en dat effect wordt behouden over toekomstige celgeneraties, het 
effect is erfelijk. 
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Wanneer cellen zich delen moeten ze eerst hun DNA verdubbelen, ofwel 
repliceren, zodat elke dochtercel een identieke set aan genetische informatie 
ontvangt. Tijdens DNA replicatie wordt de DNA dubbele helix ontwonden en 
elke streng wordt gebruikt als een template. Na de celdeling is dan een streng 
afkomstig van de moedercel en een streng is identiek nieuw gesynthetiseerd. In 
theorie is DNA replicatie een probleem voor DNA methylatie. De dochter DNA 
streng zou een normale cytosine bevatten in plaats van een gemethyleerde (C in 
plaats van 5mC) aan het einde van het proces. Dit zou schadelijk zijn voor de cel. De 
voorbeelden in de vorige paragraaf demonstreren het belang van epigenetische 
geheugen. Cellen hebben dus een mechanisme ontwikkeld om dit probleem te 
voorkomen. Een specifiek enzym genaamd DNA-methyltransferase 1, DNMT1, 
zorgt ervoor dat cytosines op nieuw gesynthetiseerd DNA gemethyleerd worden. 
Dit gebeurt al tijdens DNA replicatie. 
In Hoofdstuk 4 van deze scriptie hebben we de vraag gesteld of 5hmC, 
net als 5mC, geërfd wordt tijdens DNA replicatie. Dit onderzoek is niet alleen 
gericht om een basale wetenschappelijke vraag over 5hmC the beantwoorden, 
maar ook om zicht te werpen op de discussie of DNA hydroxymethilatie een 
stabiele epigenetische mark is, of alleen een intermediair in de pathway dat het 
onderdrukken van genen omzet door DNA methylatie. We hebben zowel 5mC (als 
controle) als 5hmC gemeten. Door het mechanisme voor 5mC transmissie tijdens 
DNA replicatie zijn de gehaltes onveranderd gebleven tijdens de verschillende 
fases van de celcyclus. De gemeten niveaus van 5hmC waren in contrast verminderd 
tijdens DNA replicatie, wat aantoonde dat deze epigenetische mark niet op een 
vergelijkbare manier behouden wordt, zoals 5mC. Dit laat ons geloven dat, ook 
al is 5hmC een belangrijk component van de DNA (de)methylatie pathway, het is 
geen epigenetiche mark op zich, maar eerder een tussenstap in het proces. Het 
zou erg interessant zijn om nader te onderzoeken welke factoren de formatie 
van 5hmC op specifieke DNA locaties dicteren en hoe dit gerelateerd is aan de 
levenscyclus van de cel.
Het is mijn hoop dat toekomstig onderzoek vele van deze vragen over TET2 
en 5hmC zal beantwoorden, maar vooral dat het resultaat zal bijdragen aan 
ontwikeling van gerichte epigenetische therapiën voor patiënten met defecten in 
de DNA (de)methylatie pathway.
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January till November 2007, she studied genetic mutations in patients with 
myelodysplastic syndromes (MDS), under the supervision of Dr. Saskia Langemeijer 
and Prof. Dr. Joop Jansen, at the Hematology Lab. Afterwards, from December 
2007 till July 2008, Mariam performed research on the topic of Usher Syndrome 
in the group of Prof. Dr. Hannie Kremer at the Department of Human Genetics, 
under the supervision of Dr. Ferry Kersten and Dr. Erwin van Wijk. Upon completion 
of this internship, she obtained her MSc diploma (cum laude) in August 2008. In 
September that same year, she returned to the Hematology Lab to begin her 
PhD studies following up on an exciting discovery that was made during her first 
research internship – namely, the sequencing of the first TET2 mutation in an MDS 
patient. The focus of her PhD project was the TET2 gene/protein. 
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Милички мои, мами, тате и Кевчо, започвам с вас! Закъде бих била без вас... Вие 
сте всичко за мен!!! Независимо от разстоянието и времето ние винаги сме заедно 
(нека да благодарим на всички иновативни технологии за тази привилегия), което 
ми помогна да оцелея далеч от вас през всички тези години. Това приключение 
и поредният му успех дължа на вас и на никой друг! Няма думи, с които да опиша 
колко съм благодарна, че ви има. Няколко реда са крайно недостатъчни, за да изкажат 
какво означавате за мен! Дълбоко оценявам вашата неспирна подкрепа, тя е извор 
на сила за мен. Много ви о.!!!
Чичо, лельо, Они, малко хора на този свят са толкова привилегировани, колкото 
съм аз! Моето семейство е голямо и прекрасно! Няма по-голямо удоволствие от 
това да се прибера вкъщи и празникът да се мести от 7-мия към 6-ия етаж и обратно. 
Много ви обичам!!!
Did you just skim to get to this part?! Gotcha! That’s ok though, I know this is 
THE most anticipated chapter in one’s thesis! 
At the end of this long, winding road, with all of its ups and downs, there are a 
lot of people I would like to acknowledge for their direct, or indirect, contribution 
to this thesis.
Dear Joop, it has been almost nine years since this (slightly scared) MMD 
student first set foot at the Hematology Lab in late November of 2006. What a 
long way we have come since then! Admittedly, it was Bert who really inspired 
me to request an internship at the MHU, but due to circumstances, I ended up 
starting my internship under yours and Saskia’s supervision. PCRs paid off and we 
made a phenomenal (at least for Master’s student standards!) discovery. A gene 
noone had ever reported before turned out to be frequently mutated in patients 
with MDS. You must have seen potential in me back then, because following this, 
you fully supported my wish to write a NWO Toptalent grant proposal and even 
though, eventually, I did not get it, you hired me as a PhD student on that very 
same project nonetheless. Little did we know at the time that TET2 would become 
such a celebrity within the research community, causing quite some let downs 
on my side. Thank you for always noticing the moments when I really needed a 
pep talk! One of the best qualities you possess as a supervisor is your humane 
touch and care that extends beyond the work place. And, I must say, despite 
the hardships, new ideas always kept flowing in our work discussions...at time, 
perhaps, in too many different directions. Thank you for your “helicopter” view! 
Whenever I seemed to be drowning in the details, you were always there to pull 
me back and show me the bigger picture! I hope to someday be able to sift out 
the important out of the ocean of irrelevant, with the ease that you seem to do 
it with! I admire and respect so many things about you as a supervisor, but my 
fondest memories of you will always be the moments when I used to knock on 
your door late in the afternoon with the question, “Do you want to see something 
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cool?!”, and then you would turn to me, your eyes would light up, and you’d reply, 
“ALWAYS!”.
Dear Bert, you are the most inspired researcher I have ever met!!! I still 
remember, clear as day, my first encounter with you. I was an MMD student and 
you were leading one of our master classes. The topic was CML, and we discussed 
some articles you had given us the task to read over lunch about ABC transporters 
on CD34+ cells that pump out Imatinib, causing resistance to the drug. You were 
telling all of this with such zest, as if it were the most interesting thing on the planet! 
Then and there, I knew, I have to do my first internship in your group! You couldn’t 
offer me an internship position though, and after my initial disappointment, it was 
arranged that I start with Joop and Saskia instead. Later, I found out that your 
passion far outreaches ABC transporters and, basically, covers most things science 
(is there a science you are not passionate about?). Thank you for the wonderful 
discussions, ideas, advice, but most of all your contagious enthusiasm! I hope that 
you will always be able to do research! 
Lieve Thess, where do I even begin?! We only met at the very start of my PhD, 
but like me, you were an “old” face at the lab...albeit coming from the enemy lines 
haha! Whatever passion you had for Triad though (sorry Triad folks!), was quickly 
re-directed to the TET2 front. You were the Robin to my Batman, the salt to my 
pepper, the best co-pilot I could have wished for! Through the years we fought, 
side-by-side, to unravel the mysteries of our baby - TET2. And our baby sure 
wasn’t an easy one! But we prevailed, and in spite of this love-hate relationship we 
had with our child, we did manage to make a thesis out of it! This is not only my 
achievement, Thess, but it is yours too! I am so glad that besides being colleagues, 
we became good friends too. Thank you for introducing Nederlandse Vrijdag, for 
the lively scientific discussions, for our long conversations about life and the future! 
Lieve Sas (L.), do you remember the afternoon when I came into your office to 
show you the nonsense mutation I had just found in TET2?! It was the first time 
after months and months of fruitless PCRs that I finally had something, and I was 
not quite sure whether it wasn’t merely my imagination playing tricks on me, so I 
had to come and show you. We were both exhilarated!!!... It seems to me like it was 
only yesterday, but in fact, it has been nine years since...Thanks to you, MDS patients 
were not just an abstract notion in my head, a source of DNA material and cells. 
You taught me to look past the cold science and appreciate the fact that there are 
actual people involved, and that we are doing this research for them. At the start of 
my PhD, I found it very difficult to evolve out of our supervisor -student relationship, 
and, in a way, perhaps I never quite did. Your professionalism and dedication have 
always evoked my admiration and respect for you. Thank you for allowing me not 
only in your research project, but also in your life! I cannot wait to meet him/her?!?!
Lieve Leeuwtje, dear Leonie, you joined the TET2 forces later, but quickly 
became an indispensable wheel in the carriage. You joined the group in a way 
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that was so natural and effortless, and I have no doubts you owe that to your easy-
going and lively personality. I enjoyed working with you, just as much as I enjoyed 
going to the SYTYCD show together. Thank you for sharing the TET2 laughs, the 
TET2 tears and all the in-betweens! I very much look forward to reading your thesis! 
Only, I fear leaving you alone with ‘The Boys” in the AIO kamer may have had some 
lasting consequences on your English vocabulary! 
Dear Ruth, thank you for contributing you extensive experimental skills and 
knowledge to the TET2 project! You are now busy with some 5-hmC-related work 
and I am very curious what you will discover!
Lieve MHD mensen: Marion, Patric, Ellen, Ad, Evelyn, Louis en Laura, veel 
van jullie waren op een of ander moment direct betrokken bij het TET2 project. 
Wat hebben we veel samen gesequenced!!! Jullie zijn net een kleine familie en 
ik volede me altijd op mijn gemak bij de diagnostiek. Bedankt voor jullie inzet en 
enthusiasme! Het was mij een plezier om jullie te leren kennen! 
My dear Minh, you were the first (MMD) student I supervised and you turned 
out to be so much more than a talented student. I really enjoyed doing TET2 WB 
and transductions together with you, whilst throwing Friends quotes at each other 
every few minutes! We have remained good friends and I cherish that! Could I be 
any clearer hehe!?!?! I have no doubt you will bring your own PhD project to an 
excellent end!
Dear Sudeep, your task was not an easy one! Cell cycle synchronizations, 
endogenous TET2 WB, testing different lysing buffers, were among the few 
experiments you had on your plate during your very first MMD internship. It can 
be utterly overwhelming, but you did it with pleasure and never complained, even 
when at first there was not much to be seen on your blots. Thank you for the hard 
work and enthusiasm! Good luck with your PhD!
My AIO room homies, Davide, Pedro, Jimmy and Nicco, how I have enjoyed 
your company in the past years!!! Davide, bello, noone can make me laugh by just 
opening the door to a room, the way you can! You are as much a talented researcher, 
as you are a wonderful friend! There is so much I would like to say to you, so much 
I’d like to thank you for, but scribbling a few lines in an acknowledgments section 
doesn’t feel enough. Thank you for always being there for me (also on behalf of 
Naso Gigio!)! Jim, J-man, it has been an honour and a privilege for me to be your 
ass buddy! We have been through so many ups and downs in the past few years, 
but we shall prevail; even in our non-scientific endeavors we remain a great team. 
I hope that you will not let anything stop you in achieving your goals in life! Thank 
you for being you! Davide and Jimmy, I am so honored that you have agreed to be 
my paranimfen! Pedro, my dearest Pjotr, never have I imagined that one of my best 
friends in this life will be Jesus/the Wolverine himself! Thank you for our Sunday 
evening tradition, thank you for all of our splendid scientific and non-scientific 
discussions, our visits to the Marienburg bibliotheek, and, for playing the smallest 
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violin in the world (when the occasion called for it)! Nicco, although you joined the 
lab almost at the very end of my lab adventures, I still feel like I’ve known you for 
years! Noone tells a made-up story and makes it sound so perfectly believable like 
you do...or, perhaps I am too gullible?! Thank you for the great times!
Lieve Goric, sweetie, only one month spent under your supervision in November 
2007 learning ChIP, convinced me that you are all kinds of amazing! You are not only 
a true lady, but also a talented researcher. I am so proud of you for choosing to do 
a PhD! Look how far you’ve come! Thank you for the appeltaart met moccachino 
at the Blonde Pater, for our long talks (even when we disagree!), but most of all, 
for being such a great friend!
Dear Lau, I remember that evening when you and Sas taught me my first 
sentence in Dutch (De kleren zijn op zolder. *wink, wink*), and the day we were 
at the Electrophoresis room at the old lab, when you and Sas finally admitted to 
being a couple (which I suspected all along). So many great memories! You kind 
of felt sorry for my ever-failing PCRs and decided to take me under your wing to 
learn some more techniques. Sadly you left the lab soon after I started my PhD, 
but as far as I am concerned, you were utterly missed! Thank you for always being 
so kind to me! 
Dear Sas (B), Sylvie, Maaike and Lei Lei, I may not have been very close to you 
over the years, but I will remember each and every one of you. Sas, you were always 
there to answer my questions and help me out with my experiments, reagents, 
or just simple orders. Sylvie, how are you so good in everything you do?! Maaike, 
thank you for your encouraging words and sweet cards! Chocolate can solve any 
problem, right! Lei Lei, it always amazed me how much courage and kindness 
there is in such a tiny girl, such as yourself. Thank you for the good times at the 
Hematology Lab!
Dear Arno and Ron, thank you for working with us on the 5(h)mC measurements! 
Your contribution to this thesis has been indispensable and I deeply appreciate it!
Dear Rob, thank you for helping me/us with the cell cycle sorting experiments! 
You were always ready to push your boundaries (and those of the cell sorter!) in 
order to get the appropriate populations of cells. Thank you for the enthusiasm!
Lieve, lieve Nelleke, bedankt voor al je hulp tijdens mijn promotie!!! Je bent net 
als een superheld die altijd in de schaduw blijft, maar zonder jou zijn wij allemaal 
verloren! Jij bent een schat!
My dearest family, Nin&Mo, Shankar&Helene, Manu, Ruggero, Vinc&Dani, 
Jordan, there are not enough words in my vocabulary to express what you mean 
to me. I owe you some of the best times of my life! It breaks my heart that so many 
of you moved away over the past few years, but then again it means I have family 
in Sweden, Italy, Canada and Barcelona! Not too shabby!!!
Lieve Ali, Zoran, Damir en Marion, jullie hebben mij verwelkomd in de familie 
Popovic met open armen (en harten). Ik voelde me na een korte tijd een van jullie! 
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Wat een geluksvogel ben ik, om een familie te hebben gevonden in dit vreemde 
land, net zoals jullie! Hvala!
And, before I conclude this long (long) acknowledgments section, I turn to you 
Vanja. Baby (a word only you know all the nuances of!), you mean everything to me! 
You are my past, my present and my future... and I will not even attempt to thank 
you in the few short lines that I have left here. You have made my life brighter, 
happier and more meaningful, and for that I should thank you every day!
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